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Abstract 
 
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by a 
progressive cognitive decline, and accumulation of amyloid-β (Aβ) in senile plaques that 
are associated with inflammatory molecules released by activated glial cells. Among glial 
cells, microglia that constitute the intrinsic defense system within the central nervous 
system, may become activated by Aβ aggregates and develop critical neuroprotective 
and neurotoxic functions with implications in AD onset and progression. 
Actually,inflammation has been associated with AD, although nonsteroidal anti-
inflammatory drugs have not proven efficacy in halting the progression of the disease, 
reason why they are indicated as beneficial only in the very early stages of AD. 
Therefore, features of neuroinflammation and associated microglia phenotypes are still 
open questions in the understanding of AD pathogenesis and neurodegeneration. 
Another important issue is the association of AD with ageing and the observation of few 
microglia and accumulation of dystrophic/desensitized microglia in samples from AD old 
subjects, strongly suggesting their progressive degeneration and diminished 
replenishment. Investigation of the multiple activated states of microglia when stressed 
by Aβ, in particular the increased inflammatory status of microglia with aging, referred as 
primed reactive, or sensitized cell, or in opposite the proposed state of irresponsive aged 
microglia, are challenged issues once there are no appropriate procedures to isolate 
degenerative and senescent microglia for experimentation.  
Therefore, the global aim of this thesis was to explore how different microglia 
phenotypes and ageing may influence Alzheimer’s disease (AD) pathogenesis and 
neuroinflammation, by unraveling their associated neuroprotective and neurotoxic 
functions in in vitro and in vivo models. To achieve these objectives, we first (i) developed 
an experimental model to naturally age primary microglia, which allowed the evaluation 
of microglia defensive mechanisms (e.g. migration, phagocytosis, autophagy), of a 
panoply of inflammatory mediators and of senescence-associated markers, in an acutely 
isolated and activated microglia [2 days in vitro (2 DIV)] and an aged cell culture (16 
DIV). With the characterization of such differently aged microglia, we (ii) progressed 
towards the assessment of their responsiveness when treated with 1000 nM of Aβ1-42 for 
24 h. Finally, in an attempt to translate our in vitro research into the triple transgenic AD 
(3xTg-AD) mice model, we decided (iii) to explore the inflammatory status of the 
hippocampus and cortex in animals with 3-, 6- and 9 months-old, by assessing microglia 
phenotypes, as well as the expression of inflammatory cytokines and microRNAs. 
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We observed in our first study, already published (Caldeira et al Front Cell Neurosci 
2014), that (i) in vitro aged microglia switch from a predominant reactive phenotype into 
cells that although not showing decreased survival, revealed increased dormancy, with 
morphometric features characteristic of ramified morphology, together with compromised 
migration, impaired autophagy, reduced phagocytosis, decreased expression of 
inflamma-miRNAs, and increased presence of senescence-associated markers. In the 
second study, recently submitted to publication by invitation (Caldeira et al Front Aging 
Neurosci), using the ageing microglia model and Aβ1-42 treatment, we observed that (ii) 
Aβ treatment caused soma volume increase and process shortening compatible with 
activated microglia, in both 2 DIV and 16 DIV cells, together with impairment of 
neuroprotective functions, namely phagocytosis and migration abilities, as well as 
autophagy, in in vitro aged microglia. Interestingly, Aβ led to an increased expression of 
senescence-like associated markers in 2 DIV microglia, similarly to those of the aged 
cells. Age-dependent changes included the decrease in the expression of inflammatory 
mediators and surface receptors, together with the reduction of CD11b+ cells and gain 
of CD86+ microglia and downregulation of miR-155 and miR-124. Lastly, in our in vivo 
studies at the early-AD stage in the 3xTg-AD at 3 months-old, when Aβ accumulates 
intraneurally, we observed a downregulation of some activated microglia markers, as 
well as both typical M1 pro-inflammatory and M2 anti-inflammatory/damage resolution 
markers. Interestingly, miR-155 revealed to be early upregulated and its increase was 
sustained at 9 months-old, when extracellular Aβ accumulation is an AD hallmark. At this 
stage, increase of HMGB1 and decrease of both miR-146a and miR-124 expression is 
apparent. Curiously, when looking at miR-155 target gene expression we observed new 
immune-associated molecules that were differently expressed in the 3xTgAD animals by 
comparison with the wild type mice, both at 3-months and 9-months of age, which will be 
the subject of study in future works.  
We may then conclude that the aged in vitro microglia model is very suitable to 
unravel microglia phenotypic alterations that may explain different cell reactivity in 
neurodegenerative disorders associated with neuroinflammation and diverse states of 
disease progression, thus requiring diverse disease-modifying therapies depending on 
the inflammatory status. We further demonstrate that Aβ induce a heterogeneous 
population of microglia subtypes instead of only M1 and M2 polarization and that their 
distribution are age-dependent and influenced by microglia activation state. The 
increased expression of miR-155 in very early stages of AD in the 3xTg-AD animal 
model, to be confirmed in AD patients, may additionally reveal as a sensitive biomarker 
with predictive value if detected in the peripheral blood.  The work developed in the 
present thesis contributed to better define microglial activation phenotypes, in particular 
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the notion of “good” or “bad” states during AD pathogenesis, while identified new targets 
to be modulated and assessed as predictive biomarkers, with potential relevance for 
diagnosis and therapeutic tools for developing innovative medicines. 
 
 
 
 
 
Keywords: Alzheimer’s disease; amyloid-β peptide; neuroinflammation; 3xTg-AD; 
microglia phenotypes. 
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Resumo 
 
A Doença de Alzheimer (DA) é considerada como a causa mais comum de 
demência na população idosa, sendo o envelhecimento apontado como o maior fator de 
risco associado a esta doença. A DA é uma doença neurodegenerativa que afeta 
regiões do cérebro relacionadas com a memória e funções cognitivas, levando à 
incapacidade de estabelecer e manter memórias recentes, a um estado de confusão e 
à deterioração da linguagem. Esta alteração é progressiva e irreversível tendo como 
consequência a incapacidade de realizar tarefas diárias, culminando na total 
dependência de terceiros que se traduz num impacto significativo para os doentes, 
familiares, cuidadores e sociedade em geral. Atualmente, não existe um tratamento 
eficaz para curar ou atenuar a progressão da DA. 
A DA pode ser classificada em dois tipos com base na idade em que se dá o início 
da doença: esporádica e familiar. A DA esporádica é a forma mais comum da doença, 
com um início tardio, afetando normalmente adultos com mais de 65 anos, que podem 
ou não ter antecedentes familiares desta doença. Até à data, não existem dados que 
comprovem a existência de hereditariedade na DA esporádica, no entanto o gene 
ApoE4 tem sido associado a uma maior probabilidade para algumas pessoas 
desenvolverem esta forma de doença. A DA familiar é a forma menos comum, onde a 
doença é transmitida entre gerações e afeta habitualmente indivíduos entre os 40 e os 
60 anos de idade. 
O cérebro dos doentes de Alzheimer é caracterizado por uma grande atrofia que 
pode ser causada por alterações neuropatológicas, tais como a acumulação extracelular 
de placas senis do péptido β-amilóide (Aβ), a formação de tranças neurofibrilares de 
depósitos da proteína tau hiperfosforilada, a perda de comunicação entre os neurónios 
(perda de sinapses) e a morte neuronal, que ocorrem em regiões específicas do cérebro. 
As zonas mais afetadas pela DA são o hipocampo, relacionado com a memória, e os 
lobos frontal e temporal, relacionados com a linguagem e outras funções cognitivas. De 
facto, vários estudos na zona do hipocampo e do córtex entorrinal, regiões 
habitualmente relacionadas com o desenvolvimento precoce da patologia da DA, 
apontam para que a deposição intraneuronal de Aβ preceda a sua acumulação 
extracelular, sugerindo ser um acontecimento precoce na patogénese da DA e 
contribuindo para a progressão desta doença. Outra característica frequentemente 
observada em cérebros autopsiados de doentes com DA é a neuroinflamação, 
principalmente em regiões que evidenciam elevados níveis de patologia da doença. No 
entanto, a neuroinflamação pode estar associada a efeitos benéficos ou prejudiciais ao 
Resumo 
 
xxviii 
nível neuronal. Assim, enquanto uma resposta neuroinflamatória aguda pode ser 
benéfica para o sistema nervoso central, pois promove a reparação do tecido danificado, 
uma neuroinflamação continuada em resposta ao estímulo inicial pode originar 
neurodegeneração e consequentemente disfunção cerebral. A neuroinflamação parece 
ter um início precoce na DA sendo acompanhada por uma ativação de diversas vias 
inflamatórias, habitualmente associadas à ativação das células gliais. De facto, a gliose 
é uma característica neuropatológica frequentemente observada em cérebros de 
doentes com DA, em que a microglia responde através da alteração do seu fenótipo, 
produzindo diversos mediadores pro-inflamatórios, e até anti-inflamatórios, criando um 
ciclo de auto-perpetuação do quadro neuroinflamatório que contribui para o cenário de 
inflamação crónica observado na DA. Esta ativação continuada da microglia, associada 
a uma disfunção associada ao envelhecimento e ao estímulo tóxico, contribui para o 
início e progressão da DA. Modificações dos fenótipos microgliais, ocorrendo de forma 
diferente na população de células de um determinado local, ou mesmo de forma diversa 
entre as várias regiões do encéfalo, podem estar na origem do fracasso do tratamento 
com medicamentos anti-inflamatórios não esteróides como prevenção da DA. De facto 
sabe-se hoje que apenas são eficazes na prevenção da progressão da doença quando 
iniciadas, ou em curso, na fase pré-clínica da mesma e que até poderão ser prejudiciais 
nas fases mais avançadas, onde até a inflamação tem vindo a ser referida como já não 
tendo lugar. 
Esta tese teve como objetivos: (i) desenvolver um modelo experimental in vitro de 
células de microglia capaz de reproduzir uma célula ativada (mimetizando a existência 
de inflamação) e uma célula envelhecida em cultura (mais senescente) que permitisse 
caracterizar o seu diferente comportamento funcional e traçar a sua assinatura de 
reatividade (Capítulo 2); (ii) identificar a resposta dos fenótipos ativados e mais 
senescentes da microglia a uma concentração não tóxica de Aβ e estabelecer os seus 
perfis de resposta ao estímulo (Capítulo 3); e (iii) definir o contexto inflamatório e as 
subpopulações de microglia na região cortical e hipocampal do cérebro de ratinhos do 
modelo animal triplo transgénico para a DA, o 3xTg-DA, em 3 períodos bem definidos 
(3-, 6- e 9 meses de idade) e correspondentes a diversas fases de progressão da doença 
(Capítulo 4). 
Este estudo iniciou-se, então, com o desenvolvimento e estabelecimento dos 
modelos que melhor definissem a microglia ativada (decorrente do processo de 
isolamento) e a envelhecida em cultura, manifestando marcadores associados a 
senescência celular. Para tal, as células foram isoladas a partir de cérebros de ratinhos 
CD1 recém-nascidos, tendo sido mantidas até 2 dias in vitro (DIV) (“ativadas”) ou até 16 
DIV em cultura (“envelhecidas”), tendo sido analisadas, quer relativamente à existência 
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de marcadores inflamatórios, quer quanto às suas propriedades funcionais. As células 
com 2 DIV, tal como esperado, apresentaram uma morfologia mais amebóide que se 
alterou para uma morfologia mais ramificada, havendo também diminuição da 
expressão de marcadores característicos de fenótipo mais reativo, com o tempo em 
cultura. Além disso, observámos ocorrer perda de funcionalidade microglial com 
diminuição da capacidade de migração, autofagia e fagocitose por parte destas células 
envelhecidas em cultura. É interessante assinalar que dos 2 DIV para os 16 DIV se 
verificou haver ativação da metaloproteinase (matrix metalloproteinase, MMP)-2 que se 
acompanhou de uma descida da MMP9, juntamente com uma redução da libertação de 
glutamato, da ativação do fator nuclear kappa-B, e da expressão dos recetores Toll-like 
(TLR)-2 e TLR4. Curiosamente, verificou-se ainda uma redução na expressão dos 
microRNA (miR)-124 e miR-155, acompanhada por um aumento de marcadores 
associados à senescência, como a de beta-galactosidade associada à senescência e 
de expressão do miR-146a. Estes resultados indicam que as células microgliais jovens 
(2 DIV) têm uma resposta mais reativa, enquanto que com o aumento da idade in vitro 
as células microgliais (16 DIV) tendem a perder a sua capacidade de resposta e ficar 
mais senescentes. 
O estabelecimento deste modelo de microglia ativada e envelhecida, permitiu-nos, 
então, avaliar a sua resposta diferencial ao estímulo de concentrações não tóxicas do 
péptido Aβ1-42. Para isso, células microgliais com 2 e 16 DIV foram expostas durante 24 
horas a 50 nM e 1000 nM do péptido A1-42, após o que se avaliou a capacidade de 
resposta ao estímulo. Verificámos novamente que algumas das funções 
neuroprotetoras desempenhadas pela microglia, como a fagocitose, migração e 
autofagia, se encontravam comprometidas com o envelhecimento in vitro. Por outro 
lado, observámos que a exposição das células ao Aβ desregulou a capacidade 
fagocítica da microglia de 2 DIV, ao mesmo tempo que estimulou a autofagia e contribuiu 
para o aumento dos marcadores senescentes. Contudo, foi evidente a resposta da 
microglia de 2 DIV ao Aβ em termos do aumento da expressão de mediadores 
inflamatórios, tais como citocinas pró-inflamatórias (TNF-α, IL-1β e IL-6), proteínas 
relacionadas com o inflamasoma (HMGB1, IL-18 e NLRP3) e recetores reguladores 
(TLR2, TLR4 e CX3CR1). Esta reatividade foi contudo significativamente diminuída com 
o tempo em cultura, ocorrendo redução da expressão de miRs relacionados com a 
inflamação (miR-155 e miR-124) e marcadores de microglia reativa (células CD11b+). 
Curiosamente, observámos que o tratamento com Aβ foi capaz de induzir a polarização 
das células tanto para o fenótipo M1 (iNOS e MHC class II), como para o fenótipo M2 
(Arginase 1 e TGF-β) nas células de 2 DIV e 16 DIV. Os resultados mostram, assim, que 
a exposição ao Aβ leva a uma heterogeneidade de fenótipos microgliais, incluindo o 
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típico M1/pró-inflamatório, o M2/anti-inflamatório/resolução do dano e o mais 
distrófico/senescente associado à perda da capacidade de resposta, com uma 
distribuição que se verificou depender do estado de ativação da célula aquando do 
estímulo. 
Por fim, para melhor perceber os fenótipos microgliais no contexto do parênquima 
cerebral em estádios diferentes da doença, em particular nos mais precoces e nas 
regiões do hipocampo e do córtex fomos avaliar, em ratinhos 3xTg-DA, os marcadores 
inflamatórios aos 3 meses de idade, onde se verifica a oligomerização do A 
intraneuronal, aos 6 meses onde se inicia a acumulação de placas no exterior da célula 
e aos 9 meses, correspondentes a uma fase mais avançada da doença com evidente 
acumulação de A extracelular. Curiosamente, aos 3 meses observámos uma 
subexpressão de alguns marcadores de ativação da microglia (TNF-α, IL-1, IL-6, IL-18 
e HMGB1), tanto do tipo M1 pró-inflamatórios (MHC class II e CEBP-α), como de M2 
anti-inflamatórios e/ou relacionados com a resolução do dano (SOCS1, TGF- e 
Arginase 1), sugerindo que haja uma tentativa de prevenir o dano e a expressão de 
proteínas mal-formadas. Aos 6 meses verificámos não haver alterações assinaláveis, 
uma vez que corresponde ao período onde se verifica uma diminuição da acumulação 
do A intraneuronal sem grande acumulação extracelular, pelo que decidimos não incluir 
os resultados obtidos na presente tese. No entanto, ao avaliar os resultados obtidos aos 
9 meses, verificámos um aumento da expressão de alguns marcadores inflamatórios 
(TNF-α, IL-1 e HMGB1), e típicos de um fenótipo M1 (iNOS) e M2 (SOCS1 e Arginase 
1). Verificámos ainda uma elevada expressão do miR-155 logo na fase inicial da doença 
(3 meses), o qual se manteve elevado aos 9 meses, indicando a sua potencialidade 
como biomarcador preditivo da DA. Por outro lado, os miR-146a e miR-124, embora 
elevados aos 3 meses, estavam diminuídos aos 9 meses, que poderá favorecer o 
ambiente inflamatório nesta etapa. Curiosamente, a análise de alvos do miR-155 
identificou a expressão distinta de moléculas relacionadas com a resposta do sistema 
imunitário, encontrando-se estas menos expressas no modelo 3xTg-DA tanto aos 3 
meses, como ainda de forma mais marcada aos 9 meses. Estes resultados demonstram 
uma resposta imune disfuncional no modelo 3xTg-DA quando comparado com animais 
controlo da mesma idade. 
Concluindo, conseguimos desenvolver e estabelecer um modelo celular de dois 
fenótipos microgliais, com comportamento que mimetiza a microglia mais ativada e mais 
envelhecida. O modelo foi útil para o estudo do efeito do A em ambas as situações e 
poderá ajudar a perceber a disfuncionalidade da microglia pelo envelhecimento, bem 
como testar e identificar moléculas capazes de recuperar a funcionalidade 
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neuroprotetora da microglia. Os nossos resultados mostraram que o péptido A poderá 
contribuir para a perca da funcionalidade da microglia quando num ambiente 
inflamatório, envelhecendo-a de forma prematura e indicando que a imunossupressão 
pode estar relacionada com o surgimento da DA associada à idade, e que a presença 
de Aβ poderá contribuir para a perca da funcionalidade da microglia e favorecer a 
progressão da doença. Os estudos realizados permitiram evidenciar igualmente, que a 
microglia assume diversos fenótipos quando estimulada pelo Aβ e que a microglia mais 
envelhecida se torna incapaz de combater o dano. Isto pode, em parte, explicar o insucesso 
das terapias anti-inflamatórias utilizadas para combater a DA. No modelo in vivo, o miR-
155 revelou ser um potencial biomarcador precoce da inflamação na DA. Por outro lado, 
a resposta atenuada da microglia na fase inicial da doença, pode estar associada à 
contenção do dano causado pelo Aβ intraneuronal. Com a acumulação do A a nível 
extracelular, e apesar da perca das funcionalidades neuroprotetoras associadas à 
migração e fagocitose, a microglia torna-se mais reativa. Posteriormente, parece entrar 
numa fase de maior latência o que se poderá traduzir num ambiente mais favorável à 
progressão da doença e exigir terapêuticas de “rejuvenescimento” da célula. Estes 
dados reforçam a existência de diversas fases de progressão patológica da DA, bem 
como de distintos subtipos de fenótipos constituindo uma população microglial 
heterogénea e influenciável pelo ambiente patológico que a envolve, o que nos remete 
para a necessidade de utilização de diferentes estratégias terapêuticas consoante o 
estadio e as alterações de natureza inflamatória que lhe estejam associadas. 
 
Palavras-chave: Doença de alzheimer; péptido β-amilóide; neuroinflamação; 3xTg-DA; 
fenótipos da microglia.  
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1. Alzheimer’s Disease 
  Historical perspective 
Alzheimer’s disease (AD) was discovered in 1906 by Alois Alzheimer, a German 
psychiatrist and neuropathologist that characterized and described the case of Auguste 
Deter, a 51-year-old woman who had died of an unusual mental illness (Balducci and 
Forloni, 2011). Her symptoms included memory loss, confusion, hallucinations, 
disorientation, language problems, and unpredictable behaviour, which are several of 
the fundamental features observed in most patients nowadays (Balducci and Forloni, 
2011). Autopsy of Auguste brain revealed changes in the brain tissue like a highly 
shrunken brain, dying cells and the presence of two kind of aggregates, plaques and 
tangles, that have become hallmarks of the disease (Kidd, 2008).  
About one hundred years after this discovery, AD became one of the most 
common neurodegenerative diseases and the most prevalent cause of dementia among 
old people (Khairallah and Kassem, 2011). Estimates vary, but is suggested that more 
than 5 million people in the Unites States (Huynh et al., 2017), and more than 35 million 
worldwide (Isik, 2010), may be affected by AD. Meanwhile, due to the increase in 
population life expectancy this number is expected to triple by 2050 (Bettens et al., 2013; 
Hebert et al., 2003). However, a recent report where dementia prevalence among 65 
years or older were compared between 2000 and 2012 showed a reduction from 11.6% 
to 8.8%, and associated to increased educational attainment, although there is still the 
need to evaluate other social, behavioural, and medical factors (Langa et al., 2016). 
 
AD is a neurodegenerative disorder characterized by subacute chronic 
inflammation, neurotoxicity, oxidative stress, and reactive gliosis (Lopategui Cabezas et 
al., 2012), that affect regions of the brain related with memory and cognitive functions, 
leading to the inability to establish and maintain recent memories, confusion and 
language deterioration (Rubio-Perez and Morillas-Ruiz, 2012). Symptoms of AD occur 
for several years to a decade, being mortality often related with resulting secondary 
issues, such as opportunistic infections or multi-organ failure (Siciliano et al., 2011). The 
lengthy and progressive cognitive decline seriously interferes with daily life (Khairallah 
and Kassem, 2011), having a significant impact in patients and their families, caregivers, 
and society in general (Kidd, 2008). The tremendous need of care required by 
Alzheimer’s patients, in association with the lack of an effective treatment for this 
disease, makes AD a high financial burden to both families and health systems  (Salawu 
et al., 2011). 
Advanced age is the most important risk factor associated with AD, with the 
incidence of the disease doubling every five years after 65 years of age (Salawu et al., 
Chapter 1 
 
4 
2011). AD can be classified either as late-onset AD (LOAD or sporadic) or early-onset 
AD (FAD or familial), based on the age of first signs of disease (Kidd, 2008). The late-
onset AD is the most common form of the disease, comprising about 90-95% of cases, 
and usually occurs 65 years of age. In contrast, early-onset AD is relatively rare, arising 
in people aged 40-60, and represents the other 5-10% of AD cases (Harman, 2006). 
Some FAD cases are caused by inherited change in one of three genes: the amyloid 
precursor protein (APP) gene on chromosome 21, the presenilin 1 (PS1) gene on 
chromosome 14, and the presenilin 2 (PS2) gene on chromosome 1 (Salawu et al., 
2011). LOAD develops without any specific and known cause, showing no significant 
genetic link, with the exception of apolipoprotein E (ApoE) gene carrying the ε4 allele 
(ApoE4), which appears to be a major genetic susceptibility AD risk factor (Kidd, 2008). 
Although AD has been traditionally associated with ageing, recent approaches 
refer an early origin. Indeed, abnormally phosphorylated tubulin-associated unit (tau) 
protein was recently identified in brains of people aged between 4 and 29 years (Braak 
and Del Tredici, 2011), suggesting that AD-related pathological process may begin 
before puberty or in early young adulthood. 
 
 Pathophysiology and histopathological findings 
A wide atrophy of the brain is observed in AD patients due to a high number of 
neuropathological modifications, like abnormal deposition of amyloid plaques, formation 
of neurofibrillary tangles, loss of connections between neurons, and neuronal death 
(Figure 1.1). Nevertheless, these modifications in the brain are not evenly spread 
throughout the brain (Wenk, 2006). Indeed, preferentially affect specific brain areas 
which are essentially consistent from patient to patient (Braak and Braak, 1991). 
Although the size, shape, and distribution pattern of amyloid aggregates vary from 
individual to individual, its onset usually begins in the basal portions of the isocortex, 
spreading then to the areas in association with isocortex, and finally reaching the 
hippocampal region. In contrast, neurofibrillary tangles occur according to a set pattern, 
first affecting the entorhinal cortex, following the hippocampal neurons and, finally, 
extending to surrounding neurons in extra hippocampal regions, like isocortical areas 
(Braak and Braak, 1991). 
The neuronal damage appears to be caused by changes that occurs both inside 
and outside the neuron, and is characterized by the presence of intracellular both 
amyloid- (A) peptide and filamentous deposits of tau protein, named neurofibrillary 
tangles (NFTs), as well as by extracellular aggregates of Aβ, named amyloid plaques 
(Bayer and Wirths, 2010; Sheng et al., 2012) (Figure 1.1C). Emerging evidences link 
the intraneuronal accumulation of A to synaptic dysfunction, cognitive dysfunction and 
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formation of plaques in AD (Gouras et al., 2005; Gouras et al., 2010; Wilson et al., 2016). 
The accumulation of all these pathological materials in the brain is considered the main 
histopathological hallmarks of AD. In fact, although healthy brains also display amyloid 
and tangles, mainly with aging and the presence of the ApoE4 gene, the AD brains 
effectively have a higher number of plaques and tangles (Kidd, 2008). Furthermore, the 
increased number of reactive microglia and astrocytes close to site of injury, called 
gliosis, is also observed in AD brain (Rubio-Perez and Morillas-Ruiz, 2012) (Figure 
1.1C). Another feature of the disease is the malfunctioning of once-healthy neurons, 
selectively in the limbic system and neocortex, losing connections with other neurons, 
and dying. This synaptic loss and selective neuronal death is currently the one that best 
correlate with cognitive deficits observed in AD (Bi, 2010; Isik, 2010).  
 
Figure 1. 1 – Alzheimer’s disease neuropathology. (A) An overall shrinkage of brain tissue is observed 
in later stages of Alzheimer’s disease (AD), accompanied by extended sulci, narrowed gyri and enlarged 
ventricles. Temporal lobes are the most affected. Short-term memory begins to fail when hippocampal 
neurons, forming part of the limbic system, degenerate. Due to the spread of the disease through the cerebral 
cortex, the ability to perform daily tasks declines and language becomes impaired. (B) In healthy brain, 
features of the disease are generally absent, although they can be observed as a result of ageing. (C) 
Neurofibrillary tangles are found within a large number of degenerated neurons, as well as extracellular 
amyloid plaques which are often surrounded by activated microglial cells. Adapted from picture at 
BrightFocus Foundation website. 
 
Actually,, there are not a clear understanding of the complex brain changes 
involved in the onset and progression of AD. In this context, research has focused on 
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the various mechanisms that are associated with this disease, such as Aβ aggregation 
and neurotoxicity, tangle formation by hyperphosphorylated tau protein, 
neuroinflammation, oxidative stress and mitochondrial dysfunction. 
 
1.2.1. Amyloid-β peptide 
According to the amyloid hypothesis, deposition of Aβ peptide in the brain is the 
triggering of AD pathogenesis due its neurotoxicity (Cavallucci et al., 2012; Puzzo and 
Arancio, 2013). Aβ is a hydrophobic protein derived from proteolytic cleavage of APP, 
which is a transmembrane protein located on the plasmatic membrane, or in intracellular 
compartments, of neurons and glial cells that exist in high quantity in the brain (O'Brien 
and Wong, 2011; Puzzo and Arancio, 2013). It is known that APP is expressed by 
neurons in response to cell damage (Rubio-Perez and Morillas-Ruiz, 2012). 
The proteolytic cleavage of APP occurs in a series of sequential steps beginning 
with the cleavage by α- or β-secretase, followed in both cases by cleavage by γ-
secretase, originating, or not, various fragments of Aβ peptide with several lengths. APP 
can be processed by the non-amyloidogenic pathway in which α-secretase, an enzyme 
from the disintegrin and zinc metalloproteinase (ADAM) family (Allinson et al., 2003), 
cleaves APP within the Aβ domain, originating a membrane-bound C-terminal fragment 
of 83 amino acids (C83) and an N-terminal soluble ectodomain fragment (sAPPα), which 
is released extracellularly. The C83 fragment is further cleaved by γ-secretase giving rise 
to a short fragment dominated P3. Thus, the Aβ peptide formation is prevented in the 
non-amyloidogenic pathway of APP processing, since the α-secretase cleavage takes 
place in Aβ sequence (Figure 1.2) (Cavallucci et al., 2012). Alternatively, APP can be 
processed by amyloidogenic pathway, being first cleaved by β-secretase, which acts in 
the β-site APP-cleaving enzyme 1 (BACE1) (Vassar et al., 1999), producing a 
membrane-bound C-terminal fragment of 99 amino acids (C99) with a N-terminal soluble 
ectodomain fragment (sAPPβ) released into the extracellular medium. The C99 fragment 
starts at residue 1 of Aβ region and the subsequent cleavage by γ-secretase results in 
the Aβ peptide formation (Figure 1.2) (Cavallucci et al., 2012). While α-secretase and β-
secretase cleave APP at single sites, γ-secretase, a complex of proteins which uses PS1 
and PS2 as catalytic subunits, performs a set of intramembranous cuts, giving rise to 
products of various lengths (Sheng et al., 2012). Aβ peptide length can vary between 39 
and 43 amino acids (Chromy et al., 2003), but most of the Aβ produced is formed by 40 
residues (Aβ1-40), although a slightly larger variant of 42 residues (Aβ1-42) can also be 
formed (Lewczuk et al., 2004; Wesson et al., 2011). These Aβ peptides can 
spontaneously self-associate into larger structures, ranging from low molecular 
oligomers (Aβo) to insoluble aggregates of fibrils (Aβf), until be deposited as senile 
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plaques (Figure 1.2) (Maezawa et al., 2011; Rubio-Perez and Morillas-Ruiz, 2012). 
However, as Aβ1-42 variant is more hydrophobic, it is more conducive to form aggregates 
(Cavallucci et al., 2012). Although amyloid plaques are formed from several different 
peptides and proteins (Allsop, 2000), Aβ1-42 is the prevalent form in these amyloid 
deposits and believed to be more neurotoxic than Aβ1-40 and other Aβ species (Cavallucci 
et al., 2012; Maezawa et al., 2011). 
 
The neurodegenerative process of AD is initially characterized by synaptic injury, 
which is highly correlated to the cognitive impairment of the individuals. Furthermore, 
several studies support the idea that AD pathology is related to progressive accumulation 
of Aβ peptide, due to a discrepancy among the levels of Aβ production, aggregation and 
clearance. While, in all familial forms of AD are observed mutations in APP or PS genes 
that result in an increased Aβ production or aggregation, the A accumulation in the 
sporadic form is considered to be more related with a failure in the clearance 
mechanisms (Crews and Masliah, 2010). Indeed, Down’s syndrome patients who 
possess an extra copy of chromosome 21, on which the APP gene resides, also develop 
an AD-like pathology corroborating the idea that overexpression of APP causes familial 
AD (Huang and Mucke, 2012). In turn, an association between Aβ clearance and 
clearance molecules, such as ApoE, show ApoE4 as the less efficient in clearing Aβ, 
reason why is considered as the top sporadic AD gene (Huang and Mucke, 2012; Kim 
et al., 2009; Liu et al., 2013). 
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Figure 1. 2 – Proteolytic cleavage of amyloid precursor protein (APP). APP can be processed by two 
different pathways: the non-amyloidogenic pathway and the amyloidogenic pathway. In the non-
amyloidogenic pathway, APP is first cleaved by α-secretase generating a secreted fragment of APP (sAPPα) 
and a membrane-bound carboxy-terminal fragment of 83 amino acids (C83). Thereafter, C83 is cleaved by 
γ-secretase, giving rise to P3, avoiding amyloid-β (Aβ) generation. In turn, amyloidogenic pathway is started 
by β-secretase producing a sAPPβ fragment and a membrane-bound fragment of 99 amino acids (C99), 
which is cleaved by γ-secretase originating fragments of Aβ peptide with several lengths, which self-
aggregates into Aβ oligomers (Aβo), than into amyloid fibrils (Aβf), and finally are deposited as amyloid 
plaques. These amyloid plaques promote synaptic impairment culminating in neuronal loss. APP intracellular 
domain (AICD) is an end-product in both pathways, which is translocated into the nucleus to regulate gene 
transcription. 
 
The role of Aβ in AD pathogenesis is not completely understood, but it is for long 
assumed that Aβ accumulation is essential for its neurotoxic effects (Walsh and Selkoe, 
2007). As one of the hallmarks of AD is the accumulation of extracellular Aβ, the majority 
of the works have focused on the study of insoluble Aβf, which are the main aggregated 
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constituent of amyloid plaques (Cavallucci et al., 2012). In addition, as insoluble Aβf 
aggregates are neurotoxic both in vitro and in vivo (Walsh et al., 1999),  it has long been 
hypothesized that fibrils represent a primary cause of AD neurodegeneration. 
Nonetheless, the number of plaques and the levels of insoluble Aβf present in AD brains 
have poor correlation with local amplitude of the synaptic loss and neuronal death, as 
well as with disease severity (Bi, 2010; Cavallucci et al., 2012). Furthermore, it was 
reported the presence of a significant amyloid burden in individuals who do not 
demonstrate cognitive impairment (Aizenstein et al., 2008; Pike et al., 2007). On the 
other hand, some studies suggest that the levels of Aβo are really correlated with 
synaptic dysfunction and cognitive impairment (Walsh and Selkoe, 2007). Aβo isolated 
from the brains of patients with AD show a wide range of molecular weight, from less 
than 10 kDa to more than 100 kDa (Bi, 2010). In fact, a high number of different structures 
of Aβo have been reported, being classified as Aβ dimers and trimers, Aβ-derived 
diffusible ligands, globulomers, Aβ*56 (56 kDa) and others (Fandrich et al., 2011; Lesne 
et al., 2006). These diverse soluble oligomeric forms of Aβ were shown to be more toxic 
than the fibrillar species (Tomic et al., 2009), being considered the most synapto-toxic 
ones (Crews and Masliah, 2010). Thus, Aβo are pointed out as the principal players in 
AD onset and neurodegeneration (Cavallucci et al., 2012; Shankar et al., 2008). 
  
Although the classical view is that Aβ is accumulated extracellularly, several 
studies from transgenic mice and human patients points that this peptide can also 
deposit intraneuronally, which may be an early event in the pathogenesis of AD and 
contributory to disease progression (LaFerla et al., 2007). Moreover, intraneuronal Aβ 
immunoreactivity has been observed in the hippocampus and in the entorhinal cortex, 
which are brain regions more connected to the development of early AD pathology, 
preceding Aβ extracellular deposition (Gouras et al., 2000). In addition, it was reported 
that Aβ oligomerization begins intraneuronally (Walsh et al., 2000). Furthermore, studies 
in primary cultures of neurons that overexpressed APP corroborate the production of 
intraneuronal Aβ which induces neuronal apoptosis, and this neurotoxicity seems to be 
related to the formation of intraneuronal aggregates of Aβ1-42 (Nathalie and Jean-Noel, 
2008; Octave, 2005). Besides the release of intracellular Aβ as a result of APP cleavage, 
that can occur in several cellular compartments and be confined to the cell, it can also 
result from the uptake of extracellular Aβ through receptors or transporters, like the 
receptor for advanced glycation end products (RAGE) and the α7 nicotinic acetylcholine 
receptor (α7nAchR) (LaFerla et al., 2007). 
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Interestingly, the formation of Aβo have been considered to be related to early 
and central events in the pathogenesis of AD (Shankar et al., 2008), suggesting that their 
direct effects on neuronal integrity, myelination and synaptic plasticity may be associated 
to memory problems and cognitive impairment (Hardy and Selkoe, 2002). Moreover, 
white matter damage and myelin abnormalities in the brain of AD individuals, supported 
by cytopathological studies (Braak et al., 2000; Kobayashi et al., 2002), suggest the 
participation of oligodendrocytes in the pathogenesis and progression of AD (Roth et al., 
2005). Furthermore, the high levels of Aβ in the white matter of AD patients can damage 
cholesterol rich membranes, such as those present in oligodendrocytes and myelin 
(Roher et al., 2002). Also, it was observed that neurons that are myelinated at the latest 
periods of life are the first to be affected in AD (Braak and Braak, 1996), suggesting that 
the death of myelinating oligodendrocytes represents an important step in the onset of 
disease (Bartzokis et al., 2004). 
 
Nevertheless, one must not forget that the cleavage of APP, and subsequent 
production of Aβ, is a physiological process. This idea is supported by the observation 
that the Aβ peptide is produced in its soluble form under normal conditions during cellular 
metabolism (Cavallucci et al., 2012). In addition, several studies suggest physiological 
properties of Aβ, including neurotrophic and neuroprotective effects, as well as 
stimulation of neural-progenitor proliferation and modulation of synaptic function, mainly 
at low concentrations, which although not allowing the formation of oligomers 
(Chasseigneaux and Allinquant, 2012), may be considered later on a pathological 
condition when the levels of Aβ increase (Cavallucci et al., 2012). 
 
1.2.2. Tau protein 
The presence of intracellular NFTs, constituted mainly by hyperphosphorylated 
tau protein, is another distinct hallmark in AD histopathology (Isik, 2010; Rubio-Perez 
and Morillas-Ruiz, 2012). Tau (τ) is a highly soluble protein, member of the family of 
microtubule-associated proteins (MAPs), synthesized within the neuron, and linearly 
organized in the axon promoting stability and assembly of microtubules. The binding of 
tau to microtubules is controlled by its phosphorylation level. Tau protein has the ability 
to become phosphorylated at multiple sites by several protein kinases (Cdk5, GSk3β, 
MARK and ERK2), which cause changes in its shape and regulates its biological activity, 
modulating the capacity to bind to microtubules and causing microtubule 
depolymerisation (Duan et al., 2012; Simic et al., 2016). In opposite, phosphatases (PP1, 
PP2, PP2B and PP2C) can reduce the phosphorylation of tau protein and restore its 
capacity to bind to microtubules. This balance between kinases and phosphatases 
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activity is interrupted under pathological conditions, on which the increment in the kinase 
activity and the reduction in the phosphatase activity trigger hyperphosphorylation of tau 
protein (Duan et al., 2012). In fact, during AD progression the toxicity of tau, Ao and Af 
could lead to tau-hyperphosphorylation cascade leading to subsequent dissociation from 
microtubules, with a loss of function, and formation of abnormally twisted filaments that 
aggregate into NFTs (Anoop et al., 2010; Kidd, 2008) (Figure 1.3). Commonly, NFTs 
first appear in the entorhinal cortex, spreading to the hippocampus, and then to the 
neocortex (Kidd, 2008). Also excitotoxicity, oxidative stress and inflammation have been 
associated, independently or in combination, to protein misfolding of tau, which 
contribute to an abnormal detachment of tau from microtubules (Duan et al., 2012; 
Kruger and Mandelkow, 2015). Thus, NFTs are thought to be associated with a collapse 
of the microtubule network, disturbances of axoplasmic transports, synapse loss, neuritic 
atrophy, and neuronal death (Octave, 2005). The neuronal death leads to the release of 
intraneuronal tau, in monomeric or aggregated form, into the extraneuronal space, which 
can be neurotoxic and trigger the spreading of tau pathology found in the AD brain 
(Gomez-Ramos et al., 2006). In addition, some studies relate soluble oligomeric species 
of tau protein as being more damaging to proper neuronal function than insoluble 
aggregates (Kruger and Mandelkow, 2015), similarly to what occurs with Aβ. 
 
According to the amyloid cascade hypothesis, excessive production of Aβ is the 
trigger of all other pathological changes, such as gliosis, neuronal death, synaptic 
dysfunction, as well as development of NFTs (Figure 1.3) and dementia in all AD cases 
(Simic et al., 2016). However, neurofibrillary degeneration of abnormally 
hyperphosphorylated tau appears to be required for the clinical expression of the disease 
(dementia). Moreover, while approximately 30% of normal aged individuals have a 
charge of amyloid plaques in the neocortex similar to that found in typical cases of AD, 
in several tauopathies neurofibrillary degeneration of abnormally hyperphosphorylated 
tau without plaques presence is related with dementia. Thus, the tau role in 
neurodegenerative process is also supported by the correlation of NFTs and the AD 
onset and progression (Gong et al., 2010). Several studies suggest that Aβ may drive 
tau pathology, while tau can mediate Aβ neurotoxicity, pointing out a partnership 
between Aβ and tau in AD pathology (Duan et al., 2012). However, it has not yet been 
fully elucidated how these two abnormal protein aggregates (Aβ and NFTs) are related 
in AD pathogenesis (Nicholson and Ferreira, 2009). 
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Figure 1. 3 – Tau-mediated neurodegeneration. Tau protein binds to microtubules providing microtubule 
stability. In pathological conditions, toxic Aβ oligomers (Aβo) and amyloid fibrils (Aβf) may deposit as amyloid 
plaques triggering the cascade of tau-hyperphosphorylation due to the increase in kinase activity. Upon 
hyperphosphorylation tau dissociates from microtubules, causing microtubule disintegration, and aggregates 
into neurofibrillary tangles (NFTs) within neurons. This can promote cytoskeleton destabilization, impaired 
normal axonal transport, synaptic dysfunction and neuronal death. 
 
1.2.3. Neuronal cell death 
It is well known that AD develops after a progressive death of many neuronal 
cells (neurodegeneration) across large areas of the brain. Over time, as more and more 
neurons die, both signs and symptoms related with disease become worse (Johnstone 
et al., 2016). In fact, a massive loss of hippocampal neurons is suggested as a 
pathological basis for irreversible cognitive commitment in AD patients (Xu et al., 2016). 
However, the underlying causes and mechanisms of neuronal cell death are not fully 
understood. 
Several different hypotheses have been advocated as a cause of 
neurodegeneration. One of them, previously mentioned in section 1.2.2., is the amyloid 
cascade hypothesis, which proposes the accumulation of Aβ in the brain as the primary 
driver to NFTs formation and subsequent neuronal death (Hardy and Selkoe, 2002). An 
alternative hypothesis suggests that the breakdown of cerebral capillaries as a 
consequence of ageing causes microvascular hemorrhages, which in turn lead to 
plaques deposition, NFTs formation, and subsequent neuronal death (Stone, 2008). 
Another hypothesis is that mitochondrial dysfunction is a major contributor to neuronal 
death. Mitochondria is considered to have a critical role in brain metabolism, the third 
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most energy-expensive organ in the human body, controlling cell life and death not only 
as the energy-generating organelles, but also producing potentially toxic reactive oxygen 
species (ROS) and replenishing proteins that regulate the intrinsic apoptotic pathway 
(Onyango and Khan, 2006). In fact, 95% of the cell energy supply is produced in 
mitochondria  (Bonda et al., 2010), being, however, also the major source of ROS 
generation in the generality of cells (Kim et al., 2015). Indeed, mitochondria generate 
more than 90% of the cell endogenous oxidant species (Ames et al., 2002). Thus, 
alterations in the physiological function of mitochondria decrease their efficacy, leading 
to an increase in ROS production that triggers oxidative stress, which promotes 
disturbance of cell function, sensitizes cells to neurotoxic insults and leads to subsequent 
neuronal death (Johnstone et al., 2016). 
In addition, the age-induced mitochondrial cascade of neurodegenerative events 
suggests that mitochondrial dysfunction accompanies ageing, and plays an important 
role in the AD pathogenesis (Bonda et al., 2010; Cavallucci et al., 2012). Indeed, it seems 
to be transversal to all AD stages and to worsen with disease progression (Maruszak 
and Zekanowski, 2011).  
Interestingly, some studies in postmortem brains from AD patients, as well as in 
transgenic AD mice, and in cell lines expressing mutant APP and/or cells treated with 
Aβ, suggest that oxidative damage induced by Aβ is related with disturbed mitochondrial 
metabolism in AD development and progression (Manczak et al., 2006; Reddy and Beal, 
2008; Spuch et al., 2012). The presence of Aβ within mitochondria provide a direct 
association between Aβ deposition and mitochondrial dysfunction due to the impair of 
mitochondrial respiratory function, increase of ROS generation, and change of 
mitochondrial membrane potentials, which are involved in neuronal metabolic 
dysfunction in AD (Cavallucci et al., 2012; Kim et al., 2015). It is also relevant to note 
that ROS produced by mitochondrial dysfunction seem to trigger amyloidogenic APP-
processing, probably by BACE1-activated induction, leading to a vicious cycle that 
contributes to AD pathogenesis (Leuner et al., 2012). In addition, mitochondria-derived 
ROS can promote increased mitochondrial outer membrane permeability and 
cytochrome c (Cyt c) release into the cytosol, which can induce the apoptosome 
formation and the subsequent caspases activation (Cavallucci et al., 2012). Evidence 
also suggests that Aβ accumulation within neuronal cytoplasm impairs mitochondrial 
function, leading to energetic failure and generation of ROS, which determine functional 
neuronal impairment and subsequent neuronal death (Kidd, 2008). 
Indeed, a large number of experimental and postmortem findings suggest a close 
relationship between AD and increased oxidative stress levels in the brain (Cervellati et 
al., 2016; Silva et al., 2012). Oxidative stress may result from an imbalance between 
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redox states, involving either excessive production of ROS, or dysfunction of the 
antioxidant system (Kim et al., 2015). Under healthy conditions, ROS are rapidly cleared 
to increasingly less reactive species by the enzymes catalase, glutathione peroxidase, 
and superoxide dismutase (SOD) 1 and 2 (Silva et al., 2012). However, when an 
excessive ROS production occurs, the endogenous reserves of antioxidants are not 
sufficient to counteract such generation, leading to oxidative cell damage (Silva et al., 
2012). 
Several studies suggest that levels of oxidative markers are directly correlated 
with the severity of cognitive impairment, as well as to symptomatic AD progression 
(Silva et al., 2012), which highlight that oxidative stress plays a key role in AD 
pathophysiology (Kim et al., 2015) and is an early manifestation of AD (Silva et al., 2012). 
In fact, oxidative markers generally precede all of those related with typical hallmarks of 
AD, like Aβ aggregation and NFTs formation, pointing their relevance as primary 
generators of AD pathology. Evidences demonstrate that Aβ secretion, as well as tau 
hyperphosphorylation and NFTs formation, initially occur as an antioxidant response to 
augmented ROS (Bonda et al., 2010). Thus, a chronic oxidative stress situation 
promotes Aβ production (Kim et al., 2015), which may induce the hallmark pathologies 
of AD, and intensifies the cascade of events that leads to neurodegeneration (Bonda et 
al., 2010). In addition, AD transgenic mouse models have shown that Aβ may be 
responsible for the production of hydrogen peroxide (H2O2), and peroxidation of lipids 
and proteins, implying that Aβ may enhance oxidative stress during AD progression (Kim 
et al., 2015). 
The cause of AD is still unknown, but increasing evidences suggest that 
mitochondria play an important role in the oxidative stress process that underlies this 
disease, contributing to neurodegeneration (Bonda et al., 2010; Cassano et al., 2016). 
In addition, studies suggest that glial cells, like microglia and astrocytes, which release 
inflammatory cytokines and ROS, among other factors, contribute to neuronal damage 
(Lynch et al., 2010). 
It is important to highlight that most likely all the hypotheses previously mentioned 
play some role in AD progression and that none of them are unique (Stone et al., 2015). 
 
1.2.4. Neuroinflammation 
Neuroinflammation is a feature frequently observed in postmortem brains of AD 
patients (Wu et al., 2015), particularly localized in brain areas exhibiting high pathological 
markers (Krause and Muller, 2010), thus corroborating its involvement in the disease 
(Janssen et al., 2015). The term neuroinflammation refers to an inflammation of the 
nervous tissue, as an intrinsic cellular response in the central nervous system (CNS) to 
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several stimuli, that may include infection, head injury, toxic metabolites, or 
autoimmunity, all of them contributing to AD progression (Pasqualetti et al., 2015; 
Peixoto et al., 2015) with degeneration of cholinergic neurons and memory impairment 
(Skok and Lykhmus, 2016). However, it is often accepted that neuroinflammation can 
have both beneficial and detrimental effects on neurons (Agostinho et al., 2010). While 
an acute neuroinflammatory response is beneficial to the CNS, since it promotes the 
repair of damaged tissue, a continued chronic neuroinflammation after an initial toxic 
stimulus may originate degenerative alterations in neurons leading to brain dysfunction 
(Eikelenboom et al., 2010; Lucas et al., 2006), and microglia senescence (Njie et al., 
2012). In fact, studies in transgenic mouse models have showed that neuroinflammation 
has a diversified role in amyloid plaques and NFTs progression (Sudduth et al., 2013). 
Curiously, Colton and colleagues revealed that brains of mice with amyloid accumulation, 
and human AD tissue, express not only classical inflammatory genes, but also additional 
inflammatory markers (Colton et al., 2006), known to be important in damage repair 
(Sudduth et al., 2013). In addition, Sudduth and colleagues found remarkable 
heterogeneity of microglia polarization towards either the M1 or M2 inflammatory 
phenotype in early-stage of AD patients (Sudduth et al., 2013). Nevertheless, 
neuroinflammation is not exclusively associated with AD. In fact, healthy brains of aged 
individuals show inflammatory-related markers, which are even more increased during 
AD pathology. In addition, lower levels of inflammatory markers are found in individuals 
that exhibit Aβ and tau aggregates at levels identical to AD patients, but lacking a clinical 
presentation of dementia, reinforcing the idea that inflammation is required or associated 
to AD clinical symptoms (Krause and Muller, 2010). 
Neuroinflammation seems to start early during AD (Parachikova et al., 2007; Xu 
et al., 2014), which is always accompanied by an exacerbated activation of many 
inflammatory pathways (Najem et al., 2014; Streit et al., 2014). Besides the abnormal 
accumulation of Aβ and tau protein (Echeverria et al., 2016), also includes the production 
of inflammatory mediators by resident CNS cells (pro-inflammatory cytokines, 
prostaglandins, free radicals and complement system), which in turn induce chemokines 
and adhesion molecules, recruit immune cells, and activate glial cells (Lucas et al., 
2006). Indeed, gliosis, a prominent neuropathological feature, is observed in the brains 
of AD patients (Osborn et al., 2016), since an elevated number of activated astrocytes 
(astrogliosis) and microglia (microgliosis) are usually found in the proximity of neurons 
and amyloid plaques (Rubio-Perez and Morillas-Ruiz, 2012). Both astrocytes and 
microglia play several protective roles that contribute to neuronal homeostasis in the 
healthy brain. However, these activated glial cells may have both beneficial and 
detrimental effects. On the one hand, glial activation is an endogenous defensive 
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mechanism against plaque deposition, while on the other hand, the continued activation 
and associated inflammatory status may contribute to AD progression (Osborn et al., 
2016). Thus, any change in their functions has repercussions on neuronal function 
leading consequently to cognitive impairments (Lynch et al., 2010; Osborn et al., 2016). 
In fact, astrocytes and microglia activation by Aβ deposition triggers neuroinflammatory 
processes by the production of several pro-inflammatory cytokines, among other signal 
molecules, promoting excitotoxicity and neurodegeneration (Lopategui Cabezas et al., 
2012; Wyss-Coray, 2006; Wyss-Coray and Rogers, 2012), reason why they are part of 
the inflammatory components associated to neuroinflammation in AD (Rubio-Perez and 
Morillas-Ruiz, 2012). 
Microglia were shown to alter their morphologic phenotype and produce several 
pro-inflammatory cytokines and mediators in response to Aβ (Manocha et al., 2015), 
which in turn activate astrocytes. In fact, astrocytes become highly reactive in response 
to any insult to the CNS, often stimulated by inflammatory cytokines (Eng et al., 2000). 
This astrogliosis is characterized by alterations in the cytoskeleton and morphological 
changes (hypertrophy) (Osborn et al., 2016), cell proliferation, and is associated with 
increased expression of glial fibrillary acidic protein (GFAP) (Eng et al., 2000). In 
addition, astrocytes appear to surround and isolate dying neurons, after neuronal 
damage (Lynch et al., 2010). Activated astrocytes in AD are part of the inflammatory 
process when they start to secrete the pro-inflammatory cytokines interleukin(IL)-1 and 
tumor necrosis factor(TNF)-α (Heneka et al., 2010). In addition, activated microglial cells 
become also a source of TNF-α, IL-1β, IL-1α, as well as superoxide, nitric oxide (NO), 
chemokines, and glutamate, which can promote neuronal death and contribute to onset 
and progression of AD (Block et al., 2007; Mizuno, 2012; Peixoto et al., 2015). Also, 
overexpression of astrocytic S100B induced by Aβo has a detrimental impact on 
neuronal survival and may further exacerbate the activation and migration of microglia 
(Bianchi et al., 2011; Mori et al., 2010). Furthermore, some of these inflammatory 
mediators associated to Aβ accumulation and tau phosphorylation, further activate glial 
cells, triggering a vicious neuroinflammatory cycle that contributes to the chronic 
inflammatory scenario observed in AD (Osborn et al., 2016), causing additional neuronal 
death. 
Interestingly, it was suggested that age-dependent neuroinflammatory changes 
may play a significant role in the decreased neurogenesis and cognitive impairments in 
AD (Lynch et al., 2010; Varnum and Ikezu, 2012), while in late phases of AD is suggested 
that inflammation disappears (Wojtera et al., 2012). In fact, a recent study showed that 
AD has a transcriptional signature that is related to a metastable subproteome at risk of 
aggregation (Ciryam et al., 2016). Ciryam and colleagues found a global downregulation 
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in the expression of the genes that encode proteins that are metastable to aggregation, 
which is associated with the transcriptional response to AD (Ciryam et al., 2016). 
Moreover, many of the inflammatory processes observed in AD patients are similar to 
those present in the periphery, which are considered cytotoxic, and therefore have 
cytotoxic effects in the brain (Krause and Muller, 2010). In fact, AD patients who suffer a 
short-term peripheral infection manifest an abrupt cognitive decline, rarely achieving a 
full recovery, even after eliminating the infection (Perry et al., 2007). Indeed, treatment 
with nonsteroidal anti-inflammatory drugs (NSAIDs) have failed until now as protective 
against AD, unless the use is initiated in a very early stage of AD (Zou et al., 2016), to 
prevent disease progression (Krause and Muller, 2010; Varvel et al., 2009). 
 
 Diagnosis and treatment 
The typical Alzheimer’s symptom pattern begins with a subtle decline in short-
term memory followed by a more general decline in overall cognitive abilities (Osborn et 
al., 2016), making AD one of the most significant healthcare problems nowadays 
(Bredesen, 2016). However, it is difficult to establish an accurate diagnosis of AD due to 
the frequent existence of co-morbidities in older people, which can also contribute to 
cognitive impairment (Alves et al., 2012). In addition, effective control of AD seems 
difficult to achieve because, in addition to having a relentless progression, AD diagnosis 
can only be performed on a stage already quite advanced of neurodegeneration (Kidd, 
2008). In fact, the clinical diagnosis of AD can achieve an accuracy rate of 95% when 
realized by highly experienced clinicians (Alves et al., 2012), but a definitive diagnosis of 
AD is actually based on clinical and pathological hallmarks, as amyloid plaques and 
neurofibrillary tangles (Rubio-Perez and Morillas-Ruiz, 2012; Varvel et al., 2009), 
although it is now possible to identify the formation of amyloid plaques in patients using 
the Pittsburgh Compound-B (PiB)-PET imaging, as it will discussed below (Cohen et al., 
2012). Since these hallmarks are definitively identified at autopsy, the Alzheimer’s 
diagnosis is usually based on exclusion criteria (Kidd, 2008). So, there is a need for a 
non-invasive, cheap and validated test to diagnose early AD, as diagnosis may allow 
immediate treatment and service planning (Fletcher et al., 2013). 
The most widely accepted diagnostic criteria for AD was developed by the 
National Institute of Neurological and Communicative Disorders and Stroke - Alzheimer’s 
Disease and Related Disorders Association (NINCDS-ADRDA) joint-working group in 
1984, lately reviewed in 2011 by expert panels convened by the National Institute of 
Aging and the Alzheimer’s Association (NIA/AA) (Ihara, 2016; McKhann et al., 2011). 
The diagnostic criteria established the definition of pre-clinical stages of AD (or pre-
symptomatic phase) (Sperling et al., 2011), the diagnosis of a symptomatic or pre-
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dementia phase (or MCI – mild cognitive impairment) (Albert et al., 2011), and the 
diagnosis of dementia phase (McKhann et al., 2011), and incorporated some biomarkers 
information used in research proposes to improve diagnosis (Alves et al., 2012; 
McKhann et al., 2011). 
These biomarkers are physiological, biochemical, or anatomic parameters which 
can be objectively measured in vivo and reflect particular characteristics of disease-
related pathophysiological processes, as well as normal biological processes, or 
responses to a therapeutic treatment (Jack et al., 2011; Jack and Holtzman, 2013). It is 
well known that both Aβ deposition and elevated phosphorylated tau are hallmarks of 
AD. As the deposition of Aβ seems to be more specific than changes in tau, the 
biomarkers were divided into two major categories. The first group includes biomarkers 
reflecting Aβ deposition in the brain, comprising both positive positron emission 
tomography (PET) amyloid imaging and low cerebrospinal fluid (CSF) Aβ1-42. The second 
set is constituted by those related to neuronal degeneration or injury: elevated CFS tau, 
as well as both total and phosphorylated tau; decreased 18fluorodeoxyglucose (FDG) 
uptake on PET in the temporo-parietal cortex; and atrophy on structural magnetic 
resonance imaging (MRI) in medial, basal and lateral temporal lobe, and medial and 
lateral parietal cortices (Jack et al., 2011; McKhann et al., 2011). Recently, it was 
reported that the most commonly used biomarker is MRI, followed by CSF, FDG, and 
amyloid-PET (Bocchetta et al., 2015), and the combination of amyloid and neuronal 
damaged biomarkers provides the most accurate prognosis of AD (Bocchetta et al., 
2015; Vos et al., 2015). Beyond these, other promising biomarkers under research are 
the level of isoprostanes, which are markers of oxidative stress (Montine et al., 2011), 
and β-secretase (BACE1) in CFS (Zhong et al., 2007). Moreover, studies showed that a 
dysregulation of iron metabolism contribute to AD pathophysiology due to increased 
oxidative stress (Crespo et al., 2014; Guerreiro et al., 2015). Additionally, also ApoE 
gene, a well-known risk factor for AD, was identified as significantly related with this 
disease (Crespo et al., 2014). 
Recently, it was suggested the usefulness of small extracellular vesicles, named 
exosomes, as biomarkers in the diagnosis of neurodegenerative diseases, including AD 
(Vella et al., 2016). It is possible that exosomes containing Aβ are released from neurons 
to clear and regulate increased levels of intracellular Aβ, which can be transferred into 
microglial cells and contribute to Aβ degradation (Yuyama et al., 2012), suggesting that 
exosomes may have a protective role in the brain of AD patients (An et al., 2013). Recent 
studies suggest that exosomes, which are generally isolated from extracellular fluid, can 
be extracted from brain tissue (Dinkins et al., 2014; Perez-Gonzalez et al., 2012). Indeed, 
exosomes can be isolated from extracellular fluids like CFS (Street et al., 2012; Vella et 
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al., 2008), blood (Cheng et al., 2014b) and urine (Cheng et al., 2013), suggesting its 
utility as peripheral non-invasive biomarker for AD (Vella et al., 2016). In fact, it was 
found CSF exosomes containing Aβ (Yuyama et al., 2014; Yuyama et al., 2015), and 
elevated total tau and Aβ1-42 were detected in derived blood exosomes of AD patients 
(Fiandaca et al., 2014). Though plasma, serum and urine-based biomarkers have been 
studied, none of them showed a diagnostic accuracy as CSF biomarkers for AD (Anoop 
et al., 2010; Demarin et al., 2011). In addition, exosomes were found to be enriched with 
microRNA (miRNA) species (Gallo et al., 2012), which were differentially expressed in 
exosomes of AD patients and directly related with other methods of diagnosis (Cheng et 
al., 2014a), suggesting the use of exosomal miRNA as a complementary tool with other 
biomarkers to diagnose AD (Vella et al., 2016). Although it is believed that biomarkers 
will enable to improve diagnosis, and ultimately to provide an effective therapy (Jack et 
al., 2011), mainly at early AD stages, they are not yet ready for trials of clinical utility in 
primary care (Fletcher et al., 2013), and more studies are need to overcome their 
deficient standardization and their limited access (McKhann et al., 2011). 
Beyond a deficient characterization of accurate biomarkers, the available 
pharmacological treatments are not cost-effective (Cacabelos et al., 2016). In addition, 
there are very few options in conventional medicine to treat AD (Kidd, 2008), although, 
for the past 20 years, several studies have been performed with more than 1000 different 
compounds in view of their use as potential candidate drugs for AD treatment. These 
candidate compounds can be classified according to their pharmacological properties 
and/or the AD-related pathway they target to avoid disease progression (Cacabelos et 
al., 2016). The Food and Drug Administration (FDA)-approved drugs for AD include 
acetylcholinesterase inhibitors (AChEIs), such as galantamine, donepezil and 
rivastigmine, which are prescribed to treat mild to moderate AD, and the N-methyl-D-
aspartate (NMDA) antagonist memantine, which is prescribed to treat moderate to 
severe AD (Alves et al., 2012; Raina et al., 2008). AChEIs inhibit the degradation of 
acetylcholine, the major neurotransmitter related with attention and memory, slowing the 
rate of cognitive decline, while NMDA antagonist prevent neurotoxicity in the brain by 
reducing excessive glutamate activation (Nelson and Tabet, 2015; Parsons et al., 2013). 
However, although these pharmaceutical drugs show to delay some symptom evolution, 
they cannot stop AD progression (Echeverria et al., 2016; Khairallah and Kassem, 2011). 
Lamentably, though these limitations these drugs are the only available therapies, 
because all other new drugs tested until now failed to improve cognitive abilities in phase 
3 clinical trials (Echeverria et al., 2016). Thus, several studies are being made in an 
attempt to develop new effective treatments for AD. 
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A candidate strategy to AD treatment are novel cholinergic agents including direct 
and allosteric muscarinic acetylcholine receptor agonists and also agonists of some 
subtypes of nicotinic receptors (Alves et al., 2012), the latter having been reported to be 
decreased in AD brains. Indeed, modulators of α7nAChRs, such as nicotine and some 
of its derivatives, can decrease the abnormal activation of microglia and diminish 
neuroinflammation, abnormal protein aggregation and synaptic dysfunction, because of 
their anti-inflammatory, anti-apoptotic, anti-protein aggregation and pro-cognitive effects. 
Nonetheless, the fact that the α7nAChRs are rapidly desensitized, they regarded as a 
constraining factor to their potential therapeutic use (Echeverria et al., 2016). 
The suggested correlation between neuroinflammation and AD (Janssen et al., 
2015), lead to several epidemiological studies of NSAIDs showing their anti-inflammatory 
effect in AD (McGeer et al., 2006). However, so far, these drugs revealed limited benefits 
and to be an ineffective treatment in clinical trials (Echeverria et al., 2016; McGeer et al., 
2006). Indeed, treatment with NSAIDs has failed until now as protective against AD, 
unless the use is initiated as early as possible to prevent disease progression (Krause 
and Muller, 2010; Varvel et al., 2009). This probably occurs due to the previous 
deterioration in cognitive function in AD patients prior to medication, or to several 
pathways other than cyclooxygenase-dependent activity target by NSAIDs (Ryu et al., 
2015). A recent analysis of clinical trials studying the effectiveness of the NSAIDs 
diclofenac/misoprostol, nimesulide, naproxen, rofecoxib/ibuprofen, indomethacin, 
tarenflurbil, and celecoxib, showed no clinical significance of the treatment with these 
drugs when compared with placebo in AD progression, which has been attributed to the 
dose and its administration at advanced stages of the disease (Miguel-Alvarez et al., 
2015). 
Also immunotherapy has been suggested for AD treatment (Villoslada et al., 
2008), as a therapeutic approach to clear Aβ aggregates, and/or tau 
hyperphosphorylated in AD brains, by the use of antibodies against these proteins. In 
fact, active immunization with Aβ vaccines reduced amyloid aggregates, as well as 
memory and learning deficits in animal models. However, it can induce undesired 
adverse autoimmune responses that can be fatal (Alves et al., 2012; Echeverria et al., 
2016). New attempts have been made to find safe approaches such as the passive 
immunizations with antibodies targeting different regions of the Aβ peptide, which are 
actually in various stages of clinical trials. However, some of the monoclonal antibodies 
used may damage the cerebral vasculature already affected by Aβ accumulation 
(Echeverria et al., 2016). In addition, also immunization to target tau pathology allowed 
tau clearance and improved cognitive deficits in a tau transgenic model, but again it can 
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be deleterious if targeting non-phosphorylated tau since it is a normal neuronal 
component (Rosenmann et al., 2006; Troquier et al., 2012). 
Some drugs designed to reduce Aβ production by inhibiting β- or γ-secretase, 
blocking calcium channel, or stimulating α-secretase, as well as preventing Aβ 
aggregation, have also been tested, but they did not show global clinical benefits (Alves 
et al., 2012). Although most of the treatments have A as the main target, drugs aiming 
at inhibiting tau hyperphosphorylation, tau oligomerization or at promoting 
hyperphosphorylated tau degradation, were investigated (Jiang et al., 2012b). Recently, 
oral administration of the naturally occurring monoterpene linalool to the triple transgenic 
model of AD (3xTg-AD) mice reversed the histopathological hallmarks of AD and 
restored cognitive functions via an anti-inflammatory effect, pointing to a potential AD 
prevention candidate for preclinical trials (Sabogal-Guaqueta et al., 2016). In addition, 
light in the near infrared range is emerging as a safe and effective therapy with the ability 
to stop neuronal death, which is a feature of AD (Johnstone et al., 2016). Various other 
strategies are under research, such as mitochondria-targeted antioxidants to inhibit 
mitochondrial dysfunction and oxidative stress (Isaev et al., 2015), pharmacological 
modulation of the receptor CXCR2 to inhibit receptor-mediated inflammatory reactivity 
(Ryu et al., 2015), inhibitors of specific nuclear factor of activated T cells (NFAT) 
expressed by microglial cells to attenuate microgliosis and Aβ plaque deposition 
(Rojanathammanee et al., 2015), and tyrosine kinase inhibition to reduce microgliosis 
(Dhawan and Combs, 2012). 
Evidence so far indicates that therapies targeting a single hallmark of AD show 
limited efficacy in reducing disease progression. Probably, drugs alone or in combination, 
that are able to target more than one aspect of AD pathology, including the cholinergic 
deficit, neuroinflammation, and neuronal loss, as well as Aβ and tau abnormal 
aggregation, may have more chance of success in decreasing the negative side effects 
of neuroinflammation while maintaining its beneficial effects (Echeverria et al., 2016). 
 
  
2. Microglia involvement in AD 
Increasing evidences suggest the influence of microglial activation in AD 
pathology, being Aβ hypothetically responsible for this activation that leads to a pro-
inflammatory response by microglia, thereby contributing to disease progression 
(Dhawan and Combs, 2012; Rojanathammanee et al., 2015). 
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 Microglia origin and functions 
Microglia are one of the three glial cells (together with oligodendrocytes and 
astrocytes) found in the CNS (Krause and Muller, 2010), and have been first mentioned 
by Pio del Rio-Hortega (del Rio-Hortega, 1993), constituting around 10% of the total brain 
cell population (Echeverria et al., 2016; Rubio-Perez and Morillas-Ruiz, 2012). Although 
microglia cells are distributed ubiquitously throughout the normal CNS, in both grey and 
white matter, their density is higher in the hippocampus, substancia nigra, olfactory 
telencephalon, and basal ganglia (Lawson et al., 1990; Tambuyzer et al., 2009). Despite 
some controversy about the origin of microglial cells, the general consensus is that 
microglia have hematopoietic origin, being derived from myeloid precursor cells from yolk 
sac that migrate into the brain during embryogenesis (Ginhoux et al., 2013; Greter and 
Merad, 2013). 
In the normal brain, and under normal conditions, microglial cells display a highly 
branched and ramified morphology, with a small body and long, thin processes with 
dynamic protrusions to constantly survey the surrounding environment (Kettenmann et 
al., 2013; Nimmerjahn et al., 2005). Each cell seems to occupy a defined territory, not 
overlapping with neighbouring microglial cells (Kettenmann et al., 2011). In addition, 
although microglia are regarded as long-lived cells, microglia homeostasis may be 
maintained by local self-renewal under physiological conditions (Ajami et al., 2007; 
Greter and Merad, 2013). 
Microglia exhibit some properties of macrophages as part of the mononuclear 
phagocyte lineage (Vilhardt, 2005), and, in fact, they are considered the resident 
immunocompetent and phagocytic cells in the CNS, as they act as the innate immune 
brain system (Aloisi, 2001; Streit, 2002). However, more recent studies show that, at 
resting conditions, microglia differ from macrophages since they express much lower 
levels of cluster of differentiation protein(CD)45, being the only available way to 
distinguish them phenotypically (Greter and Merad, 2013). Healthy brain microglia act 
as sentinels and change their phenotype in response to any homeostatic disturbance, 
such as pathogenic invasion or tissue damage (Davalos et al., 2005; Nimmerjahn et al., 
2005), migrating to the local of injury (Rubio-Perez and Morillas-Ruiz, 2012). Some of 
the markers commonly used to evaluate microglial reactivity are the β-integrin CD11b, 
also known as complement receptor(CR)-3, and the ionized calcium-binding adaptor 
molecule 1 (Iba1) protein, which are upregulated in activated microglia (Ito et al., 2001; 
Kim and de Vellis, 2005; Roy et al., 2006). 
Similar to macrophages, in order to detect potential insults that disturb CNS 
homeostasis, microglia express several different surface receptors, including major 
histocompatibility complex class II (MHC class II) antigens and T-cell costimulatory 
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molecules, such as CD40, CD80 and CD86 (Ransohoff and Perry, 2009). In addition, 
microglia can also express neurotransmitter receptors and pattern recognition receptors 
(PRRs), such as toll-like receptors (TLRs), or nucleotide-binding oligomerization domain 
(NOD)-like receptors (NLRs), that recognize danger-associated molecular patterns 
(DAMPs) and pathogen-associated molecular patterns (PAMPs) (Greter and Merad, 
2013; Heneka et al., 2015; Kettenmann et al., 2011). After recognition of a DAMP or a 
PAMP, the microglial activation occurs intending to remove the detected abnormality or 
pathological change (Heneka et al., 2015), which leads to a change of their ramified 
morphology to an amoeboid shape (Kettenmann et al., 2011). Indeed, microglia are 
constantly surveilling, with small cell bodies and long, thin processes, changing to an 
activated state upon a stress-stimulus, with a phagocytic morphology (amoeboid) and 
shifting from long to short processes presentation (Zlokovic, 2008). By phagocytosis, 
microglia can remove cellular debris, damaged cells, unwanted protein aggregates, or 
pathogens, from CNS (Becher et al., 2000; von Bernhardi, 2010), and support tissue 
repair and remodelling (Ginhoux et al., 2013). However, TLR-induced microglia 
activation promotes the upregulation of MHC class II (Olson and Miller, 2004), having 
these activated microglia an important role in onset and progression of 
neurodegenerative diseases, as AD, by the release of potentially cytotoxic molecules, 
like pro-inflammatory cytokines, ROS and inducible nitric oxide synthase (iNOS) (Block 
et al., 2007; Greter and Merad, 2013; Kettenmann et al., 2013). These features suggest 
that their phagocytic function can be beneficial while their inflammation-related functions 
may be detrimental (Krause and Muller, 2010). 
In addition to their immune functions, emerging results demonstrated the role of 
microglia in controlling neuronal proliferation and differentiation, as well as in formation 
of synaptic connections (Graeber, 2010; Hughes, 2012), as well as in modification and 
removal of synaptic structures (Tremblay et al., 2010). Thus, microglia, besides the 
immune role, have distinct gene expression signatures highlighting functions exclusively 
adapted to the CNS, such as synaptic modulation and neurotrophic support (Wes et al., 
2016), promoting the defence and the maintenance of the CNS (Ginhoux et al., 2013). 
 
 Microglia activation in AD 
Microglia can present at least five clearly recognizable stages in the adult CNS: 
the surveilling or ramified microglia, which move dynamically and are distributed 
ubiquitously throughout the normal and nonpathological CNS; the activated or reactive 
microglia, which appear in pathological conditions, although not always phagocytic but 
hypertrophic with wide processes; the phagocytic microglia, which occur as amoeboid 
brain macrophages; the rod-shaped microglia with a narrow cell boby and few planar 
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processes; and the dystrophic microglia, which are senescent cells with spheroidal or 
fragmented processes (Bachstetter et al., 2015). In fact, microglia are active sensors in 
the brain that rapidly switch to an adequate functional activity state in response to a 
variety of stimuli in order to restore microenvironment homeostasis (Figure 1.4). This 
microglial activation depends on the stimuli to which the cells are exposed and can 
explain why engagement of microglia can be either neuroprotective or neurotoxic, 
resulting in a delay or worsening of disease progression (Hanisch and Kettenmann, 
2007; Schwartz et al., 2006). In what concerns AD, it has been indicated that microglia 
may be activated by oligomeric and fibrillar species of Aβ and by molecules derived from 
degenerated neurons (Mizuno, 2012). 
 The terms resting or quiescent to define the behaviour of microglia in the healthy 
brain do not reflect what really occurs. It suggests a kind of inactivity that is not 
compatible with the constant movement of ramified microglial processes used to 
dynamically monitor the microenvironment, always in a surveilling state to maintain 
homeostasis (Gomez-Nicola and Perry, 2015; Kettenmann et al., 2011; Nimmerjahn et 
al., 2005). In contrast, reactive or activated microglia can acquire diverse and complex 
altered morphologies/phenotypes, including hypertrophic cell morphology with enlarged 
processes or amoeboid morphology, enabling their participation in the cytotoxic 
response, immune regulation and damage resolution (Chhor et al., 2013; Gemma and 
Bachstetter, 2013). Interestingly, a recent study showed a high heterogeneity in microglia 
morphology in the human brain, which is usually underestimated since this diversity is 
scarcely seen in animal models (Bachstetter et al., 2015). In addition, a large part of 
ramified microglia observed in the healthy brains, become dystrophic with AD 
progression, although microglial morphology diversity still remains (Bachstetter et al., 
2015). 
Regarding activation, and depending on the stimulus and the level of activation, 
microglia were categorized into different phenotypes (Figure 1.4), being the M1 and M2 
subtypes the ones most often appointed (Brites and Vaz, 2014). The M1 phenotype, also 
known as classically activated, is induced by pro-inflammatory mediators, such as 
lipopolysaccharide (LPS) and interferon(IFN)-γ (Czeh et al., 2011). Although initially 
intending to protect and repair the CNS, the cell also display cytotoxic properties (Cherry 
et al., 2014; Chhor et al., 2013), by overproduction of mediators to kill the pathogenic 
agent, namely pro-inflammatory cytokines, such as TNF-α, IL-1β, IL-6 and IL-12, and 
several chemokines, proteases, redox proteins, ROS, and iNOS, that uses arginine to 
produce NO (Boche et al., 2013; Cherry et al., 2014; Colton, 2009; Kraft and Harry, 
2011). The M2 phenotype, or the alternatively activated state, is related with inhibition of 
inflammation and homeostasis recovery (Brites and Fernandes, 2015), by production of 
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anti-inflammatory cytokines, like IL-4, IL-13, IL-10 and transforming growth factor(TGF)-
β (Colton, 2009). In addition, the M2 phenotype may be subdivided into different 
subtypes, including M2a, with an alternate activation associated with the dampen of 
inflammation by production of anti-inflammatory cytokines and neurotrophic factors 
(Chhor et al., 2013; Colton, 2009; Kraft and Harry, 2011); M2b is considered to be both 
pro- and anti-inflammatory, i.e., to show combined M1/M2a subtypes (Brites et al., 2015); 
and M2c, or acquired-deactivating phenotype, related with phagocytosis and 
suppression of the innate immune system (Brites and Vaz, 2014; Chhor et al., 2013). 
This phenotype downregulates innate immune responses and show a distinct gene 
profile. Acquired deactivation is distinguished from alternative activation by the induction 
agents. While alternative activation is induced by IL-4 or IL-13, acquired deactivation is 
produced by inducing agents such as TGF-β, IL-10 and apoptotic cells, leading to the 
suppression of MHC class II antigens, inhibition of the production of pro-inflammatory 
cytokines, increase of the expression of scavenger receptors (SRs), increase of neural 
growth factor (NGF) levels, as well as of IL-10 and TGF-β production, both anti-
inflammatory cytokines (Colton, 2009; De Simone et al., 2004; Minghetti et al., 2005; 
Minghetti and Pocchiari, 2007). Nonetheless, one should be careful in considering that 
the M2 phenotype is always beneficial, since it was pointed as corresponding to a 
deactivated, irresponsive population (Chakrabarty et al., 2012), and both M2a and M2c 
microglia were shown to be implicated in AD progression in the APP/PS1 transgenic 
mice (Weekman et al., 2014). Really, it is believed to be too simplistic to consider 
microglial cells either as beneficial or detrimental, since microglia are able to switch 
between these phenotypes and may occur in several intermediate states (Brites and 
Fernandes, 2015). Other M2 markers often used are the enzyme arginase 1 which 
competes with iNOS for substrates, the chitinase 3-like protein 3 (Ym1), a heparin-
binding lectin, which prevent degradation of extracellular matrix compounds, and the 
protein found in inflammatory zone 1 (FIZZ1) which promotes extracellular matrix 
deposition (Cherry et al., 2014; Raes et al., 2002). In addition, in the context of 
immunoregulatory characteristics, M1 microglia phenotype express higher levels of MHC 
class II, CD80, CD86 and chemokine receptor CCR7, while M2 microglia is associated 
with upregulated levels of CD209 (DC-SIGN) (Cherry et al., 2014; Durafourt et al., 2012). 
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Figure 1. 4 – Microglia activation states/phenotypes. In the healthy central nervous system, microglia 
present a highly ramified morphology with long and thin processes, which dynamically monitor brain 
parenchyma to maintain the homeostasis. These microglial cells are commonly designated as surveillant 
microglia, or M0 phenotype, which produce several beneficial substances, such as insulin-like growth 
factor(IGF)-1, transforming growth factor (TGF)-β, brain-derived neurotrophic factor (BDNF), and nerve 
growth factor (NGF), being characterized by low expression levels of microRNA (miR)-155 and relatively 
high expression of miR-124. Depending on the stimulus, surveillant microglia may react and show different 
activation profiles with distinct morphologies, from hypertrophic with enlarged processes to amoeboid shape. 
The pro-inflammatory lipopolysaccharide (LPS) induces a classical activation of microglia (M1), mainly 
through toll-like receptors (TLRs)2 and 4, resulting in a pro-inflammatory profile characterized by an 
increased production of interleukin (IL)-6, IL-12, IL-1β, tumour necrosis factor (TNF)-α, nitric oxide (NO), 
reactive oxygen species (ROS), inducible nitric oxide synthase (iNOS), and major histocompatibility complex 
class II (MHC class II) antigens. Besides their supportive role, the overproduction of these mediators is 
commonly associated to neurotoxicity. Beyond the downregulation of miR-124 and miR-146a, the miR-155 
upregulation is thought to have a pivotal role in the establishment of the M1 phenotype, since this miRNA 
directly targets anti-inflammatory molecules, such as suppressor of cytokine signalling (SOCS) 1. In contrast, 
alternative activation (M2a) and acquired deactivation (M2c) are both associated with an anti-inflammatory 
and neuroprotective phenotype, being the first characterized by the upregulation of IGF-1, arginase 1, 
chitinase 3-like protein 3 (Ym1) and IL-1 receptor antagonist (IL-1Ra), and related with tissue repair, while 
the second one by releasing IL-10, is more associated with the suppression of the immune system and 
phagocytosis of cellular debris. These last phenotypes also show a downregulation of the pro-inflammatory 
miR-155 expression, and an upregulation of miR-124 and miR-146a. In addition, phagocytosis can also be 
mediated by the release of milk factor globule-8 (MFG-E8) from microglia M1 and M2c phenotypes which 
recognizes phosphatidylserine (Ps) in apoptotic cells. The M2b immunoregulatory phenotype has as reliable 
markers IL-10, IL-6, IL-1β and TNF-α, being considered a combination between anti- and pro-inflammatory 
phenotypes. To note that after a prolonged stimulus, microglia may become dystrophic or senescent, a 
condition where an increased expression of miR-146a is observed. 
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In regard to M1 and M2 polarization, some small endogenous RNA molecules, 
known as microRNAs (miRNAs), have been described as mediators of inflammation, 
either as modulators of pro-inflammatory response or related with suppression of the 
pro-inflammatory microglial behaviour (Freilich et al., 2013; Su et al., 2015). These 
miRNAs act by modulation of complementary messenger RNA (mRNA) molecules or by 
inhibiting their translation through binding to the 3’ untranslated region (3’UTR) (Cardoso 
et al., 2012). The complementary between the nucleotides 2-8 on the 5’ region of the 
miRNA and the mRNA is responsible for this binding, allowing the recognition of different 
mRNA targets simultaneously by a single miRNA molecule (Bartel, 2009), giving them 
the ability to modulate a great number of proteins (Su et al., 2015), and making them a 
set of molecules with potential to be used in diagnostics and therapy (Guedes et al., 
2014). The miRNA mediated regulation of gene expression is reached either by 
translation repression or degradation of the mRNA target molecule (Macfarlane and 
Murphy, 2010), and has been related with inflammation and diverse essential processes, 
such as apoptosis, proliferation, differentiation, development and angiogenesis (Guedes 
et al., 2013). 
 
 Several miRNAs associated with innate immunity and neuroinflammation have 
been shown to be dysregulated in AD (Guedes et al., 2014). MiR-155 is a pro-
inflammatory miRNA, playing a significant role in the modulation of the innate immune 
responses by regulation of chemokine and cytokine production (Guedes et al., 2014). In 
this respect, it has been shown that miR-155 is upregulated in microglial cells after a pro-
inflammatory stimulus (Lu et al., 2011), inducing the M1 phenotype (Figure 1.4) 
(Ponomarev et al., 2013) and the overexpression of several inflammatory mediators by 
targeting the anti-inflammatory-related protein suppressor of cytokine signalling(SOCS)1 
(Cardoso et al., 2012). Furthermore, it has also been demonstrated that miR-155 is able 
to target M2-associated genes, including CCAAT/enhancer-binding protein (CEBP)-β, a 
transcription factor crucial for IL-10, arginase 1, and CD206 expression, as well as the 
one encoding SMAD2, a protein involved in the TGF-β pathway (Guedes et al., 2013). 
In addition, miR-155 expression has also been found increased in the 3xTg-AD mice 
model (Guedes et al., 2014), while in the SOD1 mice the genetic ablation of miR-155 
restored the microglia phagocytic ability (Butovsky et al., 2015). Also miR-124 , firstly 
identified as a mouse brain-specific miRNA and the most predominant in the brain 
(Lagos-Quintana et al., 2002), has been reported to promote microglial M2 phenotype 
(Figure 1.4), including a reduction of M1-related markers expression, like IL-6, TNF-α, 
and iNOS, and an increasing of markers related with the M2 phenotype, such as TGF-β, 
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arginase 1, and FIZZ1 (Ponomarev et al., 2011). Indeed, knock-down of miR-124 in 
microglia induced a pro-inflammatory activation in vitro and in vivo (Bird, 2011; 
Ponomarev et al., 2011). Additionally, while an overexpression of miR-124 has been 
found in nonactivated microglia cells (CD45low/MHC class IIlow), a marked decrease 
occurred following treatment with IFN-γ and granulocyte-macrophage colony-stimulating 
factor (GM-CSF), which induce the expression of CD45 and MHC class II and promote 
the M1 phenotype (Ponomarev et al., 2011). Interestingly, cultured microglia have shown 
decreased expression of miR-124 when exposed to LPS, or when treated with IL-4, a 
cytokine that promote alternative activation (Freilich et al., 2013), thus being its 
expression supressed by both types of activation signals. More recently, it has also been 
suggested that miR-124 is involved in the surveillance state of microglia by triggering 
transcriptor factor CEBP-α (Ponomarev et al., 2011). Curiously, miR-124 expression 
occurs abundantly in microglial cells but not in other tissue macrophages (Liu and 
Abraham, 2013). In addition, miR-146a is another well studied regulator of innate 
immune response, acting as a negative feedback promotor of pro-inflammatory 
responses (Su et al., 2015), by targeting several key inflammatory mediators (Cui et al., 
2010). Indeed, a pro-inflammatory induction through nuclear factor-kappa B (NF-κB) 
transcriptional pathway promotes an increased expression of miR-146a, which in turn 
inhibits NF-κB transcriptional activity (Li et al., 2011). It was also suggested that a 
reduced expression of miR-146a can promote hyperactivation or prolonged inflammation 
(Liu and Abraham, 2013). In fact, in Aβ and TNF-α stressed human microglial cells, the 
expression of miR-146a was inversely correlated with the level of inflammation-
associated proteins (Li et al., 2011). Additionally, miR-146a has been directly related with 
AD (Alexandrov et al., 2014; Lukiw et al., 2008), as well as implicated in age-related 
dysfunction of macrophages (Jiang et al., 2012a), as depicted in Figure 1.4. 
Interestingly, studies in PS2 dysfunction, originated by aging or mutations, suggested 
that it may promote neurodegeneration by inducing microglial pro-inflammatory 
responses through misregulation of miR-146a (Jayadev et al., 2013). 
 Ultimately, evidence demonstrate that miRNAs can play crucial regulatory roles 
when acting together, leading to alteration of neuroimmune functions (Su et al., 2015). 
In fact, miR-155 and miR-146a are often associated to act together in modulation of 
several stages of the innate immune response during inflammation and infection (Elton 
et al., 2013; O'Connell et al., 2010), namely in the microglial inflammatory profile (Su et 
al., 2015). While miR-155 usually induces microglia-mediated pro-inflammatory 
responses, miR-146a supresses inflammation by inhibition of NF-κB transcriptional 
activity (Su et al., 2015). Additionally, miR-146a has also been demonstrated to 
negatively modulate expression of pro-inflammatory cytokines, such as TNF-α and IL-6, 
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in contrast with miR-155 which increases pro-inflammatory responses, by inhibiting 
expression of anti-inflammatory mediators, and may play a role of negative feedback 
regulator of miR-146a (Su et al., 2015). 
  
Therefore, microglia are seen as the guardian of the CNS providing the first line 
of defence whenever it occurs any injury or disease. In this concern, microglia perform 
various functions varying from immunological surveillance to neuroprotection or 
neurotoxicity, including migration to the site of damage, proliferation, morphological 
changes, phagocytosis of cellular debris, synaptic modulation, and production of 
inflammatory mediators. 
 
2.2.1. Microglia-Aβ peptide interaction     
 Several studies have revealed the accumulation of phenotypically activated 
microglia surrounding amyloid plaques (Cameron and Landreth, 2010; Floden and 
Combs, 2011; Lue et al., 2010) in AD patients (McGeer et al., 1987), as well as in AD 
mouse models (Frautschy et al., 1998; Yan et al., 2009), being considered a hallmark of 
AD pathology (Doi et al., 2009). Indeed, in age-matched human controls, which do not 
show Aβ deposits, microglial agglomeration does not occur (Streit, 2002). This microglial 
accumulation can be explained by chemotactic signalling mediated by Aβ, or by other 
molecules also related with plaques, like complement factors or chemokines (Lue et al., 
2001; Sokolowski and Mandell, 2011). In fact, it was observed by in vivo imaging 
techniques that microglia migrate and accumulate at newly formed amyloid plaques 
(Meyer-Luehmann et al., 2008), being their number proportional to the size of plaques 
and their presence indicated as preventing plaque expansion, suggesting that plaque-
associated microglia can manage plaque dynamics (Bolmont et al., 2008). In addition, 
microglial activation depend on the amyloid load (Rubio-Perez and Morillas-Ruiz, 2012), 
and has been considered an early event in the pathogenesis of AD (Cagnin et al., 2001). 
However, microglia undergo an age-associated decrease in their ability to interact with 
Aβ aggregates (Floden and Combs, 2011). 
 In AD, Aβ peptides, either as monomers, oligomers, and/or fibers, which are 
compounds of amyloid plaques (Mizuno, 2012), constitute the most likely immune 
stimulus (Colton, 2009), as it induces a high expression of MHC class II surface 
molecules  (McGeer et al., 1988). In fact, it was shown that Aβ induces activation of 
microglia (El Khoury and Luster, 2008; Solito and Sastre, 2012). The microglia-A 
interaction depends on the physical and biochemical properties of Aβ (Lue et al., 2010), 
once it differs depending on whether it will be Aβf and Aβo (Mizuno, 2012). Both Aβf and 
Aβo are able to bind and induce activation of microglia through several receptors (Figure 
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1.5), including different PRRs (Salminen et al., 2009). Indeed, Aβ may act as a PAMP 
molecule and interacts with TLRs expressed by microglial cells (Cameron and Landreth, 
2010; Lotz et al., 2005; Reed-Geaghan et al., 2009), among which TLR2 and TLR4 were 
shown to be involved in Aβ-induced microglial activation (Liu et al., 2012b; Lue et al., 
2010; Mizuno, 2012; Salminen et al., 2009; Stewart et al., 2010). Indeed, it was observed 
that TLR2 mediates Aβ peptide-induced activation of microglia, promoting the expression 
of iNOS, pro-inflammatory cytokines, such as TNF-α, IL-1β and IL-6, and integrin 
markers, including CD11b (Jana et al., 2008). Moreover, several in vitro and in vivo 
studies have shown that TLR4 mediates the neurotoxicity induced by microglia (Lehnardt 
et al., 2003; Walter et al., 2007). Beyond TLRs, other receptors were demonstrated to 
be involved in Aβ-induced microglial activation. These include RAGE receptors (Meraz-
Rios et al., 2013), TLR coreceptor CD14 (Landreth and Reed-Geaghan, 2009; Liu et al., 
2005), other scavenger receptors, such as CD36 and CD47 (Bamberger et al., 2003; 
Salminen et al., 2009), and purinergic P2X7 receptor (P2X7R) (Sanz et al., 2009). The 
microglial activation induced by Aβ through these receptors promotes microglia migration 
and causes inflammatory responses against Aβ aggregates, inducing the production of 
NO, ROS and pro-inflammatory cytokines (Cameron and Landreth, 2010; Heneka et al., 
2015; Mantovani et al., 2004; Mizuno, 2012). The activation of signalling cascades 
(Figure 1.5) mediated by the NF-κB-dependent pathway (Combs et al., 2001) may 
directly originate neuronal damage (Meraz-Rios et al., 2013). 
TLRs, and the coreceptor CD14, may likewise enhance Aβ phagocytic uptake by 
microglia (Doi et al., 2009; Liu et al., 2005), being both TLR2 and TLR4 necessary for 
Aβf-stimulated phagocytosis (Reed-Geaghan et al., 2009). Thus, activated microglia can 
be beneficial, since they can reduce Aβ accumulation through increased phagocytosis, 
clearance and degradation (Cameron and Landreth, 2010; Morgan, 2009; Solito and 
Sastre, 2012), though the progressive accumulation of Aβ in AD disease may promote a 
chronic stimulus to microglia (Krause and Muller, 2010). Microglia also internalize soluble 
Aβ from the extracellular milieu through a macropinocytic mechanism that is distinct from 
that of phagocytosis (Mandrekar et al., 2009). 
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Figure 1. 5 – Interaction between microglial receptors and amyloid- (Aβ) peptide. Microglia express 
several surface receptors and may sense signals from the surrounding environment and respond to different 
stimuli. Amyloid- (Aβ) is able to interact with several of these receptors, promoting microglial activation. 
Among the receptors involved in Aβ binding are: toll-like receptors (TLRs), such as TLR2 and TLR4; 
scavenger receptors (SRs), like CD36, CD47 and CD14; receptor for advanced glycation endproducts 
(RAGE); purinergic P2X7 receptor (P2X7R); and major histocompatibility complex class II (MHC class II) 
molecules. The binding of Aβ to microglial receptors trigger a pro-inflammatory classical activation state in 
microglia, with the release of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-α, and 
interleukin (IL)-1β and IL-6, probably via activation of the nuclear factor-kappaB (NF-κB) signalling pathway, 
although it may also induce phagocytosis. 
 
 It should be noted that, even though both Aβf and Aβo are able to promote the 
classical microglial activation, they display different activation profiles (Parvathy et al., 
2009; Sondag et al., 2009), having Aβo revealed to be a stronger inducer of M1 
phenotype than Aβf in the same conditions (Maezawa et al., 2011). Actually, Aβo at low 
nanomolar concentrations (5-50 nM), although not neurotoxic, induces indirect microglia-
mediated neurotoxicity by increasing the production of NO (Maezawa et al., 2011).  Thus, 
Aβo may more potently cause neuronal damage indirectly by activating microglia in AD 
than plaque-associated microglia, playing a more significant role in the cognitive decline 
of AD patients (Maezawa et al., 2011). However, Aβo concentrations ranging from 100 
nM to 10 µM were found to cause neuronal death (Nicholson and Ferreira, 2009), and 
reduce survival of mature oligodendrocytes (Horiuchi et al., 2010). Interestingly, has also 
been shown that nanomolar concentrations of Aβ promote microglia phagocytosis of 
viable neurons and synapses in culture, which may modulate neuronal loss and AD 
progression (Neher et al., 2012; Neniskyte et al., 2011). Taking these findings in 
consideration, it is likely that Aβo can reach the low nanomolar concentrations required 
for microglia activation in the very early stages of AD development and progressively 
accumulate into higher and more neurotoxic concentrations priginating specific AD 
symptoms (Hardy and Selkoe, 2002). 
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2.2.2. Microglia release of inflammation-related factors 
In the AD brain, interaction between microglia and Aβ induces the phenotypic 
activation of microglia and release of pro-inflammatory mediators (Cameron and 
Landreth, 2010). Microglia, along with astrocytes, are the major source of cytokines in 
AD, which contribute to many inflammatory-related events, including pro- and anti-
inflammatory processes, chemoattraction, and response of microglia to Aβ. Thus, 
microglial activation can be both characterized and modulated by cytokines (Heneka et 
al., 2015). Indeed, several works, either in vitro or animals models, demonstrate that 
increases in Aβ concentration are related with enhanced release of pro-inflammatory 
cytokines by Aβ-induced microglia, including TNF-α, IL-6, IL-1β, and IL-1α (Lue et al., 
2001; Patel et al., 2005; Rubio-Perez and Morillas-Ruiz, 2012), which eventually could 
promote neuronal death (Akiyama et al., 2000). These cytokines may further induce 
cytokine production by acting in an autocrine manner or by activating astrocytes (Rubio-
Perez and Morillas-Ruiz, 2012). In fact, inflammatory cytokines have been shown to be 
increased in vulnerable brain regions in AD, and were found to be associated with 
amyloid plaques (Agostinho et al., 2010; Rubio-Perez and Morillas-Ruiz, 2012). 
Furthermore, Aβ-induced microglia, together with astrocytes, are the main 
producer of chemokines in the CNS (Meraz-Rios et al., 2013). Chemokines, such as 
monocyte chemotactic protein-1 (MCP-1 or CCL2) and macrophage inflammatory 
protein-1α (MIP-1α or CCL3), as well as chemokine receptors CCR3 and CCR5, in 
reactive microglia surrounding senile plaques of AD patients were already identified (El 
Khoury et al., 2003; Meraz-Rios et al., 2013; Xia et al., 1998). Thus, it is consensual that 
such chemokines in the CNS are able to promote recruitment of microglial cells and 
astrocytes to the site of Aβ aggregation and to the area of neuroinflammation, expanding 
the extent of local inflammation and leading to chronic production of chemokines, which 
contribute to AD progression (Meraz-Rios et al., 2013; Rubio-Perez and Morillas-Ruiz, 
2012). 
Several studies have shown interaction between Aβ and the production of other 
inflammatory-related molecules, like ROS and reactive nitrogen species (RNS), by 
microglial cells (Meda et al., 1995). The ROS generation is also frequently related with 
production of pro-inflammatory factors by activated microglial cells to eliminate 
pathogens and to mediate destruction of cellular debris, but a high production of ROS by 
prolonged microglial activation can aggravate inflammation, entering in a vicious 
inflammatory cycle, which may induce neuronal death (Kraft and Harry, 2011; Pasqualetti 
et al., 2015). As ROS, NO can be either detrimental to neurons and be implicated in the 
onset and progression of multiple brain insults, including AD (Guix et al., 2005; 
Pasqualetti et al., 2015), or induce neuroprotective signaling events (Kraft and Harry, 
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2011). Indeed, under normal conditions, NO is synthesized in the microvasculature and 
regulates β-secretase activity which participates in APP processing (Austin et al., 2010). 
Other studies have shown that NO release by microglia can result from several stimuli, 
as LPS (Nayak et al., 2010) and Aβ (Maezawa et al., 2011), which by causing neuronal 
damage contribute further increase microglia neurotoxicity in AD. In addition to their 
direct actions via surface receptors, cytokines can induce iNOS expression in microglia, 
originating high levels of NO that can be neurotoxic (Combs et al., 2001; Heneka et al., 
2015; Murphy, 2000). Thus, damage by activated microglia to neurons may occur via 
NO from iNOS, which inhibits neuronal respiration leading to glutamate release and 
subsequent excitotoxicity, contributing to neuronal cell death in neurodegenerative 
diseases (Bal-Price and Brown, 2001), like AD. Also pro-inflammatory cytokine TNF-α 
can stimulate microglia glutaminase to release glutamate, thus producing excitotoxicity 
(Takeuchi et al., 2006). Indeed, the glutamate released from microglia when subjected 
to pro-inflammatory stimuli, is sufficient to promote excitotoxicity in neighbouring 
neurons. Microglia can produce various defined agonists of excitatory amino acids 
(EAAs), including glutamate (Barger, 2004), which can mediate microglia activation 
(McMullan et al., 2012). Under pathological conditions, microglia can upregulate the 
astroglial glutamate transporter GLT-1 (or EAAT-2), which is known to play a role in 
glutamate clearance (van Landeghem et al., 2001). However, the presence of ROS or 
pro-inflammatory cytokines compromises the function of astrocytes in clearing the 
glutamate released by microglia under physiological conditions (Korn et al., 2005; Trotti 
et al., 1998). These studies suggest that the relation between neuroinflammation and 
excitotoxicity in several diseases such as AD has inflammation-excitotoxic intersections 
(McMullan et al., 2012). Also, Barger and Basile found that microglia activated by APP, 
but not by Aβ, release high levels of glutamate, which induces excitotoxicity via NMDA 
receptor signaling, leading to synaptic degeneration and neuronal death (Barger and 
Basile, 2001). 
Extracellular ATP is a prominent signalling molecule involved in several 
intercellular communications (Ralevic and Burnstock, 1998) that can be released at high 
concentrations during tissue injury (Zimmermann, 1994). In fact, treatment of microglia 
with Aβ was shown to cause a fast release of ATP, which was associated to ROS 
production by microglia (Kim et al., 2012; Kim et al., 2007). The ATP released from 
damaged neuronal tissues mediate the recruitment of microglia towards the site of injury, 
in order to minimize the damage. It was suggested that microglia respond to extracellular 
ATP by further release ATP through lysosomal exocytosis, thus providing a positive 
feedback reaction to yield a long-distance extracellular signal, leading to migration of 
distant microglia towards the site of injury (Dou et al., 2012). 
Chapter 1 
 
34 
 In addition, microglia can secret matrix metalloproteinases (MMPs), including 
MMP9 and MMP2, which are gelatinases implicated in inflammation. These MMPs are 
responsible for extracellular matrix degradation, impairment of blood-brain barrier (BBB) 
dynamic properties and inducers of pro-inflammatory cytokines production (Nagase et 
al., 2006; Nakanishi, 2003), reason why they are considered to also being involved in 
AD (Wang et al., 2014). In addition, MMP3, MMP9, MMP12, and MMP13, have likewise 
been demonstrated to be released by Aβ-induced microglia (Ito et al., 2007; Wang et al., 
2014). Previous studies have suggested an association between MMP2 activation and 
ageing (Wang et al., 2003), as well as with myelin degradation (Ihara et al., 2001) and 
BBB disruption (Liu et al., 2012a). Increased expression of MMP2 in the 
microvasculature of AD mice models and in brain sections of AD patients was also 
observed (Grammas et al., 2011). In turn, despite the association of MMP9 with Aβ 
degradation (Aston-Mourney et al., 2013; Backstrom et al., 1996), MMP2 seems to be 
also able to degrade Aβ (Merlo and Sortino, 2012; Roher et al., 1994), and their dual 
importance to amyloid deposition was further corroborated in animal models (Miners et 
al., 2008; Yin et al., 2006). 
 In parallel with these mediators related with neuroinflammation, microglia can 
also release anti-inflammatory cytokines, like IL-4, which can exert neuroprotective role 
through inhibition of IFN-γ and the consequent decrease in the levels of TNF-α and NO 
(Chao et al., 1993). In addition, although Aβ do not directly induce IL-10 production by 
microglia in vitro (Franciosi et al., 2005), when cells were pre-treated with IL-10 it showed 
to inhibit Aβ-induced production of pro-inflammatory cytokines (Szczepanik et al., 2001). 
Also, the microglial release of TGF-β, a cytokine with pleiotropic functions, revealed to 
have an anti-apoptotic role and to promote neuronal survival (Meraz-Rios et al., 2013). 
However, it is believed that the uncoupling of TGF- signal transduction pathway with 
inhibition of SMAD3 activation is involved in neurodegenerative diseases (Konig et al., 
2005; von Bernhardi et al., 2015). 
 
2.2.3. Microglia migration ability 
 Microglia display chemokinesis (Vincent et al., 2012), being highly active in their 
surveilling state, continually surveying the microenvironment with their motile processes 
and protrusions (Nimmerjahn et al., 2005). They exhibit a dynamic behaviour involving 
rapid process motility and cellular migration (Damani et al., 2011). In the presence of 
injury, microglia retract their branching processes and migrate to the site of injury in order 
to repair CNS homeostasis. Migration, also called chemotaxis, either to the site of 
neuroinflammation or of Aβ accumulation, is mediated by chemotactic molecules 
originated in the site of injury, namely ATP, as well as by damaging cells (Gyoneva et 
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al., 2009; Rubio-Perez and Morillas-Ruiz, 2012). Microglia constitutively express several 
chemokine receptors (Noda and Suzumura, 2012), including α-amino-3-hydroxyl-5-
methyl-4-isoxazoleproprionic acid (AMPA), DAMP, metabotropic P2Y12 purinoceptors 
and metabotropic glutamate receptors, which mediate their direct chemotaxis (Haynes 
et al., 2006; Liu et al., 2009; Lynch et al., 2010). Chemotactic response was observed 
after local injection of ATP in intact brain (Davalos et al., 2005) and in in vitro co-culture 
system, where ATP promoted the migration of microglia across the brain endothelial cell 
monolayer associated to MMPs secretion that act as a chemoattractant (Maeda et al., 
2016). Although ATP is the most used chemoattractant, some other molecules have 
been proven to control microglia movement, such as adenosine diphosphate (ADP) 
(Davalos et al., 2005), neuregulin(NRG)1, fractalkine and chemokines, like chemokine 
motif ligand(CCL)2 (Bose et al., 2016; Calvo and Bennett, 2011). Aβ was similarly 
indicated to induce a chemotactic response and extensive clustering of microglia around 
Aβ plaques in the AD brain (Lue et al., 2001). Interestingly, NO seems to be a signal, 
produced both directly at the lesion and likely by the glial calcium wave, that regulates 
microglia movement to the site of injury, though without chemoattractant potential 
(Parkhurst and Gan, 2010; Samuels et al., 2010). 
 
2.2.4. Microglia phagocytic ability 
 Phagocytosis of pathogens, of cellular debris and of unwanted extracellular 
protein aggregates is performed by microglia, given that they share some properties of 
macrophages (Ransohoff and Perry, 2009; Vilhardt, 2005). In the CNS, microglial 
phagocytic reaction is initiated by the release of attractive signals, designed as “come-
get-me” or “find-me” signals (Kettenmann et al., 2013; Neher et al., 2012), for which 
microglia express a wide variety of receptors (Southam et al., 2016). Such signals lead 
to the recruitment of microglial cells towards the insult (Echeverria et al., 2016; 
Nimmerjahn et al., 2005). After recognition of cell-surface signals, or “eat-me” signals, 
on the target cells, microglia initiate their uptake (Kettenmann et al., 2013; Neher et al., 
2012). ATP released from apoptotic or damaged cells acts as a powerful signal for 
microglial phagocytosis, triggering the purinergic receptor P2Y2 (Elliott et al., 2009). 
Also, fractalkine released by damaged cells as neurons is recognized by the microglial 
chemokine (C-X3-C motif) receptor 1 (CX3CR1), promoting microglial phagocytosis 
(Noda et al., 2011). In addition, phosphatidylserine (Ps) is expressed on plasma 
membrane of apoptotic cells (Noda and Suzumura, 2012), which may be recognized by 
Ps receptor (PsR), through MFG-E8 (Hanayama et al., 2002), triggering also 
phagocytosis (Noda and Suzumura, 2012). Under normal conditions, Ps is located in the 
inner leaflet of the cell membrane. However, in the course of several inductive factors, 
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Ps may flip to the extracellular membrane of an apoptotic cell and be recognized by 
specific receptors on microglia, with a direct binding or by indirect interaction promoting 
cell phagocytosis (Neher et al., 2012). One example is the connection to vibronectin 
receptor αvβ3 (VR) through the bridging protein MFG-E8 (Neher et al., 2012). The 
removal of apoptotic cells and of degenerated neuronal debris in the CNS is the main 
function of microglia (Colton, 2009) that express MFG-E8 (Fuller and Van Eldik, 2008; 
Noda and Suzumura, 2012). Phagocytosis is crucial to reduce inflammation and maintain 
neuronal homeostasis (Noda and Suzumura, 2012). Microglia also express a variety of 
scavenger receptors (Wilkinson and El Khoury, 2012), and receptors for several 
components of the complement system (Kettenmann et al., 2011). 
 According to the type of receptor that is stimulated, phagocytic microglia can 
produce pro-inflammatory or anti-inflammatory mediators (Napoli and Neumann, 2009), 
thus presenting a neurotoxic or a neuroprotective role. During uptake of pathogens via 
TLRs, phagocytosis is associated with inflammation but phagocytosis of apoptotic cells 
occurs without associated inflammation via PsRs (Neumann et al., 2009). Many of the 
surface receptors expressed by microglia regulate more than one microglial response 
beyond the phagocytosis, as follows: CCR1 is the migration-inducing receptor also 
associated with phagocytic activity; CCR2 and CCR5 are the migration-inducing 
receptors that induce an anti-inflammatory response; CX3CR1 collaborates in migration, 
phagocytosis and anti-inflammatory response; triggering receptor expressed on myeloid 
cells(TREM)2 and MFG-E8 promote phagocytosis and anti-inflammatory response; 
CD47 and CD200R normally induce phagocytosis under pathological conditions, leading 
indirectly to an anti-inflammatory response; TLR9 induces phagocytosis and production 
of pro- and anti-inflammatory substances; and some receptors, such as CD14, CD36, 
RAGE, TLR1, TLR2, TLR4, and TLR6, induce not only phagocytosis but also 
inflammatory response (Noda and Suzumura, 2012). 
 
In what concerns AD, it has been demonstrated the ability of microglia to 
phagocytose and degrade Aβ (Lee and Landreth, 2010; Morgan, 2009), preventing the 
senile plaque expansion (Bard et al., 2000; Sha et al., 2014). However, an insufficient 
clearance by microglia have also been suggested to be prevalent in this 
neurodegenerative disease, leading to increased Aβ accumulation (Cherry et al., 2014; 
Napoli and Neumann, 2009), observed both in AD patients (Streit, 2004) and in AD 
transgenic mice (El Khoury et al., 2007). In some studies with microglia in in vitro cell 
cultures it was demonstrated that the cell was able to phagocytose Aβ, though 
ultrastructural analysis of tissues from AD patients was unable to evidence amyloid fibrils 
in the lysosomal compartments of local microglia (Meraz-Rios et al., 2013). These 
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findings suggest that microglia phagocytic capacity may depend on the Aβ species, once 
other in vitro studies reinforced an effectiveness of microglia in degrading the Aβ that 
was phagocytosed (Lee and Landreth, 2010). Otherwise, it was observed an unusual 
presence of macrophages infiltrating from the periphery with Aβ within lysosomal 
compartments (Meraz-Rios et al., 2013). These macrophages that are able to cross the 
BBB are recruited into the CNS by chemokines and specific cytokines released by 
microglial and astrocytic activated cells (Meraz-Rios et al., 2013). It has been suggested 
that such macrophages may be more efficient in Aβ removal and degradation than brain 
microglia, probably due to the higher acidity of their lysosomes comparatively to those of 
microglia (Majumdar et al., 2008; Majumdar et al., 2007). However, this macrophage 
infiltration is thought to only occur under specific conditions, as those of 
neurodegenerative diseases, such as AD (Ginhoux et al., 2013; Lee and Landreth, 
2010). Even so, this issue is still controversial, due to the difficulty in distinguishing 
macrophages from the activated microglia. Actually, specific immunophenotypic markers 
for each type of cell are still missing (Lee and Landreth, 2010). 
 
In sporadic cases of AD, insufficient removal of Aβ has been reported as a main 
pathogenic pathway (Mawuenyega et al., 2010). Pathologic conditions may promote 
chronic activation of phagocytic pathways that can overburden microglia, thus triggering 
impairment of their phagocytic activity and leading to a deficient clearance of Aβ in the 
AD brain (Hickman et al., 2008). It was shown that the activation of TLR2 on microglia 
increases Aβ phagocytosis (Chen et al., 2006). Other studies demonstrated that 
microglia require CD14 for phagocytic uptake of A (Reed-Geaghan et al., 2009). 
Nevertheless, both TLR2 and TLR4 should contribute for A-stimulated phagocytosis 
(Cameron and Landreth, 2010; Reed-Geaghan et al., 2009), because TLR4 mutation 
was shown to exacerbate the Aβ load in AD mouse models (Tahara et al., 2006). Besides 
the direct influence of Aβ in microglia phagocytic property, increased pro-inflammatory 
cytokines also downregulate the expression of the receptors involved in A 
phagocytosis, contributing to inefficient microglial phagocytic ability (Hickman et al., 
2008; Koenigsknecht-Talboo and Landreth, 2005). Among surface receptors expressed 
by microglial cells, CD14-TLR2-TLR4 and CD36-TLR2-TLR6 synergistic signalling 
pathways are fundamental to Aβ-promoted inflammatory response (Noda and 
Suzumura, 2012). Indeed, phagocytosis may occur together with neuroinflammation in 
chronic neurodegenerative diseases as AD (Fuller and Van Eldik, 2008; Hoarau et al., 
2011; McArthur et al., 2010). In this case increased neurotoxicity may arise due to the 
production of pro-inflammatory cytokines, NO and ROS (Mizuno, 2012). 
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 As mentioned before, A phagocytosis by microglia depends on its physical and 
biochemical characteristics. Pan and colleagues have shown that Aβo triggers a potent 
inflammatory response, with alteration of microglial phagocytic function and deficient 
removal of Aβf, thus contributing to neurodegeneration in AD (Pan et al., 2011). In fact, 
while Aβf increased microglial phagocytosis in a dose- and time-dependent manner, Aβo 
decreased Aβf-stimulated phagocytosis of microglia, suggesting that microglia have a 
distinct phagocytic response to these two different Aβ forms (Pan et al., 2011). Thus, 
while microglia internalize Aβo through a nonsaturable, fluid phase macropinocytic 
process that is distinct from receptor-mediated endocytosis (Mandrekar et al., 2009), 
microglia respond to Aβf through an Aβ cell surface receptor complex that includes the 
scavenger receptor CD36, α6β1 integrin, and CD47 (Koenigsknecht and Landreth, 
2004), allowing Aβf engulfment and degradation by the endolysosomal pathway (Heneka 
et al., 2015). Contrasting with Aβf that is usually resistant to enzymatic degradation, Aβo 
was shown to be degraded by extracellular proteases (Lee and Landreth, 2010), like 
neprilysin (NEP) and insulin-degrading enzyme (IDE) (Heneka et al., 2015). 
 The ability of microglia to phagocytose may also depend on the phenotype 
acquired by the cell, in that the surveilling microglia is supposed to not be involved in 
phagocytic activity (Streit et al., 1999), while M1 microglia is indicated to be less able to 
efficiently uptake and degrade Aβ than the M2 microglia (Cherry et al., 2014). However, 
the M1 classical activation induced by LPS was suggested to trigger Aβ clearance 
(Herber et al., 2007). Therefore, further studies should explore the differentiated 
expression patterns of the phagocytic microglia subtype(s). 
 MFG-E8, whose expression is reduced in AD is also suggested to be involved in 
Aβ phagocytosis (Noda and Suzumura, 2012). Also, Beclin 1 protein is impaired in AD, 
and the decrease of its expression in vitro and in vivo was shown to interfere with the 
phagocytic efficiency, leading to decreased receptor recycling of CD36 and TREM2 
(Lucin et al., 2013), which contribute to reduced Aβ uptake (Southam et al., 2016). 
 
 Another important microglial functional property in sustaining brain homeostasis 
is the synaptic pruning (Chen et al., 2014), which contributes to control synapse density 
(Ji et al., 2013) and regulate network activity (Southam et al., 2016). Microglia prune 
synapses as an extension of normal phagocytosis (Southam et al., 2016), what depends 
on neuronal activity (Schafer et al., 2012). Curiously, Aβ is suggested to mediate 
increased synaptic pruning (Kim et al., 2013). 
 Finally, it is important to note that under certain conditions, such as inflammation, 
microglia can also phagocytose viable neurons, leading to neuronal death. In fact, 
although high concentration of Aβ (µM) can induce neurotoxicity, in mixed neuronal-glial 
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cultures low A concentrations (nM) promote neuronal loss through a microglia-mediated 
mechanism, suggesting that microglial phagocytosis is the primary cause of neuronal 
death induced by nanomolar concentrations of Aβ (Neniskyte et al., 2011). 
Externalization of Ps by neurons was shown to be induced by Aβ exposure (Mohmmad 
Abdul and Butterfield, 2005) and the number of Ps-exposing neurons was found 
increased in both AD and MCI (Bader Lange et al., 2008), thus inducing their 
phagocytosis. 
 
 Microglia activation vs dysfunction during AD progression and ageing 
Nowadays, the effective role of microglia in AD progression remains unsolved. 
However, it is known that microglial activation, depending on the stimulus, can promote 
neuroprotective or neurotoxic responses contributing to slow or accelerate disease 
progression (Hanisch and Kettenmann, 2007; Schwartz et al., 2006). As previously 
mentioned, microglia may be activated by Aβ (Mizuno, 2012). The presence of activated 
microglia near amyloid plaques suggests that Aβ accumulation may trigger a persistent 
microglial activation (Heneka et al., 2013). Consequently, microglia may become over-
activated and produce pro-inflammatory factors that are prejudicial to neuronal cells, 
triggering the release of alarmin molecules by damaged neurons which in turn will 
activate more glial cells creating a vicious cycle that intensify the generation of more 
inflammatory signals (Glass et al., 2010; Mizuno, 2012). This process of inflammation 
may contribute to AD progression by increasing neuronal death (Solito and Sastre, 
2012). However, it is possible that early in AD disease microglia may have a more 
protective instead of a detrimental role, with a prevalent phagocytic phenotype that 
allows a more efficient removal of Aβ by producing increased amounts of enzymes 
involved in Aβ degradation (Agostinho et al., 2010; Hickman et al., 2008). It was also 
suggested that microglia may become dysfunctional instead of a gain in inflammatory 
function, losing their capacity to support neurons and to remove neuronal debris or Aβ, 
favoring neurodegeneration (Streit and Xue, 2012). All these alterations on microglial 
function contributing to disease progression may be due to ageing (Streit, 2006). 
In studies carried in the last decade, Damani and colleagues reported that the 
ageing phenotype of microglia involves alterations in their morphology and dynamic 
behavior (Damani et al., 2011). They found that aged microglia in resting/surveilling state 
have significantly smaller and less branched processes, and slower process motilities, 
which probably compromise their ability to survey and interact with their environment 
continuously. They also found that dynamic microglial responses to injury were age-
dependent. While young microglia responded to extracellular ATP by increasing their 
motility and become more ramified, aged microglia exhibited a contrary response 
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becoming less dynamic and ramified. Microglia proliferation is also suggested to increase 
with ageing (Lasiene et al., 2009), but microglia activation and repeated rounds of 
replication may also promote replicative senescence (Conde and Streit, 2006; Streit, 
2006). Indeed, Streit and colleagues have found a morphological aged  phenotype that 
differs from microglia activation, which they designated as dystrophic or senescent 
microglia (Streit et al., 2004). This dystrophic phenotype is characterized by cytoplasmic 
structure abnormalities with deramified, atrophic, fragmented, and abnormally-twisted 
processes (Streit, 2006; Streit et al., 2004). It is important to note that fragmentation of 
the microglial cytoplasm (cytorrhexis) is not accompanied by nuclear fragmentation 
(karyorrhexis), which is typical of apoptosis (Streit, 2006). Also, work in the aged human 
brain has provided evidence of structural deterioration of microglia (Streit, 2002), 
suggesting its association with age-related brain dysfunction (Olah et al., 2011; Streit et 
al., 2004). Another sign of senescence is the shortening of telomere that was observed 
both in in vitro and in vivo microglial cells overtime (Flanary and Streit, 2003; Flanary and 
Streit, 2004). Accordingly, chronic activation of microglia during long periods could lead 
to their over-activation followed by degeneration of microglial cells (Graeber and Streit, 
2010), which can occur sporadically throughout the aged human brain (Streit and Xue, 
2009). These observations raise the hypothesis that ageing adversely affect viability and 
self-renewal capacity of microglia, resulting in the generation of senescent and/or 
dysfunctional cells (Streit, 2006), that compromise the neuroprotective role performed by 
microglial cells (Olah et al., 2011). 
Overall, these altered features of microglia behavior at rest and following injury 
reveal an age-dependent dysregulation of immune response in the CNS that can 
facilitate the emergence of AD. Indeed, these aged microglia morphological 
abnormalities seem to be more pronounced in AD (Streit, 2002). It is well established 
that AD is an age-related neurodegenerative disease (Lynch et al., 2010). In fact, ageing 
shares many pathophysiological conditions with AD, such as increased oxidative stress 
and inflammation, with increased levels of cytokines and glial cell reactivity (Akiyama et 
al., 2000; Demarin et al., 2009; Fratiglioni and Qiu, 2009; Tan et al., 2007). Additionally, 
Aβ-removal mechanisms decrease with age (Akiyama et al., 2001), and during AD 
(Caccamo et al., 2005). Thus, it is believed that changes on microglial phenotype and 
function during ageing have an important role in neurodegenerative diseases (Streit and 
Xue, 2009; von Bernhardi et al., 2011). Indeed, the degeneration of microglial cells is 
highly increased in AD, where severely dystrophic microglia, rather than activated 
microglia, are colocalized with degenerating neuronal structures, further supporting the 
idea that neurodegeneration could be a consequence of reduction of microglial 
neuroprotection (Streit et al., 2009; Streit and Xue, 2009). However, neuronal loss and 
   General Introduction 
 
41 
cognitive decline are features of an aged healthy brain that have been also related with 
microglial activation. Post-mortem studies that indicate the presence of activated 
microglia in aged brains may derive from some degree of neuronal damage during 
normal ageing (Schuitemaker et al., 2012). Thus, the progressive ageing-related 
microglial degeneration and loss of microglia neuroprotection together with chronic 
microglial activation may contribute to the onset of neurodegeneration (Streit et al., 
2009). The accumulation of dystrophic microglia may derive from increased cell 
vulnerability to several factors that may include the presence of Aβ, although its 
prevalence was shown to increase by amyloid load and to favor AD neurodegeneration 
(Flanary et al., 2007; Graeber, 2010; Miller and Streit, 2007; Streit, 2006).  
Although phagocytic activity of microglia obtained from young and aged rats 
seems to increase with age (Lynch et al., 2010), the decreased microglial phagocytic 
capacity towards Aβ and the lower microglia migratory capacity (Njie et al., 2012; Pan et 
al., 2011), may result in amyloid accumulation (Floden and Combs, 2011; Lynch et al., 
2010). Further studies indicate microglia cannot efficiently degrade Aβ aggregates in 
aged brains, what favors senile plaque accumulation mainly in the elderly (Echeverria et 
al., 2016). These issues may relate with a downregulation of receptors related with Aβ 
phagocytosis, such as CD36, and RAGE, and a decrease of Aβ degradation enzymes, 
namely MMP9, observed in old non-disease mice (Hickman et al., 2008). 
Furthermore, aged microglia, although producing elevated pro-inflammatory 
cytokines, namely IL-6 and TNF-α, when compared to younger cells, are less responsive 
to stimulation (Njie et al., 2012). Progressive age-related MHC class II and CD11b 
expression support the idea that microglial activation occurs during ageing (Streit et al., 
2004; Wong, 2013), together with upregulated mediators indicative of both inflammation 
and oxidative stress (Lynch et al., 2010). Interestingly, it was also suggested that 
microglia lose their lysosomal capacity due to changes in cathepsin activity, promoting a 
decrease in autophagic and mitochondrial activity, which subsequently leads to less ATP 
and more ROS production, culminating in an energy deficit and oxidative stress (Ralay 
Ranaivo et al., 2006). Dystrophic microglia may additionally contribute to 
neurodegeneration due to their reduced phagocytic function and autophagy (Olah et al., 
2011). This situation may induce neighboring microglia activation, with increased release 
of inflammatory factors and more neuronal cell death, thus originating a vicious cycle 
that can aggravate disease progression (Olah et al., 2011). 
Interestingly, microglial cells were described to be overactivated increasingly 
reacting to inflammatory stimuli in the ageing CNS of mice, rats, and primates, similar to 
that of microglia in brains with progressive neurodegeneration (Perry and Teeling, 2013). 
This phenomenon, known as priming, is characterized by a more immediate and 
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exacerbated production of inflammatory cytokines and ROS (Heneka et al., 2015). This 
state of activation seems to be related with increased expression of TLRs and MCH class 
II (Olah et al., 2011). All of these alterations in the dynamic microglial behavior with 
ageing may therefore contribute to AD progression in the ageing CNS. 
 Another evidence of microglia neuroprotective loss derives from their switch from 
M2 to M1 phenotype during ageing in the APP/PS1 AD mouse model (Jimenez et al., 
2008), with less responsiveness to M2 induction factors (e.g. IL-4) suggested to be 
related with an age-associated decrease in IL-4Rα (Fenn et al., 2012). These findings 
that include age-related alterations on microglia Aβ-induced inflammation, as well as 
decreased microglia ability to switch phenotypes and attenuate injury (Cherry et al., 
2014) may create the conditions fro AD onset and progression. 
  
 Microglia-neuron interplay in AD 
Microglia have the function to protect and support neuronal cells but their immune 
function are regulated by inhibitory factors intrinsic to the CNS (Streit, 2002). In fact, 
neurons release several signals, named “on” and “off” signals that can modulate 
microglial activation (Biber et al., 2007), involving multiple mechanisms with different type 
of action (Olah et al., 2011). Thus, an imbalance of this regulation may contribute for the 
age-related alterations and vulnerabilities observed in neurodegenerative processes 
(Wong, 2013). Accordingly to this, several studies suggested that to maintain the 
microglia surveillance phenotype it is required their interaction with neurons. Indeed, it is 
known that under physiological conditions neurons produce a lot of inhibitory or calming 
signals to prevent unwanted damage of neurons (Gemma and Bachstetter, 2013), 
namely chemokine (C-X3-C motif) ligand 1 (CX3CL1 or fractalkine), CD200 and CD47 
(Figure 1.6). These factors can modulate the response of microglia and decrease their 
activation (Clark et al., 2007; Puntener et al., 2012; Streit et al., 1999; Tambuyzer et al., 
2009), by their binding to receptors on microglial cells (Kierdorf and Prinz, 2013). 
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Figure 1. 6 – Microglia-neuron signalling pathways that regulate microglial responses in AD. (A) To 
maintain microglia in a surveillant/quiescent state, neurons inhibit microglia activation through the cell-cell 
contact (CD200-CD200R) and the release of “off” signals, such as chemokine (C-X3-C motif) ligand 1 
(CX3CL1 or fractalkine) mediated by metalloproteinases (ADAMs) or cathepsin S, through its exclusive 
receptor CX3CR1 on microglia. CX3CL1 released by neurons increases the removal of neuronal debris by 
microglia, mediated by phosphatidylserine receptor (PsR) and milk fat globule factor-E8 (MFG-E8) 
recognition. (B) In case of injury, degenerated neurons release mediators that activate microglial cells, like 
adenosine triphosphate (ATP) which is recognized by P2Y and P2X receptors in microglia, and glutamate, 
which is recognized by both ionotropic and metabotropic glutamate receptors (mGluRs) in microglia, 
inducing a neurotoxic or neuroprotective response depending on the receptor stimulated. Also the alarmin 
high-mobility group box 1 (HMGB1) released by activated microglia and injured neurons contribute for a 
vicious cycle regulating chronic, progressive degeneration related with neuroinflammation. HMGB1 may 
activate microglia through the receptor for advanced glycation end products (RAGE) and toll-like receptors 
(TLRs) 2 and 4, triggering downstream signalling cascades, like nuclear factor-κB (NF-κB) activation that 
induces the transcription of inflammatory cytokines. HMGB1 can also inhibit amyloid- (Aβ) peptide 
phagocytosis by microglia, further contributing to AD progression. Moreover, Aβ may lead to the release of 
several inflammatory factors by microglia, like oxide nitric (NO), promoting neurotoxicity. 
 
The chemokine fractalkine is one of the best-characterized examples of a 
neuronal mediator, and its soluble form mediates microglial chemoattraction, while its 
membrane-anchored form promotes cell adhesion (Gemma and Bachstetter, 2013; 
Noda and Suzumura, 2012). Fractalkine is highly expressed by healthy neurons (Figure 
1.6), allowing the modulation of microglial function through its exclusive receptor 
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CX3CR1, which is basically expressed in microglia keeping microglia in a 
surveillant/ramified state (Gemma and Bachstetter, 2013; Noda and Suzumura, 2012). 
Indeed, several evidences indicate that fractalkine can repress the activation of microglial 
cells (Gemma and Bachstetter, 2013), and microglia-induced neurotoxicity (Noda et al., 
2011). CX3CL1 directly influences several microglial functions, namely migration, 
proliferation, suppression of glutamate-induced neurotoxicity and inhibition of pro-
inflammatory cytokine production (Noda and Suzumura, 2012). Soluble fractalkine 
released by neurons directly increases microglial removal of degenerated neuronal 
debris, which is regulated by PsR and MFG-E8 (Noda et al., 2011). Indeed, MFG-E8 is 
upregulated in microglial cells after detection of neuronal fractalkine signaling leading to 
recognition of apoptotic neurons by microglial cells (Leonardi-Essmann et al., 2005). The 
membrane-anchored CX3CL1 is cleaved by various proteases, such as a disintegrin and 
ADAM family metalloproteinases (ADAM10 and ADAM17), and cathepsin S (Noda and 
Suzumura, 2012).  Interestingly, it was observed that levels of fractalkine, which are 
highly expressed in young healthy rat brains, were diminished in aged rats probably 
favoring neuroinflammation. In fact, fractalkine administered to aged rats reestablished 
microglial cells in a more ramified morphology (Bachstetter et al., 2011). Selective 
activation of CX3CR1 was also shown to increase synaptic strength suggesting that 
neuronal fractalkine may regulate synaptic strength (Clark et al., 2015). In contrast, 
impairments in synaptic plasticity and cognitive function, originated by an increased 
microglia activation and inflammation in the CNS, together with increased tau pathology, 
were suggested to be due to fractalkine/CX3CR1 signaling loss (Bhaskar et al., 2010; 
Rogers et al., 2011). Other studies evidenced that loss of microglia-neuron fractalkine 
signaling prevented Aβ accumulation in mouse models of AD, in the course of cell 
activation and increased phagocytic ability of CX3CR1-deficient microglia (Fuhrmann et 
al., 2010; Fuhrmann et al., 2011; Lee et al., 2010). Therefore, CX3CR1 is relevant to 
modulate microglia functions in neurodegenerative diseases (Cardona et al., 2006; Lee 
et al., 2010). Even so, the importance of CX3CL1-CX3CR1 in AD is still controversial 
and needs further clarification. 
The CD200-CD200R interaction (Figure 1.6) has similarly been related with 
microglial-neuronal communication (Hanisch and Kettenmann, 2007). CD200 is a 
transmembrane glycoprotein expressed by neurons that exerts inhibitory regulation of 
CD200R in microglia (Greter and Merad, 2013; Koning et al., 2009; Noda and Suzumura, 
2012). Both molecules are expressed and distributed throughout the brain (Varnum and 
Ikezu, 2012). CD200 was shown to have a pivotal role in both autoimmune response and 
inflammation in AD (Varnum and Ikezu, 2012). CD200-CD200R interaction leads to an 
anti-inflammatory state that protects against neurotoxic stimuli (Noda and Suzumura, 
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2012). Addition of neuronal cells to LPS-treated or Aβ-treated microglial cultures was 
demonstrated to suppress the expression of surface markers of microglia and secretion 
of inflammatory cytokines, a condition that was inhibited by the anti-CD200 antibody 
(Lyons et al., 2007a; Lyons et al., 2009). Intriguingly, it was observed an inverse 
correlation between CD200 expression and the expression of cell surface receptors of 
microglial activation by age (Lyons et al., 2009), either in Aβ-treated rats (Lyons et al., 
2009), or in AD patients (Lynch et al., 2010), suggesting that suppression of CD200-
CD200R axis is involved in AD pathology (Walker et al., 2009). CD200 deficient mice 
show a profound impairment in synaptic plasticity in hippocampal slices and increased 
microglial activation (Costello et al., 2011). In aged AD animal models with increased 
microglial activation and Aβ-induced reduced in CD200 expression, IL-4 was shown to 
restores such deficit (Kiyota et al., 2010; Lyons et al., 2007a; Lyons et al., 2007b). 
Actually, IL-4 is deficient in AD models favoring increased inflammatory responses to 
LPS (Lyons et al., 2009). IL-4 revealed to enhance the removal of Aβ and to improve 
spatial learning in APP/PS1 mice, but only in the pre-symptomatic stages of the disease 
(Kiyota et al., 2010), suggesting that the decreased CD200 expression in the aged and 
AD brain may compromise the IL-4 signalling at later stages of disease (Varnum and 
Ikezu, 2012). 
CCL21 is another neuronal chemokine that is upregulated in degenerating 
neurons and triggers microglia recruitment through CXCR3, which also interacts with the 
neuronal CXCL10 regulating microglia migration (Noda and Suzumura, 2012). Thus, 
CCL21 and CXCL10 synergistically promote microglia migration through the receptor 
CXCR3, having CXCL10 the ability to suppress CCL21-induced migration in microglia 
through such receptor (Noda and Suzumura, 2012). 
 
Moreover, microglia may be activated by molecules derived from degenerated 
neurons, namely when exposed to Aβ aggregates (Mizuno, 2012; Streit et al., 1999; 
Varnum and Ikezu, 2012). Injured neurons release several signalling factors (Figure 
1.6), known as find-me, eat-me, and help-me signals (Noda and Suzumura, 2012), or 
just “on” signals (Biber et al., 2007), such as nucleotides, cytokines, and chemokines, to 
recruit and activate microglial cells (Biber et al., 2007; Koizumi et al., 2007). This 
microglial activation may produce trophic or other factors that promote neuronal recovery 
(Streit, 2005), but may also contribute to exacerbate neuronal death due to release of 
neurotoxic mediators by microglia, further suggesting that microglial cells are responsible 
for the highly neurodegeneration that occurs in AD (Ralay Ranaivo et al., 2006). 
However, during neurodegeneration, the injured neurons may remain viable and trigger 
microglial activation. Reversible neuronal injury induce the release of trophic factors by 
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microglial cells as survival-promoting signals (Streit et al., 1999), with protective and 
remodeling role (Parkhurst et al., 2013). Irreversible neuronal injury may, otherwise, 
trigger the production of neurotoxic factors by microglia, as death-promoting signals that 
contribute to neurodegeneration and subsequent phagocytosis by microglial cells (Streit 
et al., 1999). Among the signals released by injured neurons (Figure 1.6) are purines 
and neurotransmitters (Biber et al., 2007). Purines like ATP are recognized by the 
nucleotide receptors P2Y and P2X in microglia (Inoue, 2006). Several works suggest 
that purines play a crucial role in microglial activation and induce their migration to the 
site of damage (Koizumi et al., 2013; Sperlagh and Illes, 2007). In addition, it was shown 
that microglia migration is mediated by the extracellular ATP (Dou et al., 2012). Also the 
neurotransmitter glutamate is indicated to have an important role in neuron-microglia 
interplay. Indeed, although glutamate directly may induce neurotoxicity, it also can 
activate microglial cells, which express both ionotropic and metabotropic glutamate 
receptors (Kettenmann et al., 2011). So, depending on the stimulated microglia receptor 
for glutamate it may originate neurotoxicity or neuroprotection (Biber et al., 2007). 
Exposure of microglia to Aβ aggregates may also promote the release of several 
neurotoxic factors (Figure 1.6), such as NO (Maezawa et al., 2011), suggesting a 
significant contribution of Aβ for microglial-induced neurotoxicity, rather than a direct Aβ-
induced neurotoxicity in AD. Also, the microglial Aβ phagocytosis dysfunction caused by 
HMGB1, a chromosomal protein that inhibits phagocytosis and accumulates 
extracellularly on Aβ plaques, may be involved in the progression of AD (Takata et al., 
2003a; Takata et al., 2012). The “on” signal HMGB1 (Figure 1.6B) is an inflammatory 
factor that acts as an alarmin being released by necrotic or damaged astrocytes, 
microglia and neurons (Fang et al., 2012; Muller et al., 2001), and during acute 
inflammatory responses (Park et al., 2004). It seems that HMGB1 has two different 
functions in cellular systems (Park et al., 2004). Intracellular or nuclear HMGB1 stabilize 
DNA structure and regulates transcription of several genes, including pro-inflammatory 
ones (Bianchi and Manfredi, 2009; Park et al., 2009; Wong, 2013). In opposite, during 
activation or cell necrosis, HMGB1 increase in the cytoplasm and is released to the 
extracellular space, where it promotes inflammation that contributes to 
neurodegeneration (Kawabata et al., 2010). These inflammatory responses may be 
induced through the microglial receptors RAGE, and TLRs 2 and 4 (Park et al., 2006). 
HMGB1 was suggested to decrease in neurons, while increase in astrocytes with ageing 
(Enokido et al., 2008). 
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3. Models to assess microglia activation/Dysfunction profiling 
Several models can be used to assess the importance of microglia in the 
pathogenesis of AD. Indeed, in vitro models using pure cultures of microglia allow the 
exploration of microglia specific molecular mechanisms, while ex vivo models, such as 
the organotypic hippocampal slice cultures, permit the understanding of microglia 
reactivity within the tissue environment. Moreover, the use of an in vivo model of AD is 
the only suitable way to identify the role of microglia on the initiation and progression of 
AD. However, the new spheroids with human cells derived from AD-induced pluripotent 
stem cells (iPSCs) have recently shown to better recapitulate the AD disease. 
 
 In vitro and ex vivo models 
The cell culture systems are important tools to evaluate microglia functionality, 
including the activation state, released factors and mobility, among others, which cannot 
be properly evaluated in vivo (Stansley et al., 2012). Microglia primary cultures and cell 
lines of microglia, like murine BV2 and N9, are the cell culture models most frequently 
used in the laboratory. Indeed, due to their resemblance with in vivo cells, the primary 
cultures are commonly used in studies to evaluate microglial function in AD models, 
especially on Aβ-related effects (Maezawa et al., 2011; Takata et al., 2003b; Takata et 
al., 2012). Usually, microglia are isolated from the cortex of rodents, such as mouse or 
rat, either prior to, or shortly after birth (Stansley et al., 2012). However, because it is a 
time consuming technique with a relative low cell yield, many studies use microglia cell 
lines rather than primary cells to assess the microglial role in physiological and 
pathological conditions (Stansley et al., 2012). The use of cell lines is less expensive and 
have less variation between different cultures (Ni and Aschner, 2010). Nonetheless, 
microglia cell lines are genetically modified, like N9 that is derived from mouse and 
immortalized by oncogene-carrying retrovirus (Righi et al., 1989). Such genetic 
modifications cause changes in adhesion and proliferative ability of the cells, what makes 
their inflammatory responses different from primary microglia (Horvath et al., 2008). 
Nevertheless, they constitute an advantageous tool to explore the role of microglia in 
inflammation-associated neurodegenerative diseases as AD. 
Although cell cultures from young, as well as old human or animal donors, have 
been considered the most appropriated model (Schneider and Mitsui, 1976), we have 
already shown that both neurons and astrocytes show maturation and ageing along time  
in culture (Falcão et al., 2006). These findings indicate that microglia can probably be 
similarly aged in culture, what may be important to evaluate microglia-induced 
neurodegeneration. Successive shocks with LPS have also shown to cause microglia 
ageing (Yu et al., 2012). Until now there is no convenient protocol to obtain reproducible 
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aged microglia, even from murine models at different ages (Njie et al., 2012). The most 
senescent do not survive and the isolation procedure may induce activation (Cristovão 
et al., 2010). Therefore, these aspects should be considered when microglia response 
to a stress-stimulus is to be determined. 
Recently, studies in human stem cell and three-dimensional (3D) culture 
technologies allowed the development of new 3D neuronal cell culture models that mimic 
AD pathologies (Choi et al., 2016). These models use AD patient-derived induced 
pluripotent stem cells (iPSCs) or genetically modified human stem cell lines, which are 
cultured on a Matrigel that functions as a 3D support matrix providing a brain tissue-like 
environment (Choi et al., 2014; Choi et al., 2016). In addition, cerebral organoid cultures 
have also been used to obtain 3D structures to study AD pathology (Choi et al., 2016). 
 
 Many studies have been performed in an attempt to better understand the 
relationship between neurons and microglial cells. Although, a pure microglia culture is 
the only model to assess cell reactivity when microglia-neuron interplay is intended in 
what concerns the effects produced by soluble factors released by neurons on microglia 
reactivity, it may be used the conditioned media model. This microglial and neuronal 
conditioned media isolated after a given stimulus may be incubated with neurons or 
microglia to evaluate the functional impairments. Another useful tool to evaluate the 
interaction between microglia and other cell types is the mixed co-culture system 
(Stansley et al., 2012) that is important to unravel the role of neuroinflammation in 
neurodegenerative diseases, such as AD. Indeed, several studies using different co-
culture approaches have been performed and reported (Culbert et al., 2006; Gresa-
Arribas et al., 2012). They may mimic the in vivo environment (Carreira et al., 2012), and 
the cells may either be in contact, or separated if a transwell co-culture system is used 
instead. In spite of some drawbacks, the co-cultures system constitute a good tool 
depending on the study purpose (Carreira et al., 2012). 
 
 To mimic an AD condition, several stimuli can be used in in vitro models. While 
some authors have been treating nerve cells with Aβ fragments, namely the Aβ1-42, others 
use Aβo to better relate with the Aβ aggregation that occurs along disease progression 
(Maezawa et al., 2008; Maezawa et al., 2011). Aβo are small diffusible aggregates, 
formed by Aβ1-42 self-association, that are considered more deleterious than Aβf 
(Lambert et al., 1998). In addition, also the concentrations of Aβo used may differently 
affect cell response. Aβo at low nanomolar concentrations (5-50 nM) do not elicit 
neurotoxicity but promote a significant increase in cell immunoreactivity for SRA and 
CD11b, markers of activated microglia (Bornemann et al., 2001). However, Aβo 
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concentrations ranging from 100 nM to 10 µM were found to cause neuronal death 
(Nicholson and Ferreira, 2009) and reduced survival of mature oligodendrocytes 
(Horiuchi et al., 2010). Interestingly, recent studies show that nanomolar concentrations 
of Aβ promote microglia phagocytosis of viable neurons and synapses in culture, which 
may modulate neuronal loss and the progression of AD (Neher et al., 2012; Neniskyte et 
al., 2011). Taking this in consideration, it is likely that Aβo can reach the low nanomolar 
concentrations required for microglia activation in the first steps of AD development and 
progressively accumulate to higher and more neurotoxic levels with disease progression 
giving rise to the specific AD symptoms (Hardy and Selkoe, 2002). 
 
Although microglia cross-talk with other nerve cells may be studied using the 
conditioned media or co-culture model, the interplay between the different nerve cells, 
the matrix and tissue organization may only be studied using a more complex model, the 
organotypic slice cultures. These cultures are reported as the most approximate model 
to the in vivo conditions since it allows interaction between neighbouring cells, and also 
the maintenance of three dimensional architecture of the brain (Humpel, 2015), which is 
not achieved in primary cultures. In addition, organotypic hippocampal slice cultures 
have been considered an alternative to animal model experiments. Cultured slices 
maintain the cell architecture. They have been extensively used to investigate molecular 
mechanisms involved in cytotoxicity, such as the ones that are determined by Aβ toxicity 
(Kreutz et al., 2011), as well as to evaluate neuroprotective strategies. Although the 
organotypic slice cultures are usually prepared from young animals (5-12 day-old pups) 
to better preserve the tissue characteristics and functionality (Su et al., 2011), adult 
animals are the most appropriate to mimic AD disease (Brewer, 1997), and studies 
already used organotypic cultures from two months old rodents (Staal et al., 2011; 
Wilhelmi et al., 2002), or even from 14-16 months old rodents (Schrag et al., 2008). 
  
 In vivo models 
In vivo models are the most suitable to study disease phenotype and progression. 
Several mouse models have been generated in an effort to express similar human AD 
behavior and neuropathology as well as to validate new therapeutic approaches. Such 
transgenic animals that mimic the etiology and the progression of the disease, should 
not have symptoms that may alter the disease diagnosis (Do Carmo and Cuello, 2013). 
Initially, transgenic mice models of AD have been created by introducing mutated 
forms of the human APP and/or presenilins genes found in familial AD cases  (Schwab 
et al., 2009). Even though the early-onset of FAD only represents less than 5% of total 
AD cases, there is a broad phenotypic similarity between FAD and LOAD, suggesting 
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that findings about FAD would also be directly relevant for LOAD (Selkoe, 2001). 
Interestingly, while the introduction of wild-type forms of APP and PS1, as found in 
normal and non-familial AD cases, does not cause pathology, the transgenic mice with 
pathological human mutant proteins easily show Aβ aggregation, behavioral deficits and 
some abnormal tau-phosphorylation (Duyckaerts et al., 2008; Howlett and Richardson, 
2009; Morrissette et al., 2009). However, these models do not exhibit the development 
of neurofibrillary tangles or massive neuronal loss, which are the major pathological 
hallmarks of AD (Schwab et al., 2009). Thus, additional pathological tau mutations have 
been created to mimic this AD feature (Oddo et al., 2003b). 
 
3.2.1. A triple transgenic mouse model of AD (3xTg-AD) 
Among the transgenic mouse models created, just a small number express both 
plaques and tangles pathologies that characterize AD (Sterniczuk et al., 2010b). The 
3xTg-AD mice mimic the behavior and the neuropathological features of human AD 
patients. The 3xTg-AD mice express three mutations in a comparable manner to that 
observed in AD patients (Mesulam, 2000): human amyloid precursor protein Swedish 
(APPSwe), human presenilin-1 M146V (PS1M146V), and the P301L mutation of human tau 
(tauP301L), allowing the development of amyloid plaques, acceleration of the deposition 
rate, and neurofibrillary tangle pathology, respectively, in a temporal and spatial  
progression that mimics the pathogenic stages observed in humans (Oddo et al., 2003a; 
Oddo et al., 2003b; Sterniczuk et al., 2010a; Sterniczuk et al., 2010b). First hallmarks 
arise in hippocampal, amygdala and cortical regions, which are the most affected regions 
by AD pathology. In fact, in 6 months 3xTg-AD mice deposition of extracellular Aβ is 
apparent in frontal cortex (Oddo et al., 2003a), that continues to spread into the 
hippocampus by 12 months (Gimenez-Llort et al., 2007). Differently, tau 
immunoreactivity is only firstly observed at 12 months in pyramidal neurons in the CA1 
region (Oddo et al., 2003b). Thus, 3xTg-AD animals develop extracellular Aβ aggregates 
prior to tangle formation, corroborating the amyloid cascade hypothesis considering Aβ 
as the trigger of the disease (Oddo et al., 2003a; Oddo et al., 2003b).  
At 2-months of age no Aβ or tau pathology is observed in any brain region of the 
3xTg-AD mice (Oddo et al., 2003b), as well as no impairment in learning or memory 
(Billings et al., 2005). The earliest cognitive impairment manifests at 4-months with 
retention for spatial and contextual learning. This is in agreement with the presence of 
intraneuronal Aβ in the hippocampus, cortex and amygdala at that age, suggesting its 
role as promotor of cognitive decline onset in the 3xTg-AD mice (Billings et al., 2005). 
Extracellular Aβ deposits are not visible at this age. At 6-months 3xTg-AD animals show 
no apparent tangle pathology, but contain diffuse Aβ plaques in cerebral cortex, and 
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intraneuronal Aβ deposits within pyramidal neurons of the hippocampus, cortex and 
amygdala (Billings et al., 2005; Oddo et al., 2003b), followed by microgliosis and 
astrogliosis (Caruso et al., 2013; Janelsins et al., 2008). At 9-months the hippocampus 
of the animals is virtually plaque-free, becoming remarkable at 12-months (Oddo et al., 
2003a; Rodriguez et al., 2010), where apparent conformational alteration in tau spreads 
by the cerebral cortex (Oddo et al., 2003a; Oddo et al., 2003b). So, the 3xTg-AD model 
of AD provides a promising tool for understanding the neuropathology of AD, with 
expression of AD pathology in an age-dependent manner beyond the associated 
behavioral changes (Sterniczuk et al., 2010b) that occurs with disease progression in 
human patients (Mesulam, 2000; Vandenberghe and Tournoy, 2005; Witting et al., 
1990). Although several studies can be performed with this animal model, organotypic 
cultures from 3xTg-AD exposed to different stimuli and specific inhibitors are promising 
to obtain pre-clinical data in a more rapid and less expensive way. 
 
3.2.2. Other in vivo models 
Besides the 3xTg-AD model, there is a wide variety of other animal models of AD 
that provide different approaches depending on the mechanisms intended to be studied. 
Among them, a widely-used model is the Tg2576 mouse that expresses the human 
APP695 isoform with Swedish double mutation, showing 6-times more APP then normal 
mice (Westerman et al., 2002). This model exhibits age-dependent A deposition (Elder 
et al., 2010), with increased levels at 9-month old (Westerman et al., 2002). In turn, APP 
mouse model expresses both APP695 (APPSwe) and APP751 isoforms, showing 7-times 
more APP then normal mice and Aβ plaques at 6-months of age. These two models have 
been considered important tools to assess the correlation between amyloid deposition 
and cognitive alterations in AD (Foley et al., 2015). Also PS1 mice model which express 
human presenilin 1 with M146L or M146V mutation, show high levels of endogenous 
mouse Aβ42 (Weggen and Beher, 2012). Thus, the co-expression of the mutant PS1 
gene increases the pathology to a significantly younger age, as evidenced by the double 
transgenic APP/PS1 model (Borchelt et al., 1997; Holcomb et al., 1998). Another mice 
model is the APPSwe/PS1deltaE9 that express APP with the Swedish mutation and 
mutant human PS1 with a deletion of exon 9 (Jankowsky et al., 2001; Savonenko et al., 
2005). Interestingly, the amyloid plaques precede typical cognitive impairments in this 
model (Jankowsky et al., 2004; Volianskis et al., 2010), what allows the evaluation of 
pathophysiological events associated to preclinical AD (Zou et al., 2016). Another useful 
model of intraneuronal A42 and neurodegeneration is the 5XFAD (Eimer and Vassar, 
2013). This mouse model expresses five FAD mutations, two PS1 and three APP 
mutations, leading to A1-42 overproduction and acceleration of plaque development 
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(Oakley et al., 2006). Consequently, 5XFAD mice develop intraneuronal A1-42 at 1.5 
months of age, amyloid plaques at 2 months, and significant neuron loss at 9 months, 
with initial cognitive impairments from 4 months forward (Oakley et al., 2006). However, 
NFTs are not typical in this model, and neuronal loss only occurs by combination of 
multiple mutations (Elder et al., 2010). 
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4. Global aims of the thesis 
AD is an age-associated pathology characterized by increased accumulation of 
extracellular Aβ plaques within the brain. Histological studies have revealed high 
microglial activation in diseased brains commonly associated with these peptide 
aggregates. On the other hand, healthy brain ageing is characterized by neuronal loss 
and decline of cognitive function being inflammation a major causative factor. 
Inflammation is closely associated with microglial activation, priming and ageing which 
are now considered to be major drivers for the neuropathological findings in AD. 
Therefore, this study intends to unveil the role of microglia in AD pathogenesis using 
primary cultures of young/reactive (acutely isolated microglia) and long cultured (aged) 
microglia to assess the different representation of microglia subtypes upon A 
interaction, followed by assessment of microglia-neuron interplay in the 3xTg-AD model.  
As a first step, it will be evaluated how the phenotypes of 2 days in vitro (DIV) 
cultured (acutely isolated) and 16 DIV (aged) microglia will mimic the activated and the 
irresponsive/dormant microglia phenotypes, by evaluating microglia functional properties 
as autophagy, phagocytosis and migration, morphological features, markers of 
senescence and expression of inflammatory mediators. This will be an innovative 
approach to assess how differently activated microglia may diversely respond to stress-
stimuli, and whether aged-associated responsiveness may compromise the 
neuroprotective properties of the cell. 
Next, it will be determined how such differently aged and polarized microglia 
subsets will diversely react to 50 nM and 1000 nM A stress treatment for 24 h in terms 
of M1/M2 representation and microglia dynamic properties. It will be assessed changes 
in their morphological characteristics, viability, migration, phagocytic capacity, 
inflammatory biomarkers, as well as in the release of MMP2, MMP9 and glutamate. With 
such evaluations it will be possible to obtain the representation of polarized phenotypes 
in such Aβ-treated cells, in terms of either the classical activated M1 subtype considered 
as pro-inflammatory and non-phagocytic, or the alternatively activated M2 subtype 
associated to an anti-inflammatory and phagocytic cell, besides the number of cells that 
progress to a subclass of senescent-like, which will be related with each one respective 
specific physiological characteristics.  
To complement the in vitro studies it will be used the triple transgenic animal 
model of AD, the 3xTg-AD mice. Two main regions will be evaluated, the hippocampus 
and the cortex, at 3, 6 and 9 months-old, in order to evaluate markers of early AD disease 
and characterize the microglia population phenotypes along disease progression, when 
compared with age-matched wild-type controls. 
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Altogether, it is expected that the present study will contribute to elucidate the 
involvement of microglia cells in AD-associated neuroinflammation, and their contribution 
in the onset and progression of AD, in order to identify possible targets to modulate 
microglia towards a neuroprotective role, and to establish the most appropriated 
therapeutic strategies and their implementation timing. Indeed, we hypothesize that 
distinct therapeutic strategies may be required depending on the stage of disease 
progression. 
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Abstract 
 
Age-related neurodegenerative diseases have been associated with chronic 
neuroinflammation and microglia activation. However, cumulative evidence supports that 
inflammation only occurs at an early stage once microglia change the endogenous 
characteristics with ageing and switch to irresponsive/senescent and dystrophic 
phenotypes with disease progression. Thus, it will be important to have the means to 
assess the role of reactive and aged microglia when studying advanced brain 
neurodegeneration processes and age-associated related disorders. Yet, most studies 
are done with microglia from neonates since there are no adequate means to isolate 
degenerating microglia for experimentation. Indeed, only a few studies report microglia 
isolation from aged animals, using either short-term cultures or high concentrations of 
mitogens in the medium, which trigger microglia reactivity. The purpose of this study was 
to develop an experimental process to naturally age microglia after isolation from 
neonatal mice and to characterize the cultured cells at 2 days in vitro (DIV), 10 DIV and 
16 DIV. We found that 2 DIV (young) microglia had predominant amoeboid morphology 
and markers of stressed/reactive phenotype. In contrast, 16 DIV (aged) microglia 
evidenced ramified morphology and increased metalloproteinase (MMP)-2 activation, as 
well as reduced MMP9, glutamate release and nuclear factor kappa-B (NF-κB) 
activation, in parallel with decreased expression of Toll-like receptor (TLR)-2 and TLR4, 
capacity to migrate and phagocytose. These findings together with the reduced 
expression of microRNA (miR)-124, and miR-155, decreased autophagy, enhanced 
senescence associated β-galactosidase activity and elevated miR-146a expression, are 
suggestive that 16 DIV cells mainly correspond to irresponsive/senescent microglia. 
Data indicate that the model represent an opportunity to understand and control 
microglial ageing, as well as to explore strategies to recover microglia surveillance 
function. 
 
 
 
 
Keywords: autophagic capacity; in vitro cell ageing; microglia; microRNAs; migration; 
phagocytosis; reactivity; senescence 
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1. Introduction 
Microglia are the first line of defense against brain injury. In the healthy brain 
microglia actively survey surrounding parenchyma via dynamic movement of processes 
(Nimmerjahn et al., 2005) and are kept in a relatively quiescent state in part due to 
specific signals derived from neurons and astrocytes (Cardona et al., 2006; Lyons et al., 
2007). Upon brain injury or changes of central nervous system (CNS) homeostasis 
microglia are capable of acquiring diverse and complex phenotypes, allowing them to 
participate in the cytotoxic response, immune regulation, and injury resolution. The 
classical pro-inflammatory M1 phenotype is cytotoxic and release pro-inflammatory 
cytokines while the M2 polarization contributes to neuroprotection through the release of 
anti-inflammatory cytokines and growth factors (Chhor et al., 2013; Evans et al., 2013). 
These transitional phenotypes may exert beneficial or destructive effects depending on 
the stimuli, their duration and the environment they encounter (Schwartz et al., 2006). 
Thus, balance between M1 and M2 phenotypes can be considered a desirable 
therapeutic goal. 
 
Age-related CNS disorders have been related with chronic and progressive neuronal 
loss but also with chronic mild neuroinflammation involving activated/primed microglia 
(Maezawa et al., 2011; Williamson et al., 2011). These cells showed to switch from M2 
to M1 phenotype with age and disease progression (Solito and Sastre, 2012; Varnum 
and Ikezu, 2012). However, other studies claim that neuroinflammation is only present 
in the early stages of Alzheimer´s disease (AD), once lately disappears (Wojtera et al., 
2012) and that, instead, microglia become senescent/dystrophic (Graeber and Streit, 
2010) and less responsive to stimulation with age (Njie et al., 2012; Streit and Xue, 2012). 
The dysmorphic characteristics of aged microglia suggested that, rather than maintaining 
an overactivated state, microglia may display decreased ability to mount a normal 
response to injury. Indeed, reduced migration (Damani et al., 2011), clearance (Li, 2013) 
and production of neurotrophic factors (Ma et al., 2013), as well as inability to shift from 
a pro-inflammatory to an anti-inflammatory state to regulate injury and repair have been 
observed in aged microglia (Norden and Godbout, 2013) and related with senescence 
(Streit and Xue, 2012). These changes in microglia potentially contribute to an increased 
susceptibility and neurodegeneration as a function of age. Accordingly, nonsteroidal anti-
inflammatory drugs (NSAIDs) were only successful when administered before the 
development of neurodegeneration (Weggen et al., 2001). If administered in later stages 
of disease they showed to be detrimental (Martin et al., 2008), reinforcing that microglia 
may switch from a reactive to an irresponsive phenotype along the progression of AD 
and other age-associated CNS disabilities. Restraining of aged microglia may weak even 
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more the already decreased neuroprotective properties of the cell in removing 
extracellular protein aggregates. These changes in microglia neuroprotective properties 
will potentially contribute to enhance neurodegeneration and susceptibilities with ageing 
and reveal the need of adequate experimental models to follow the changes in microglia 
performance accordingly to cell senescence. 
 
Most of the work intended to evaluate the neurodegenerative network associated 
with ageing has used cultures of microglia derived from early postnatal brains, which 
differ from adult or aged ones (Harry, 2013). Recently, a few studies compared behaviour 
of microglia isolated from animals at different ages. In these studies young and aged 
microglia were isolated using a Percol-based method (von Bernhardi et al., 2011; Njie et 
al., 2012) or distinctly isolated using a mild-trypsinization method for embryonic/neonatal 
microglia and Percol-based method for adult and aged microglia (Lai et al., 2013). In 
addition, these cells were analyzed either 24-48 h after isolation (Njie et al., 2012; Lai et 
al., 2013) or following trypsinization when kept in culture for several weeks in the 
presence of conditioned medium containing increased levels of mitogens (von Bernhardi 
et al., 2011). Such methods may promote microglia activation and bias the translation of 
culture findings, since it has been suggested that microglia may need some time in 
culture to recover its quiescent state (Cristovão et al., 2010). Moreover, there are no 
means to isolate degenerating microglia for experimentation (Njie et al., 2012) once only 
the more resistant ones will survive to the isolation procedure. Nevertheless, the 
hypothesis of microglia senescence during aging and related neurodegenerative 
diseases emerged as a key determinant (Luo et al., 2010). In vitro ageing of astrocytes 
and neurons has demonstrated to be associated with different cell response to stimuli, 
with the younger cells evidencing an increased reactivity when compared to the older 
ones (Falcão et al., 2005; 2006). In addition, it was shown that the repeated stimulation 
of the microglia cell line BV2 with lipopolysaccharide (LPS) lead to cell senescence 
corroborating the idea that sustained neuroinflammation may ultimately contribute to a 
microglia senescent phenotype (Yu et al., 2012). Therefore, we decided to isolate 
microglia from neonatal mice and culture cells from 2 days in vitro (DIV) until 16 DIV, 
similarly to what we previously did with neurons and astrocytes, and to explore ageing-
related differences in functional response characteristics associated to “young” and 
“aged” microglia phenotypes. We assessed changes in microglia morphology, nuclear 
factor kappa-B (NF-κB) signalling pathway activation, Toll-like receptor (TLR) 
expression, phagocytic ability and migration capacity, as well as cell death, inflammatory 
microRNA (miRNA) profiling, autophagy and senescence-associated β-galactosidase 
(SA-β-gal) in mice primary cortical cell cultures maintained up to  16 DIV. 
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2. Materials and Methods 
 Animals 
Animal care followed the recommendations of the European Convention for the 
Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes 
(Council Directive 86/609/EEC) and National Law 1005/92 (rules for protection of 
experimental animals). All animal procedures were approved by the Institutional animal 
care and use committee. Every effort was made to minimize the number of animals used 
and their suffering. 
 
 Primary culture of microglia 
Mixed glial cultures were prepared from 1-to-2 day-old CD1 mice as previously 
described (McCarthy and de Vellis, 1980), with minor modifications (Gordo et al., 2006). 
Cells (4 x 105 cells/cm2) were plated on uncoated 12-well tissue culture plates (with 18 
mm coverslips) or 75-cm2 culture flasks in culture medium [DMEM-Ham’s F-12 medium 
supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, nonessential amino acids 
1X, 10% fetal bovine serum (FBS), and 1% antibiotic-antimycotic solution] and 
maintained at 37ºC in a humidified atmosphere of 5% CO2.  
Microglia were isolated as previously described by Saura et al. (Saura et al., 2003). 
Briefly, after 21 days in culture, microglia were obtained by mild trypsinization with a 
trypsin-EDTA solution diluted 1:3 in DMEM-Ham’s F12 for 45 to 60 min. The 
trypsinization resulted in detachment of an upper layer of cells containing all the 
astrocytes, whereas the microglia remained attached to the bottom of the well. The 
medium containing detached cells was removed and the initial mixed glial-conditioned 
medium was added. Mixed cultures were maintained in culture for 21 days to achieve 
the maximal yield and purity of the cultures. In fact, astrocyte contamination was less 
than 2% with 0% of neurons, as assessed by immunocytochemical staining with a 
primary antibody against GFAP and MAP-2, respectively, followed by a species-specific 
fluorescent-labeled secondary antibody (Silva et al., 2010).  
 
 Characterization of microglia along the days in culture 
After mild trypsinization, attached cells on uncoated 18-mm coverslips were 
maintained in culture until reaching 2, 10 or 16 days in vitro (DIV) for characterization, 
with medium replaced every 4 days. Microglia characterization was first performed 
considering cell morphology and NF-κB activation, at these 3 time-points, and thereafter 
only at 2 and 16 DIV for additional properties related with migration ability, phagocytic 
capacity, differential cell reactive ability and markers of cell senescence. 
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 Cell morphological analysis 
For morphological analysis, cells were fixed for 20 min with freshly prepared 4% 
(w/v) paraformaldehyde in phosphate buffer saline (PBS) and a standard 
immunocytochemical technique was performed using a primary antibody raised against 
Iba1 (rabbit, 1:250; Wako Pure Chemical Industries Ltd, Osaka, Japan), and a secondary 
Alexa Fluor 594 goat anti-rabbit (1:1000; Invitrogen Corporation, Carlsbad, CA, USA). 
To identify the total number of cells, microglial nuclei were stained with Hoechst 33258 
dye. Fluorescence was visualized using an AxioCam HRm camera adapted to an 
AxioSkope® microscope (Zeiss). Pairs of U.V. and red-fluorescence images of ten 
random microscopic fields (original magnification: 400X) were acquired per sample. To 
quantitatively characterize microglia morphology we used the particle measurement 
feature in ImageJ (1.47v, USA) to automatically measure the 2D area, perimeter, and 
Feret’s diameter of single microglia cells. Feret’s (maximum) diameter, a measure of cell 
length, is the greatest distance between any two points along the cell perimeter. We also 
evaluated the transformation index, first defined by Fujita and co-workers as [perimeter 
of cell (µm)]2/4 [cell area (µm2)], which categorizes microglia ramification status (Fujita 
et al., 1996). A cell with long processes and a small soma exhibits a large index that is 
dependent on cell shape but independent of cell size. 
 
 Detection of NF-κB activation 
For immunofluorescence detection of NF-κB nuclear translocation, cells were fixed 
as above and a standard indirect immunocytochemical technique was carried out using 
a polyclonal rabbit anti-p65 NF-κB subunit antibody (1:200; Santa Cruz Biotechnology®, 
CA, USA) as the primary antibody and an anti-rabbit Cy2 as the secondary antibody 
(1:1000; GE Healthcare, Chalfont St. Giles, UK). Microglial nuclei were stained with 
Hoechst 33258 dye. Fluorescence was visualized and acquired as above. NF-κB positive 
nuclei were identified by localization of the NF-κB p65 subunit staining exclusively at the 
nucleus and total cells were counted to determine the percentage of NF-κB-positive 
nuclei at each cell DIV group. 
 
 Determination of cell death 
We used phycoerythrin-conjugated annexin V (annexin V-PE) and 7-amino-
actinomycin D (7-AAD) (Guava Nexin® Reagent, #4500-0450, Millipore) to determine 
the percentage of viable, early-apoptotic and late-apoptotic/necrotic cells by flow 
cytometry. After incubation adherent microglia were collected by trypsinization and 
added to the cells present in the incubation media. After centrifugation cells were 
resuspended in PBS containing 1% bovine serum albumin (BSA), stained with annexin 
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V-PE and 7-AAD, following manufacturer’s instructions, and analyzed on a Guava 
easyCyte 5HT flow cytometer (Guava Nexin® Software module, Millipore), as previously 
described (Barateiro et al., 2012). Three populations of cells can be distinguished in this 
assay: viable cells (annexin V-PE and 7-AAD negative), early apoptotic cells (annexin V-
PE positive and 7-AAD negative), and late stages of apoptosis or dead cells (annexin V-
PE and 7-AAD positive). 
 
 Assessement of microglia migration 
Cell migration assays were performed in a 48-well microchemotaxis Boyden 
chamber (Neuro Probe, Gaithersburg, MD, USA), as previously described (Miller and 
Stella, 2009) with minor modifications. The bottom wells, filled with ATP (10 µM), a known 
chemoattractant for microglia migration, served as positive controls. The 8 µm diameter 
polycarbonate membranes with polyvinylpyrrolidone (PVP) surface treatment was 
equilibrated in control medium and after chamber set up, 50 µl of cell suspension 
containing 2 x 104 cells was added to each top well. After 6 h incubation in a CO2 
incubator at 37ºC for microglial migration, membrane was fixed with cold methanol and 
cells stained with 10% Giemsa in PBS. Non-migrated cells on the upper side of the 
membrane were wiped off with a filter wiper. The rate of migration was determined by 
counting cells on the lower membrane surface in 10 microscopic fields to cover all the 
well, acquired using a Leica DFC490 camera adapted to an AxioSkope HBO50 
microscope. For each experiment, at least three wells per condition were analyzed. 
 
 Evaluation of phagocytic properties of microglia 
To evaluate the phagocytic capacity of the primary microglial cultures, cells collected 
at 2 and 16 DIV were incubated with 0.0025% (w/w) of 1 μm fluorescent latex beads 
(Sigma Chemical Co., St. Louis, MO, USA) for 75 min at 37ºC and fixed with freshly 
prepared 4% (w/v) paraformaldehyde in PBS. Microglia were stained for Iba1, nuclei 
counterstained with Hoechst dye, and fluorescence was visualized and acquired as 
above. The number of ingested beads per cell was counted. Results are presented as 
mean number of ingested beads per cell and as the percentage of cells that 
phagocytosed <5, 5-10 or >10 beads. 
 
 Determination of supplementary features of microglia reactive ability 
We used several markers to assess microglia reactive ability, such as the 
concentration of glutamate and the activation of MMP2 and MMP9 in the extracellular 
media, together with the expression of TLR2, TLR4, miR-124 and miR-155. 
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Glutamate content in the media derived from microglial cultures was determined as 
described before (Silva et al., 2012) by an adaptation of the L-glutamic acid kit (Roche), 
using a 10-fold volume reduction. The reaction was performed in a 96-well microplate 
and the absorbance measured at 490 nm. A calibration curve was used for each assay. 
All samples and standards were analyzed in duplicate and the mean value was used.  
Detection of MMPs activity was performed as previously mentioned (Silva et al., 
2010). Aliquots of culture supernatant were analyzed by SDS-PAGE zymography in 
0.1% gelatine–10% acrylamide gels under non-reducing conditions. After 
electrophoresis, gels were washed for 1 h with 2.5% Triton X-100 (in 50 mM Tris pH7.4; 
5 mM CaCl2; 1 μM ZnCl2) to remove SDS and renature the MMP species in the gel. Then 
the gels were incubated in the developing buffer (50 mM Tris pH7.4; 5 mM CaCl2; 1 μM 
ZnCl2) overnight to induce gelatine lysis. For enzyme activity analysis, the gels were 
stained with 0.5% Coomassie Brilliant Blue R-250 and destained in 30% ethanol/10% 
acetic acid/H2O. Gelatinase activity, detected as a white band on a blue background, 
was quantified by computerized image analysis and normalized with total cellular protein.  
TLR2 and TLR4 mRNA expression was performed by RealTime PCR as usual in 
our laboratory (Barateiro et al., 2013). Total RNA was extracted from microglia using 
TRIzol® (LifeTechnologies), according to manufacturer’s instructions. Total RNA was 
quantified using Nanodrop ND-100 Spectrophotometer (NanoDrop Technologies, 
Wilmington, DE, USA). Aliquots of 0.5 μg of total RNA were treated with DNase I and 
then reverse transcribed cDNA using oligo-dT primers and SuperScript II Reverse 
Transcriptase under the recommended conditions. Quantitative RealTime PCR (qRT-
PCR) was performed using β-actin as an endogenous control to normalize the 
expression level of TLR2 and TLR4   transcription   factors.   The   following   sequences   
were   used   as   primers:  TLR2 sense 5’-TGCTTTCCTGCTGAAGATTT-3’ and anti-
sense 5’-TGTACCGCAACAGCTTCAGG-3’; TLR4 sense 5’-
ACCTGGCTGGTTTACACGTC-3’ and anti-sense 5’-GTGCCAGAGACATTGCAGAA-3’; 
β-actin sense 5’-GCTCCGGCATGTGCAA-3' and anti-sense 5’-
AGGATCTTCATGAGGTAGT-3’. qRT-PCR was performed on a 7300 Real time PCR 
System (Applied Biosystems) using a SYBR Green qPCR Master Mix (Fermentas). The 
PCR was performed in 96 well plates with each sample performed in triplicate, and no-
template control was included for each amplificate. qRT-PCR was performed under 
optimized conditions: 94ºC at 3 min followed by 40 cycles at 94ºC for 0.15 min, 62ºC for 
0.2 min and 72ºC for 0.15 min. In order to verify the specificity of the amplification, a 
melt-curve analysis was performed, immediately after the amplification protocol. Non-
specific products of PCR were not found in any case. Relative mRNA concentrations 
were calculated using the Pfaffl modification of the ΔΔCT equation (CT, cycle number at 
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which fluorescence passes the threshold level of detection), taking into account the 
efficiencies of individual genes. The results were normalized to β-actin in the same 
sample and the initial amount of the template of each sample was determined as relative 
expression by the formula 2-ΔΔCT. ΔCT is a value obtained, for each sample, by the 
difference between the mean CT value of each gene and the mean CT value of β-actin. 
ΔΔCT of one sample is the difference between its ΔCT value and ΔCT of the sample 
chosen as reference, in our case 2 DIV cells. 
Expression of miR-124 and miR-155, which has been related with microglia 
activation phenotype, was performed by RT-PCR. Total RNA was extracted from primary 
microglia cultures using the miRCURY™ Isolation Kit – Cells (Exiqon), according to the 
manufacturer’s recommendations for cultured cells. Briefly, after cell lysis, the total RNA 
was adsorbed to a silica matrix, washed with the recommended buffers an eluted with 
35 µl RNase-free water by centrifugation. After RNA quantification, cDNA conversion for 
miRNA quantification was performed with the universal cDNA Synthesis Kit (Exiqon) 
using 20 ng total RNA according to the following protocol: 60 min at 42ºC followed by 
heat-inactivation of the reverse transcriptase for 5 min at 95ºC. qRT-PCR was performed 
in an iQ5 thermocycler (Applied Biosystems) using 96-well plates. For miRNA 
quantification the miRCURY LNA™ Universal RT microRNA PCR system (Exiqon) was 
used in combination with pre-designed primers (Exiqon) for miR- miR146a and sRNA U6 
(reference gene). The reaction conditions consisted of polymerase 
activation/denaturation and well-factor determination at 95ºC for 10 min, followed by 50 
amplification cycles at 95ºC for 10 s and 60ºC for 1 min (ramp-rate 1.6º/s). The miRNA 
fold change with respect to 2 DIV cells was determined by the Pfaffl method, taking into 
consideration different amplification efficiencies of miRNAs in all experiments. The 
amplification efficiency for each target was determined according to the formula: E = 10(-
1/S) – 1, where S is the slope of the obtained standard curve. 
 
 Assessment of microglia senescence 
Microglia senescence was evaluated by determining the activity of SA-β-gal, 
expression of miR-146a and capacity to undergo autophagy. Microglial SA-β-gal activity 
was determined using the Cellular senescence assay kit (Millipore), according to the 
manufacturer instructions. Microglial nuclei were counterstained with hematoxylin. 
Brightfield microscopy images of ten random microscopic fields were acquired per 
sample. The number of turquoise stained microglia (SA-β-gal-positive cells) was counted 
to determine the percentage of senescent cells. 
To confirm the senescent status of microglia it was also assessed the expression of 
the senescence-related miR-146a by RT-PCR. Total RNA was extracted and expression 
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of miR-146a was assayed using pre-designed primers (Exiqon) for miR-146a and sRNA 
U6 (reference gene) as described above. 
Autophagy was determined by both immunocytochemistry of microtubule-
associated-protein-light-chain-3 (LC3) punctate and Western Blot detection of LC3 and 
Beclin 1 bands. For immunocytochemistry, cells were fixed as above and standard 
immunocytochemical technique was performed using a primary antibody raised against 
LC3 protein (rabbit, 1:500; Cell Signaling Technology Inc., MA, USA),  and a secondary 
Alexa Fluor 488 goat anti-rabbit antibody (1:1000; Invitrogen Corporation, CA, USA). To 
identify the total number of cells, microglial nuclei were stained with Hoechst 33258 dye. 
Fluorescence was visualized and images acquired as above. The method is based on 
the increased localization of LC3 autophagosomes when autophagy is induced. Thus 
the punctate fluorescence produced by LC3 staining provides a sensitive and specific 
indicator of autophagy (Aoki et al., 2008). Microglial cells presenting LC3 punctate were 
counted and the percentage of LC3 punctate-positive cells relatively to total microglia 
was determined. In addition, autophagy was further confirmed by detection of LC3-II, 
which is associated with autophagic vesicles (Kabeya et al., 2000), and Beclin 1 bands 
by Western Blot as usual in our laboratory (Barateiro et al., 2012). Cells were washed in 
ice-cold PBS, lysed in a buffer containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM 
Na2EDTA, 1 mM ethylene glycoltetraacetic acid, 1% (v/v) Triton X-100, 2.5 mM sodium 
pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4, 1 μg/mL leupeptine and 1 
mM phenylmethylsulfonyl fluoride, and sonicated for 20 s. The lysate was centrifuged at 
14,000 g for 10 min at 4ºC and the supernatants were collected and stored at -80ºC. 
Protein concentrations were determined using BioRad protein assay (BioRad). Cell 
extracts containing equal amounts of protein (50 µg) were separated on sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis and transferred to a nitrocellulose 
membrane. The membranes were blocked with 5% non-fat milk, incubated with the 
primary antibody overnight at 4ºC [rabbit anti-LC3B (1:1000) (#2775, Cell Signaling), 
mouse anti-Beclin 1 (1:500) (#MABC34, MerckMillipore) or mouse anti-β-actin (1:5,000) 
(Sigma)], and then with a horseradish peroxidase-labelled secondary antibody for 1 h at 
room temperature. After extensive washes, immunoreactive bands were detected by 
LumiGLO® (Cell Signalling, Beverly, MA, USA) and visualized by autoradiography with 
Hyperfilm ECL. Results were normalized to β-actin expression and expressed as fold vs. 
vehicle-treated cells. 
 
 Statistical analysis 
Significant differences between the parameters evaluated were determined by the 
two-tailed Student’s t-test performed on the basis of equal and unequal variance, as 
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appropriate. Comparison of more than two groups (microglia morphology, NF-kB 
activation) was done by ANOVA using GraphPad Prism 5 (GraphPad Software Inc., San 
Diego, CA, USA) followed by multiple comparisons Bonferroni post-hoc correction. p 
value less than 0.05 were considered statistically significant. 
 
 
3. Results 
 In vitro ageing changes microglia morphology to a more ramified cell shape 
Phenotypic changes in microglia are often accompanied by a morphological 
transformation, which has been widely used to categorize different activation states. In 
general, ramified quiescent microglia changes to an activated state displaying larger 
somata and shorter, coarser cytoplasmic processes progressing to a full amoeboid 
morphology (Fujita et al., 1996; Kozlowski and Weimer, 2012). Interestingly, microglia 
isolated from adult and aged animals show a propensity to acquire a more ramified 
morphology with thicker and more extensive processes (Lai et al., 2013), indicative of a 
less activated phenotype with age. So, we started by characterizing microglia 
morphology at 2, 10 and 16 DIV, following immunollabeling with the cell-specific marker 
Iba1. As shown in Figure 2.1, diverse morphological forms of microglia may be observed 
throughout cell culturing. The microglial cells at 2 DIV were almost exclusively amoeboid, 
most frequently evidencing an ovoid shape with a few cells presenting fusiform shape 
(Figure 2.1A). At 10 DIV, microglia evidence a more heterogeneous morphology with an 
increased number of cells showing a ramified morphology, bearing typically one or two 
large processes or a single large lamellipodia, together with larger amoeboid forms 
(Figure 2.1B). Microglia cultures at 16 DIV still exhibited distinct polarized populations 
showing rod-like microglia, bipolar microglia with shorter processes and the residual 
amoeboid cells (Figure 2.1C). To quantitatively evaluate the effect of age on microglia 
morphology we measured the area, perimeter, and Feret’s maximum diameter of 
microglia (Figure 2.1D-F). Consistent with a transformation of amoeboid to microglia 
ramified forms, the area, perimeter and the Feret’s maximum diameter significantly 
increased at 16 DIV (~2.0-fold, ~1.6-fold and ~1.6-fold, respectively, p < 0.05). Analysis 
of the transformation index value, a dimensionless number that reflects the degree of 
process extension, revealed a continuum of the microglial phenotype between the 
amoeboid and the ramified morphologies (Figure 2.1G). While younger cultures with a 
predominant amoeboid microglia shape present a low transformation index, older 
cultures with a more heterogeneous morphological repertoire involving cells with 
amoeboid and ramified morphologies, displayed an increased transformation index 
(~1.6-fold, p <0.05). 
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Figure 2. 1 – Microglia morphology changes from amoeboid to a more ramified shape with cell ageing 
in culture. Microglial cells were kept in culture for 2, 10 and 16 days in vitro (DIV), immunostained for Iba1 
and their morphology analyzed. (A) At 2 DIV, microglia were amoeboid with ovoid shape (arrow) and only a 
few showed a ramified bipolar morphology (arrowhead). (B) At 10 DIV, microglia became more 
heterogeneous with more cells presenting a ramified morphology (arrowhead), bearing a single large 
lamellipodia (*) and some a larger amoeboid shape (arrowhead). (C) At 16 DIV cells exhibited distinct 
polarized populations including ramified rod-like microglia (arrowhead), bipolar microglia with shorter 
processes (*) and residual amoeboid cells (arrow). Microglia area (D), perimeter (E) and Feret’s diameter 
(F) values were measured using the computer program ImageJ; transformation index values (G) were 
calculated as [perimeter of cell (µm)]2/4π [cell area (µm2)]. Cultures, n = 4 per group. Post-hoc Bonferroni 
test *p < 0.05, **p < 0.01 vs. 2 DIV cells. Each value represents the mean ± SEM. Scale bar equals 50 µm. 
 
 
 In vitro ageing reduces microglia NF-κB activation 
Microglia play key immune-related duties, intervening through the production of anti-
inflammatory compounds and trophic factors, by phagocytosing non-functional cell and 
debris, but also by releasing pro-inflammatory cytokines, depending on the stimuli. 
Production of several cytokines during microglial activation process is associated with 
the activation of the inducible transcription factor NF-κB (O'Neill and Kaltschmidt, 1997). 
To explore whether microglia morphological changes along the time in culture could be 
related with the cell activation state, we investigated NF-κB transactivation at the time 
Chapter 2 
 
94 
points used to assess morphological alterations. Following microglia immunollabeling for 
p65 NF-κB subunit, we determined the number of NF-κB-positive nuclei as an indicator 
of its activation (Figure 2.2). Our results show that microglia express maximal NF-κB 
activation at 2 DIV decreasing significantly thereafter and reaching minimal levels at 16 
DIV (~0.4-fold vs. 2 DIV, p < 0.01). These results corroborate the previous data in cell 
morphology and reinforce that microglia are highly reactive at 2 DIV but reduce their 
activation profile to a minimum state at 16 DIV. Thus, to settle that microglia at these in 
vitro stages may be associated to activated (2 DIV) and to age-like irresponsive cells (16 
DIV), we additionally explored several markers that have been associated to age-related 
alterations in the dynamic behaviour of microglia.
 
Figure 2. 2 – NF-κB activation decreases with microglia ageing in culture.  Microglial cells were 
kept in culture for 2, 10 and 16 days in vitro (DIV), immunostained for NF-κB (green) and their nuclei stained 
with Hoechst dye (blue). (A) Representative images at 2, 10 and 16 DIV. (B) Cells bearing a NF-κB-positive 
nuclei were counted and results expressed in graph bars as mean ± SEM. Cultures, n = 4 per group. Post-
hoc Bonferroni test *p < 0.05, **p < 0.01 vs. 2 DIV cells. Scale bar equals 50 µm. 
 
 Aged microglia show a residual migration ability 
Microglia directed migration towards regions of injury, also known as chemotaxis, is 
a property that seems to be more related to the classically (M1) and alternatively 
activated microglia (M2a) (Lively and Schlichter, 2013). The release of chemotactic 
molecules upon brain damage, such as ATP, was indicated to participate in the 
recruitment of microglia toward lesion sites (Miller and Stella, 2009; Kettenmann et al., 
2011). Nevertheless, it was reported that microglia respond to ATP regardless of their 
activation state (Lively and Schlichter, 2013). Hence, we evaluated the ability of 2 and 
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16 DIV microglia to migrate towards 10 µM ATP. As shown in Figure 2.3, 16 DIV 
microglia revealed a poor ability to migrate to ATP when compared to 2 DIV cells (~0.1-
fold, p < 0.01). This finding points to a 2 DIV population of reactive microglia with capacity 
to migrate to local brain injury in contrast to the aged cells that lose invasion capacity 
property. 
 
 Aged microglia show reduced phagocytic ability 
Microglia are considered the professional phagocytes of the CNS, a function that is 
crucial along brain development, as well as in pathology and regeneration (Kettenmann 
et al., 2011). Therefore, and based on the previous results, we hypothesized that ageing 
in culture could also have adverse effects on microglia phagocytic properties. As 
expected, 16 DIV microglia showed reduced engulfment ability when compared to 2 DIV 
cells (Figure 2.4A). Indeed, the average number of beads phagocytosed by each 
microglial cell was markedly reduced from 2 to 16 DIV (~0.5-fold, p < 0.01). In addition, 
we observed that aged microglia function less effectively than the 2 DIV cells based on 
the increased number of cells that engulf a small number of beads (p < 0.01) together 
with a decreased ability to digest 5 or more beads (p < 0.05) (Figure 2.4B). Altogether 
these data suggest that in vitro ageing of microglia obtained from neonatal mice change 
their dynamic behavior to a more inert or irresponsive phenotype compatible with an 
irresponsive/senescent cell. 
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Figure 2. 3 – Microglia migration ability decrease with cell ageing in culture. Microglial cells were kept 
in culture for 2 and 16 days in vitro (DIV) and then cellular chemotactic migration to 10 µM ATP was evaluated 
using the Boyden chamber method. Representative images of 2 (A) and 16 (B) DIV microglia that migrated 
towards ATP were visualized by Giemsa staining. Number of migrated cells was counted and results 
expressed in graph bars as mean ± SEM (C). Cultures, n = 4 per group. t- test **p < 0.01 vs. 2 DIV cells. 
Scale bar equals 50 µm. 
 
 Microglia retain viability during in vitro ageing 
Given our previous results we wondered whether the loss of microglia function by in 
vitro ageing was a consequence of reduced cell viability.  Therefore, we evaluated 
microglia cell death by flow cytometry following staining with annexin V-PE and 7-AAD, 
to differentiate the total amount of cells (adherent plus detached) into viable, early 
apoptotic and late apoptotic/necrotic cells. As shown in Table 2.1, we did not observe 
differences in cell death between the 2 and the 16 DIV microglia, confirming that changes 
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in aged microglia response are not due to reduced viability but rather derive from a switch 
in cellular phenotype and its properties.  
 
Figure 2. 4 – Microglia phagocytic ability decrease with cell ageing in culture. Microglial cells were 
kept in culture for 2 and 16 days in vitro and then exposed to fluorescent beads to measure their phagocytic 
capacity. Number of phagocytized beads per cell (A) and the number of microglia phagocytosing < 5, 5-10 
and > 10 beads  (B) was counted and results expressed in graph bars as mean ± SEM. Cultures, n = 4 per 
group. t- test and post-hoc Bonferroni test *p < 0.05, **p < 0.01 vs. 2 DIV cells. 
 
 
Table 2. 1 – Viability of culturing microglia 
  Viable  Early-apoptosis  Late-apoptosis/ necrosis 
2 DIV  81.8 (±2.6) 9.7 (±0.3)  6.2 (±2.2) 
16 DIV  81.7 (±3.0) 11.4 (±1.9)  7.4 (±1.6) 
 
All results are means ± SEM from at least four independent experiments. Microglial were kept in culture for 
2 and 16 days in vitro (DIV). The percentage of viable microglia and microglia in early- or late-
apoptosis/necrosis was determined by flow cytometer with phycoerythrin-conjugated annexin V (annexin V-
PE) and 7-amino-actinomycin D (7-AAD).  The three populations were distinguished as follows: viable cells 
(annexin V-PE and 7-AAD negative), early apoptotic cells (annexin V-PE positive and 7-AAD negative), and 
cells in late stages of apoptosis or dead cells (annexin V-PE and 7-AAD positive). 
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 Supplementary features of microglia reactive ability are reduced in aged 
cells 
Since 16 DIV microglia have shown decreased ability to respond to chemotactic 
signals or to phagocytose extracellular particles, features that were not related with loss 
of cell survival (Table 2.1), we next decided to evaluate whether microglia aged in culture 
would also present additional markers of reduced reactive ability. Glutamate was shown 
to be released by activated microglia (Noda et al., 1999; Barger et al., 2007; Takaki et 
al., 2012), so we decided to evaluate the extracellular content of glutamate. As depicted 
in Figure 2.5A, 16 DIV microglia showed to release lower levels of glutamate to the 
culture media than the 2 DIV cells (~0.7-fold, p < 0.01). Interestingly, when evaluating 
MMP2 and MMP9 activation in the extracellular media we verified that the influence of 
ageing was also notorious (Figure 2.5B). Indeed we observed a marked increase of 
MMP2 (~2.2-fold, p < 0.05) and a decrease of MMP9 (~0.6-fold, p < 0.05) in the aged 
microglia when compared to 2 DIV cells. Again, the expression of TLR2 and TLR4 that 
is associated with microglia activation (Banks and Robinson, 2010; Liu et al., 2012) very 
much decreased in the 16 DIV microglia (~0.4-fold, p < 0.01, Figure 2.5C). Recently, 
immune regulation by miR-124 was indicated to downregulate microglia activation 
(Ponomarev et al., 2011) in contrast with miR-155 that was shown to have a pro-
inflammatory role in microglia (Cardoso et al., 2012), to be related with the M1 phenotype 
(Ponomarev et al., 2013) and to be up-regulated upon activation (Lu et al., 2011). 
Corroborating previous findings, the decreased expression of both miR-124 and miR-
155 in 16 DIV microglia, as compared to 2 DIV cells (~0.5- and 0.4-fold, respectively, p 
< 0.01), further reinforce that the cells become irresponsive/senescent when maintained 
in culture. 
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Figure 2. 5 – Microglia supplementary features of reactive ability are reduced in aged cells. Microglial 
cells were kept in culture for 2 and 16 days in vitro (DIV). (A) Extracellular glutamate levels were determined 
using a commercial kit. (B) Metalloproteinases (MMP)-2 and MMP9 activities assessed by gelatin 
zymography. Expression of TLR2 and TLR4 (C), as well as of miR-124 and miR-155 (D) was evaluated by 
RealTime PCR. Results are expressed in graph bars as mean ± SEM. Cultures, n = 4 per group. t-test *p < 
0.05, **p < 0.01 vs. 2 DIV cells. 
 
 16 DIV microglia show common markers of senescence 
Senescent microglia have been described to become dysfunctional and less efficient 
in their neuroprotective effects during ageing in the human brain and in AD (Streit and 
Xue, 2012; Krabbe et al., 2013). The main proposal of the present study was to obtain 
an experimental model able to reproduce irresponsive/senescent microglia and be used 
for exploring detrimental effects by ageing and associated-neurodegenerative diseases. 
As so, we decided to evaluate if the in vitro aged microglia displayed typical signs of cell 
senescence. The senescence phenotype has been associated with changes in cellular 
morphology, increased activity for SA-β-gal, permanent DNA damage, chromosomal 
instability and altered inflammatory secretome (Sikora et al., 2011). More recently, new 
biomarkers of age-associated senescence have been reported including an increased 
expression of miR-146a in aged macrophages (Jiang et al., 2012) and a reduced 
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capacity to undergo autophagy (Ma et al., 2011). Quantitative assay of SA-β-gal activity 
revealed that the percentage of positively stained cells markedly increased from 2 to 16 
DIV (~2.5-fold, p < 0.01), as evidenced in Figure 2.6A-B. Similarly, we noticed a 
significant elevation in the expression of miR-146a along the cell ageing in culture (~2.3-
fold, p < 0.05, Figure 2.6C). Finally, we evaluated autophagic capacity by LC3 
immunostaining. As it may be observed in Figure 2.7A, 2 DIV cells display an increased 
amount of LC3 punctates when compared to 16 DIV microglia. Counting of LC3 punctate-
positive cells confirmed that a reduced number of 16 DIV cells were undergoing 
autophagy (~0.7-fold, p < 0.05, Figure 2.7B). Next we evaluated the expression of LC3-
II that is formed through lipidation of LC3-I during autophagy (Kabeya et al., 2000) and 
we additionally determined the Beclin-1 protein, recognized to have a central role in such 
process (Kang et al., 2011), by Western Blot (Figure 2.7C-D). Our results clearly show 
that LC3-II and Beclin-1 are markedly reduced in in 16 DIV microglia when compared to 
2 DIV cells (~0.4-fold and ~0.3-fold, respectively, p <0.01), confirming a reduced 
autophagy by the aged microglia. 
 
Overall, our data indicate that primary microglia harvested from neonatal mouse 
pups first evidence an increased reactive ability changing to an irresponsive/senescent 
cell when maintained in culture. Aged cells evidence a reduced ability to become 
activated, to migrate and to phagocytose, in parallel with markers of cellular senescence. 
Therefore, this in vitro model can be very useful in the exploitation of microglia reactivity 
and irresponsiveness to stimuli, respectively. In addition, changes in microglia miRNA 
signature may constitute a precious help in evaluating the key role of microglia as a 
determinant in age-associated CNS disorders and in modulating microglia dynamic 
properties. 
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Figure 2. 6 – Microglia aged in culture display signs of senescence, including increased senescent-
associated β-galactosidase (SA-β-gal) activity and miR-146a expression. Microglial cells were kept in 
culture for 2 and 16 days in vitro (DIV). Activity of SA-β-gal was determined using a commercial kit. (A) 
Representative images of 2 and 16 DIV microglia showing SA-β-gal staining. (B) SA-β-gal-positive cells 
were counted and results expressed in graph bars as mean ± SEM. (C) miR-146a expression was evaluated 
by RealTime PCR. Results are expressed in graph bars as mean ± SEM. Cultures, n = 4 per group. t-test *p 
< 0.05, **p < 0.01 vs. 2 DIV cells. Scale bar equals 20 µm. 
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Figure 2. 7 – Microglia aged in culture show reduced autophagic capacity. Microglial cells were kept in 
culture for 2 and 16 days in vitro (DIV), immunostained for LC3 and total cell lysates were analyzed for the 
presence of LC3-II and Beclin-1. (A) Representative images of 2 and 16 DIV microglia showing LC3 
punctates. (B) Cells displaying LC3 punctates were counted and results expressed in graph bars as mean 
± SEM. (C) LC3-I/LC3-II and Beclin 1 protein expression was assessed by Western Blot and (D) 
densitometric analysis is expressed in graph bars as mean ± SEM. Cultures, n = 4 per group. t-test *p < 
0.05, **p < 0.01 vs. 2 DIV cells. Scale bar equals 20 µm. 
 
 
4. Discussion 
Experiments in this study set out to investigate age-specific differences in the 
dynamic functional profiles of neonatal microglia aged in culture, from 2 DIV up to 16 
DIV. Here we show that microglia isolated from neonatal pups evidence markers of 
reactive ability at early time culture changing their phenotype along in vitro culture to less 
responsive cells that present senescence biomarkers and miRNA profiling characteristic 
of microglia deactivation. Collectively, our results indicate that microglia ageing can be 
reproduced in vitro using long-term murine cultures, which may be used as a model to 
evaluate microglia performance in age-associated disorders, inasmuch due to the similar 
characteristics such cells evidence to human microglia (Torres-Platas et al., 2014).  
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Mouse primary neonatal microglial cultures have the advantage to more closely 
represent their in situ counterparts when compared to immortalized cells, although by 
growing in isolation lack the normal CNS microenvironment (Ni and Aschner, 2010). 
Indeed, primary cultured microglia are not oncogene immortalized and are differentiated 
in mixed glial cultures before isolation. The protocol here described originates microglial 
cultures that exceed 97% purity and has been used as a model for activated CNS-
resident microglia (Carson et al., 1998; Schmid et al., 2009) and to prepare polarized M1 
and M2 phenotypes (Jang et al., 2013). Indeed, it was previously suggested that the 
isolation process is a sufficient stimulus to induce microglia activation (Cristovão et al., 
2010). There is a high controversy on whether neonatal microglia are less (Moussaud 
and Draheim, 2010) or more reactive than adult (Christensen et al., 2014) and aged cells 
(Njie et al., 2012). Discrepancies also exist in the scientific community based on studies 
that consider microglia overactivation and increased release of pro-inflammatory 
cytokines with age and neurodegenerative diseases (for review see (Wong, 2013; 
Mosher and Wyss-Coray, 2014), in contrast with others evidencing dystrophic microglia 
and senescence (Streit et al., 2004; Streit and Xue, 2013), decreased phagocytosis 
(Floden and Combs, 2011; Li, 2013), lower reactivity to stimulation (Damani et al., 2011; 
Njie et al., 2012), delayed response to exogenous ATP  and decreased microglial 
process motility (Hefendehl et al., 2014). Such contradictory results may be caused by 
different experimental sets and conditions. Moreover, most of the data were derived from 
experimental models using LPS-induced microglia activation, when it is well known that 
only a small amount is able to enter the brain parenchyma (Banks and Robinson, 2010). 
Therefore, the effects of peripheral immunostimulation by intravenously administered 
LPS dose are indirect and some of them mediated by the cells that comprise the BBB. 
Another important aspect to consider is that nonsteroidal anti-inflammatory drugs were 
only successful when administered before the development of neurodegeneration 
(Weggen et al., 2001). When administered in later stages of disease they showed to be 
detrimental (Martin et al., 2008). These findings may underlie a first proinflammatory 
stage in neurodegenerative diseases associated to neuroinflammmation, later switching 
to dysfunctional neurodegeneration associated with a loss of microglia dynamic 
properties. Indeed, neither the typical inflammatory nor the anti-inflammatory phenotypes 
were identified at end-stage amyotrophic lateral sclerosis (Nikodemova et al., 2013) and 
microglial dystrophy associated with their senescence (Flanary, 2005), as well as to aged 
and AD brain (Lopes et al., 2008). 
Lack of knowledge on the molecular mechanisms implicated in aged microglia 
dysfunction and how it is related to an increased individual vulnerability to 
neurodegenerative diseases has hindered the development of effective therapy for 
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preventing or even halting the CNS network degenerative process. Major problems to 
investigate such mechanisms are determined by the current in vitro microglial models 
using cell lines, primary microglia isolated from neonatal murine animals and ex vivo 
isolation from adult and aged brain. First models are not suitable for the research of 
neurodegenerative diseases where ageing is crucial since long-term culture experiments 
are critical, and the last one only provides specific microglia subsets that resist to the 
isolation procedure (Moussaud and Draheim, 2010; von Bernhardi et al., 2011) or that 
are separated based on immunomagnetic cell sorting steps (Cardona et al., 2006). 
However, mixed microglial populations may coexist in the CNS and were also shown to 
be developed in culture (Szabo and Gulya, 2013; Gertig and Hanisch, 2014). In addition, 
microglia functionality from adult and aged animals is not well preserved, the yield is low 
and the cells undergo extensive cell death resulting in activation of the surviving 
population (von Bernhardi et al., 2011). The in vitro model we developed to obtain 
microglia senescence in primary culture has been used to identify ageing-associated 
changes in fibroblasts at the molecular level (Chen et al., 2009). Finally, we have not 
used microglia culturing with astrocytes to avoid the complex interactions between these 
cells (Tanaka et al., 1999) that would be a disadvantage to assess natural microglia 
maturity and senescence. Therefore, establishment of well-defined stable in vitro 
cultures freshly isolated from neonatal mice and characterization of microglial phenotype 
with the time in culture may provide advantages over the other methods to determine 
ageing microglial dynamics modifications and therapeutic approaches to recover 
microglial functionality. 
Microglia morphology changed along in vitro maintenance from an almost exclusive 
round amoeboid shape to distinct polarized populations, including an increased number 
of ramified cells. In accordance, mixed primary glial cultures from embryonic rats have 
previously showed the existence of cells with an amoeboid morphology in the early 
stages of in vitro differentiation, which changed to mixed populations of amoeboid and 
ramified cell morphologies in older cultures (Szabo and Gulya, 2013). Interestingly, data 
from microglia isolated from different age animals also corroborate such findings with 
adult microglia presenting a more ramified morphology, in contrast with an amoeboid 
shape of embryonic and neonatal microglia (Lai et al., 2013). This is in line with in vivo 
data indicating that invading neonatal microglia have a predominant rounded 
morphology that differentiate with time into a surveying phenotype characterized by a 
small soma and highly branched processes (Hanisch and Kettenmann, 2007). Our aged 
microglia cultures besides exhibiting ramified and amoeboid cells also presented cells 
with a bipolar shape and shorter large processes. Morphological signs of microglia 
senescence with ageing were observed in vivo and defined as abnormal morphological 
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features, such as shortened, gnarled, beaded, or fragmented cytoplasmic processes, 
and loss of fine ramifications and formation of spheroidal swellings (Streit et al., 2004). 
Therefore, we hypothesize that such cells with shortened processes represent microglia 
with less ability to become reactive and should include a relevant population of senescent 
microglia. 
 
The morphological changes of in vitro ageing microglia occurred in parallel with a 
decrease in the transactivation of NF-κB. It is well known that this transcription factor is 
found throughout the cytoplasm, translocating to the nucleus upon activation triggering 
the transcription of target genes, such as the pro-inflammatory cytokines (O'Neill and 
Kaltschmidt, 1997). Therefore, maximal activation of NF-κB two days after isolation is 
consistent with an inflammatory phenotype that shifts to a deactivated microglia along 
with the time in culture. Intriguingly, although we showed a decreased NF-κB activation 
at 16 DIV, the activation of this transcription factor has been associated with the ageing 
process. A recent report has shown that hypothalamic microglial NF-κB activation 
promoting a residual inflammatory status is required for systemic ageing (Zhang et al., 
2013). Nevertheless, a marked down-regulation of NF-κB was also observed in cultured 
senescent human WI-38 fibroblasts (Helenius et al., 1996). Considering that activators 
of the NF-κB signalling pathway are determinants of inflammation and ageing process 
(Balistreri et al., 2013) and that CNS inflammation is present in the early stages of age-
related disorders such as AD but disappears with disease progression (Streit et al., 
2009), our in vitro aged microglia may represent a dystrophic and irresponsive phenotype 
whose functions have progressively declined as recently observed in mice with AD-like 
pathology (Krabbe et al., 2013).  
 
The reduced migration observed for 16 DIV cells is in line with recent data showing 
that aged microglia become less dynamic with slower acute responses and lower rates 
of process motility (Damani et al., 2011). Here we measured ATP-induced microglial 
chemotaxis, which occurs via P2X4R and P2Y12R purinergic receptors (Ohsawa et al., 
2007). Interestingly, even considering that the expression of P2X4R in microglia is not 
age-dependent, the P2Y12R expression varies with animal age increasing to a maximum 
at 6-8 months and decreasing thereafter to extremely low levels at 13-15 months (Lai et 
al., 2013). Thus, it is possible that our aged microglia present reduced expression of 
purinergic receptors which may be in the origin of the reduced ability to migrate to ATP. 
Moreover, since it was demonstrated that monocyte chemoattractant protein-1 (MCP-1) 
that is produced downstream NF-κB activation is involved in the migration of microglia 
(Deng et al., 2009), based on the age-dependent reduction of NF-κB nuclear 
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translocation we have observed it is reasonable to consider that the MCP-1-dependent 
migration pathway may also be affected. 
 
Phagocytosis is crucial to maintain tissue homeostasis and innate immune balance, 
by ingesting both foreign pathogens and autologous apoptotic cells (Napoli and 
Neumann, 2009). Infectious pathogens are phagocytosed through TLRs or complement 
receptors to elicit the release of pro-inflammatory cytokines (Napoli and Neumann, 
2009), while apoptotic cells or cellular debris are internalized through phosphatidylserine 
receptors, integrins or TREM2 to trigger immunosuppressive signaling with the release 
of anti-inflammatory cytokines (Li, 2012). During ageing, clearance of both foreign 
pathogens and autologous apoptotic cells is diminished and has been associated with 
immunosenescence (Li, 2013). In accordance, microglia from aged mice also 
internalized less amyloid-β peptide (Aβ) than microglia from neonatal or young mice (Njie 
et al., 2012), corroborating our findings that 16 DIV microglia have a reduced ability to 
phagocytose possibly due to the manifestation of a senescent phenotype. Interestingly, 
microglial cells maintained in mixed primary neuronal-glial co-cultures were shown to 
phagocytose more when amoeboid than in the ramified form, a property that decreased 
during culturing (Szabo and Gulya, 2013). In agreement, we observed a shift to a more 
ramified phenotype with cell ageing, which paralleled a reduced phagocytic ability. 
 
Activated microglia were shown to release increased levels of glutamate (Noda et 
al., 1999; Barger et al., 2007; Takaki et al., 2012). However, several studies have shown 
lower glutamate concentration in older subjects when compared to younger individuals 
(Kaiser et al., 2005; Sailasuta et al., 2008; Chang et al., 2009) and an age-dependent 
decline of glutamate release in mice (Minkeviciene et al., 2008). This finding is in line 
with the reduced glutamate levels we obtained in aged cell cultures. Similarly, the 
increased activation of MMP2 we observed in 16 DIV microglia was identified in 
senescent cells (Liu and Hornsby, 2007; Lu et al., 2009; Malaquin et al., 2013). In what 
concerns MMP9 there is some discrepancy between authors. Some indicate increased 
activity with age (Simpson et al., 2013) and others a decrease (Bonnema et al., 2007; 
Paczek et al., 2008), as we obtained. Furthermore, we think that the marked reduced 
expression we obtained at 16 DIV microglia for TLR2 and TLR4 (0.5-fold and 0.4-fold, 
respectively), as compared to 2 DIV cells, define with no doubt that 16 DIV microglia will 
be less able to respond to LPS immunostimulation. Actually, TLR4 that is critical for the 
recognition of LPS, as well as TLR2 that also recognizes some LPS species, are 
inducers of microglia activation leading to the production of proinflammatory cytokines 
(Banks and Robinson, 2010; Liu et al., 2012). Curiously, the TLR4 downregulation-
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mediated supression of TNF-α and IL-1β expression revealed to also be accompanied 
by the suppression of NF-κB (Yao et al., 2013). 
 
MicroRNAs (miRNAs) are an abundant class of highly evolutionarily conserved small 
noncoding RNAs that are involved in posttranscriptional gene silencing, regulating 
diverse biological processes (Ambros, 2004). miR-146a was first associated with the 
innate immune response as a negative feedback regulator in TLR signaling (Taganov et 
al., 2006), and more recently implicated in age-related dysfunction of macrophages 
(Jiang et al., 2012). Our results clearly showed that aged microglia express increased 
levels of miR-146a, thus corroborating their senescent phenotype. Interestingly, 
expression of miR-146a that has been associated with several neurodegenerative 
disorders (Sinha et al., 2011; Jiang et al., 2013), was found elevated in the aged mouse 
(Jiang et al., 2012; Olivieri et al., 2013), in the cerebrospinal fluid of AD patients 
(Alexandrov et al., 2012), and to be induced in microglia upon Aβ and inflammatory 
challenge (Li et al., 2011). As so, our in vitro old microglia reproduce the ageing-
associated phenotype encountered in in late-life common disorders. Moreover, 
decreased miR-124 and miR-155 that revealed a negative correlation with age 
(Fichtlscherer et al., 2010; Noren Hooten et al., 2010; Smith-Vikos and Slack, 2012), 
parallelled by the enhanced miR-146a expression, further reinforce that 16 DIV microglia 
mainly represent aged-like microglia. In addition, the reduced miR-124 obtained in these 
cells, indicated as being associated to the M2a-alternatively activated state (Freilich et 
al., 2013) and to inhibit inflammation (Prinz and Priller, 2014), strengthen their 
dormant/senescent phenotype. In contrast, the predominant amoeboid morphology 
together with increased NF-κB activation, cell migration, phagocytosis and the higher 
levels of miR-155 expression in 2 DIV microglia, as compared with aged cells, are 
indicative of a major representation of cells with a stressed/reactive phenotype. Indeed, 
a strong up-regulation of miR-155 expression was shown to have a pro-inflammatory 
role in microglia (Cardoso et al., 2012) and to drive the M1 phenotype (Ponomarev et al., 
2013) corroborating the stressful properties of 2 DIV cultured cells.  
 
Nowadays, changed morphology and increased activity of SA-β-gal of permanently 
growth arrested cells are considered cellular senescence markers (Sikora et al., 2011). 
In accordance, 16 DIV microglia displayed a marked increase of SA-β-gal activity when 
compared to 2 DIV cells. The activity of SA-β-gal was also associated with senescence-
unrelated settings, such as contact inhibition or serum starvation (Severino et al., 2000). 
Nevertheless, as observed by the Iba1 pictures, our microglia culture did not reach 
confluence and was not cultured under serum starvation, attesting that the increase of 
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SA-β-gal activity results from a senescent phenotype. Indeed, decreased microglia 
migration, phagocytic ability, NF-κB activation and increased SA-β-gal, as we here 
observed, have been indicated as hallmarks of microglial ageing and cell senescence 
(Mosher and Wyss-Coray, 2014).  
 
Several neurodegenerative diseases are characterized by the formation of 
intracellular protein aggregates in affected brain regions, indicating a failure of protein 
degradation system (McCray and Taylor, 2008). Autophagy is a stress-induced catabolic 
process responsible for the degradation of long-lived proteins and damaged organelles 
(Levine and Klionsky, 2004) that was shown to decline with ageing (Bergamini, 2006) 
and to determine cell and individual lifespan (Juhasz et al., 2007). A study using the 
senescence accelerated mouse prone 8, a rodent model of ageing and senile dementia, 
showed a reduced autophagic activity by ageing with long-lasting autophagosomes and 
increased LC3 expression (Ma et al., 2011). In accordance, affected neurons with 
abnormal autophagosomes (Lee, 2009) and impaired of autophagy (Komatsu et al., 
2006) were seen in neurodegeneration. We showed that 16 DIV microglia display a 
reduced amount of LC3 punctates suggestive of a decreased formation of 
autophagossomes. This finding was further corroborated by the decrease we also 
observed in the expression of Beclin 1 in the aged cells. Beclin 1 is known to intervene 
from autophagosome formation to autophagosome/endosome maturation but to also 
have other additional functions (Kang et al., 2011). Interestingly, Beclin 1 was recently 
considered to be required for efficient phagocytosis and to be reduced in microglia 
isolated from AD brains (Lucin et al., 2013), thus accounting to explain the reduced 
phagocytic ability in our 16 DIV cells and to such impairment in mice with AD-like 
pathology (Krabbe et al., 2013). 
 
It is worth mentioning that the 2 DIV and 16 DIV microglia differently react to some 
tested neurotoxins, as we anticipated. We used unconjugated bilirubin that has 
previously shown to induce the release of the pro-inflammatory cytokines TNF-α and IL-
1β from astrocytes and microglia in concentrations similar to those induced by 10 ng/ml 
LPS (Fernandes et al., 2004; Gordo et al., 2006; Brites et al., 2009), and Aβ at 50 nM, a 
concentration that was indicated to trigger microglia activation (Maezawa et al., 2011). 
The test was first directed to the expression of the high-mobility group box protein-1 
(HMGB1) a mediator of inflammation directly correlated with NK-κB protein activation 
(Rovina et al., 2013). Both stimuli enhanced cellular HMGB1 expression in 2 DIV 
microglia (80 and 100% increase for bilirubin and Aβ respectively; results not shown), 
without affecting the 16 DIV cells. Next, and similarly to what we have obtained for 
Microglia change from a reactive to na age-like phenotype with the time in culture 
109 
HMGB1, up-regulation of mRNA levels of IL-18 expression capable of more potently 
induce inflammatory response than IL-1β (Alboni et al., 2010) was again associated with 
the young/reactive microglia treated with bilirubin (60% increase over control) or Aβ 
(>100% increase over control) (data not shown), but no alterations were noticed in the 
aged cells. 
 
 
5. Conclusions 
Overall, we demonstrate that microglia isolated from neonatal mice and kept in vitro 
in long-term cultures switch from an activated/reactive phenotype to cells presenting 
ageing-like alterations. Our results show that in vitro aged microglia changes their 
morphology to a more ramified shape, with a reduced basal NF-κB activation, impaired 
migration and phagocytic abilities, low TLR2 and TLR4 expression, as well as reduced 
MMP9 and glutamate efflux. This study is the first to provide the inflamma-miRNA 
signature for microglia ageing in primary cultures. The cells evidenced decreased 
expression of miR-155 and miR-124, reduced autophagic capacity, and increased miR-
146a expression and SA-β-gal activity, consistent with the existence of senescent cells 
at 16 DIV in culture. In conclusion, given the phenotypical changes observed for 
young/reactive and irresponsive/senescent microglia along the time in culture, the in vitro 
model of microglia ageing could be of interest to assess how different signals may 
diversely modify cell functionality in separate microglia populations and to link increased 
age with risk for neurodegenerative diseases and other age-related phenomena. 
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Abstract 
Alzheimer’s disease (AD) is characterized by a progressive cognitive decline and 
self-aggregation of amyloid-β peptide (Aβ) into oligomers and amyloid fibrils that 
accumulate as senile plaques. Neuroinflammation is considered a hallmark of AD 
pathogenesis and is associated with the release of inflammatory mediators by the 
reactive astrocytes and activated microglia adjacent to Aβ plaques. To note, however, 
that microglia may exert either neuroprotective or neurotoxic responses depending on 
the physiological conditions they encounter and the phenotype they assume. In this 
study, we set out to determine if the 2 days in vitro (DIV) activated microglia in the course 
of the isolation procedure and the 16 DIV aged cultured microglia react differently to Aβ 
stressful stimulus. Cultured microglia were treated with 1000 nM Aβ1-42 for 24 h, which 
showed to not cause cell death, but to induce morphometric alterations that included 
soma volume increase and process shortening, less evident in 16 DIV microglia. Here 
we observed that several neuroprotective functions, namely phagocytosis and migration 
abilities, as well as autophagy, were impaired in in vitro aged microglia. Interestingly, Aβ 
treatment reduced the phagocytic capacity of the activated 2 DIV microglia and promoted 
autophagy, while increasing the activity of the senescence-associated β-galactosidase 
and the expression of miR-146a. Age-dependent changes included the decrease in the 
expression of inflammatory mediators and surface receptors from “young” to aged cells 
upon treatment with Aβ1-42. Additionally, Aβ caused a downregulation of miR-155 and 
miR-124, and reduced the CD11b+ subpopulation in 2 DIV microglia. Intriguingly, it 
increased the number of CD86+ cells in aged microglia. Finally, we observed that mixed 
M1 and M2 subpopulations occur after Aβ treatment, but that responses are largely 
attenuated in the aged microglia. Our data show the existence of key-aging associated 
alterations, with a predominant Aβ-induced microglia M1 polarization and loss of 
phagocytic ability in the 2 DIV cells, together with a decreased reactivity towards Aβ in 
the 16 DIV microglia. These findings help in improving our understanding on the 
heterogeneous responses that microglia may have along the progression of AD disease 
and imply that therapeutic approaches may differ from early to late stages. 
 
 
Keywords: Alzheimer’s Disease, amyloid-β peptide; neuroinflammation; aged-cultures 
microglia; inflammatory-microRNAs; M1/M2 microglia subtypes; CD11b; CD86 
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1. Introduction 
Alzheimer’s disease (AD) is the most common dementing disorder in the elderly 
affecting around 35.6 million people worldwide and is expected to duplicate in the years 
to come (Prince et al., 2013). Accumulation of extracellular β-amyloid (Aβ) plaques within 
the brain is suggested to result from the cleavage of the amyloid precursor protein (APP) 
which quantity is elevated in AD (Rubio-Perez and Morillas-Ruiz, 2012). Deposition of 
Aβ was shown to trigger the activation of both astrocytes and microglia leading to the 
production of pro-inflammatory cytokines such as interleukin (IL)-1β and  tumor necrosis 
factor (TNF)-α, among other compounds (Wyss-Coray, 2006), triggering 
neuroinflammation that is known to contribute  to AD progression and severity (Heneka 
et al., 2015a). However, treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) 
has consistently failed in AD patients (von Bernhardi, 2010), unless administrated early 
in the disease (Varvel et al., 2009). Recent studies in rodent models have shown that 
fenamate NSAIDS decrease microglia activation and IL-1β processing, which led the 
Authors to suggest that they may be repurposed as inhibitors of the NLRP3 
inflammasome (Daniels et al., 2016). If microglial malfunction trigger AD pathogenesis, 
contribute to altered microenvironment, and precede or facilitate AD onset (Regen et al., 
2017), clarification of the underlying molecular mechanisms should be clarified. 
Microglia are the first line and the main immune defense against disease and injury 
in the central nervous system (CNS). When activated by stress stimuli the cells migrate 
and restrict the damage by surrounding the site lesion and phagocytizing cell debris. 
Microglia are activated by oligomeric and fibrillar species of Aβ, as well as by molecules 
derived from degenerated neurons (Mizuno, 2012) and have shown capacity in amyloid 
removal (Morgan, 2009). However, at least in some conditions, the phagocytic and 
inflammatory phenotypes may alternate along time, depending on the microglia-induced 
polarization subtype (Silva et al., 2010). Actually, and depending on the stimuli, microglia 
may comprise a family of cells with diverse phenotypes exerting beneficial or destructive 
effects (Schwartz et al., 2006). Current researches also propose that age-dependent 
neuroinflammatory changes may play a significant role in the decreased neurogenesis 
and cognitive impairments observed in AD (Lynch et al., 2010; Varnum and Ikezu, 2012). 
In addition, it has been suggested that these cells may lose their ability to phagocytose 
Aβ with age and disease progression and that in late disease stages inflammation no 
longer exists (Floden and Combs, 2011; Wojtera et al., 2012). As so, there is an urgent 
need to understand age-dependent changes in microglia function and response to stimuli 
to better recognize the role of microglia in early and late-stages of Alzheimer's disease. 
Over the years there have been studies intended to identify different activation 
phenotypes in several in vitro and in vivo models, as well as in AD brain specimens, 
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trying to fit them into current polarization schemes (Walker and Lue, 2015). Although 
microglia priming and M1-like activation state in AD is suggested in the most of the works 
(Heneka et al., 2015b; Hoeijmakers et al., 2016), increased expression of Arginase 1 
(Colton et al., 2006) and co-expression of M1, M2a, M2b and M2c markers were also 
detected (Wilcock, 2012; Sudduth et al., 2013). In addition, later studies identified five 
ramified, hypertrophic, dystrophic, rod-shaped, and amoeboid microglia morphological 
phenotypes in AD patient autopsied samples, with increased prevalence of dystrophic 
microglia in cases of dementia with Lewy bodies (Bachstetter et al., 2015). Disparate 
results obtained so far derive from the difficulties in selecting experimental models that 
better recapitulate the in vivo AD condition. For instance, in vitro microglial models, such 
as microglial cell lines, or primary microglia isolated from embryonic (Gingras et al., 
2007) or neo-natal animals (Floden and Combs, 2007), though largely used (Moussaud 
and Draheim, 2010), do not mimic the adult behavior cells (Sierra et al., 2007). 
Furthermore, it was demonstrated that primary cultures of microglial cells change their 
activation profile over time in culture (Cristóvão et al., 2010), thus contributing to data 
inconsistency. 
Since AD is considered an age-related disease, the use of aging animal models has 
been proposed to circumvent the difficulties arising from researching the nervous system 
aging (Bachstetter et al., 2015). However a lot of problems should be considered. 
Actually, the need of waiting for 2-3 years for animals to age to assess differences in cell 
function and with only the survivors being used, together with the variability in the results 
that were obtained (Birch et al., 2014), have contributed to the failure in understanding 
many of the elderly processes and in successful innovative strategic approaches to AD.  
Therefore, our aged in vitro culture microglia model (Caldeira et al., 2014) may add 
additional information on the controversial microglia phenotypes in AD onset and 
progression, while allowing the work with aged microglia, once there are no processes 
to isolate degenerating microglia for experimentation (Njie et al., 2012). 
In the present study we assumed that the recently isolated microglia maintained for 
2 days in vitro (DIV) and the 16 DIV aged cultured microglia represent different cell 
populations that may react differently to the Aβ stress stimulus. These subtypes may 
underlie diverse vulnerabilities along AD progression from onset to late stages and may 
serve as models to better comprehending cell malfunction changes deriving from the 
accumulation of Aβ and age-related alterations, not clarified till now. Based in our 
previous data (Caldeira et al., 2014), we hypothesized that the 2 DIV microglia phenotype 
mainly resembled the activation of the cell in the subacute inflammation state, while the 
16 DIV cells more closely represented the inability of the cell to mount an efficient 
response against stressor stimuli. Hence, our main interest was to examine the behavior 
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of these in vitro cultured microglia phenotypes, young/reactive (2 DIV) and 
aged/desensitized (16 DIV) cells, when facing a non-toxic mixture of Aβ1-42 oligomers 
and fibrils species at a concentration of 1000 nM. For that, we assessed cell morphology, 
phagocytic ability, migration capacity, autophagy and senescence markers, as well as 
the inflammatory-associated microRNAs, mediators, key regulatory receptors and 
inflammasome, together with MMP2 and MMP9 activation. Further, we evaluated gene 
expression of microglia phenotype M1 and M2 biomarkers and explored their subtype 
distribution.  
 
Our results indicate that Aβ1-42, although prompting an acute inflammatory reaction, 
promote the switch of the activated microglia towards heterogeneous populations, while 
eliciting microglia senescence and affecting phagocytic function in the 2 DIV in vitro 
microglia. Data also highlight the presence of an increased population of CD86+ 
microglia in the 16 DIV cells, which revealed decreased ability to mount cellular immune 
responses and compromised neuroprotective effects when exposed to Aβ1-42, as 
compared to 2 DIV cells. Altogether, we may hypothesize that different microglia 
polarized cells are suggestive to distinctly contribute to AD initiation and progression, 
thus requiring therapeutic diversity. 
 
 
2. Materials and Methods 
 Animals 
Animal care followed the recommendations of the European Convention for the 
Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes 
(Council Directive 86/609/EEC) and National Law 1005/92 (rules for protection of 
experimental animals). All animal procedures were approved by the Institutional animal 
care and use committee. Every effort was made to minimize the number of animals used 
and their suffering. 
 
 Primary culture of microglia 
Mixed glial cultures were prepared from 1-to-2 day-old CD1 mice, as previously 
described (McCarthy and de Vellis, 1980), with minor modifications (Gordo et al., 2006). 
Cells (4 x 105 cells/cm2) were plated on uncoated 12-well tissue culture plates (with 18 
mm coverslips) or 75-cm2 culture flasks in culture medium (DMEM-Ham’s F12 medium 
supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, nonessential amino acids 
1X, 10% fetal bovine serum (FBS), and 1% antibiotic-antimycotic solution) and 
maintained at 37ºC in a humidified atmosphere of 5% CO2.  
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Microglia were isolated as previously described (Saura et al., 2003). Briefly, after 21 
days in culture, microglia were obtained by mild trypsinization with a trypsin-EDTA 
solution diluted 1:3 in DMEM-Ham’s F12 for 45 to 60 min. The trypsinization resulted in 
detachment of an upper layer of cells containing all the astrocytes, whereas the microglia 
remained attached to the bottom of the well. The medium containing detached cells was 
removed and the initial mixed glial-conditioned medium was added. The use of 21 days 
in vitro (DIV) cells intends to achieve the maximal yield and purity of the cultures. In fact, 
astrocyte contamination was less than 2%, as assessed by immunocytochemical 
staining with a primary antibody against GFAP followed by a species-specific 
fluorescent-labeled secondary antibody. Neuronal contamination was 0%, as assessed 
by immunocytochemical staining with a primary antibody against MAP-2 followed by a 
species-specific fluorescent-labeled secondary antibody (Silva et al., 2010). 
 
 Treatment of microglia with a mixture of A1-42 oligomers and fibrils 
Aβ1-42 peptide was diluted in DMEM-Ham’s F12 culture medium to a stock 
concentration of 111 µM and allowed to incubate for 24 h at 37°C to preaggregate the 
peptides, as formerly indicated (Hjorth et al., 2013). In previous studies (Falcão et al., 
2016), we verified that our Aβ1-42 solution were mainly constituted by large oligomers and 
fibrils with a small proportion of monomers and dimers, after a 24 h period of time, as we 
used in the incubation assays. 
Isolated microglia were differently aged in culture for 2 and 16 DIV to have two 
diverse microglia subtypes in accordance with our prior publication (Caldeira et al., 
2014). The 2 DIV cells to represent activated microglia that follows the acute process of 
isolation, and the 16 DIV to mimic an aged and less responsive population. Both in vitro 
aged cells were incubated with 50 nM and 1000 nM Aβ1-42, during 24 h, at 37ºC, although 
the lower concentration was later abandoned in favor of the more consistent results 
obtained with the higher one. Cells incubated in the absence of Aβ1-42 were used as 
controls. 
 
 Determination of cell death 
To evaluate microglia cell death we used phycoerythrin-conjugated annexin V (V-
PE) and 7-amino-actinomycin D (7-AAD) (Guava Nexin® Reagent, #4500-0450, 
Millipore) to determine the percentage of viable, early-apoptotic and late-
apoptotic/necrotic cells by flow cytometry. After incubation, microglia were trypsinized, 
added to the cells present in the incubation media and then stained with annexin V-PE 
and 7-AAD, following manufacturer’s instructions, and analyzed on a Guava easyCyte 
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5HT flow cytometer (Guava Nexin® Software module, Millipore), as previously described 
(Barateiro et al., 2012). The three populations of cells that can be distinguished by this 
assay are the viable cells (annexin V-PE and 7-AAD negative), the early apoptotic cells 
(annexin V-PE positive and 7-AAD negative), and the cells in late stages of apoptosis or 
dead cells (annexin V-PE and 7-AAD positive). 
 
 Cell morphological analysis 
For morphological analysis, cells were fixed for 20 min with freshly prepared 4% 
(w/v) paraformaldehyde in phosphate buffer saline (PBS). Standard 
immunocytochemical technique used a primary antibody raised against Iba-1 (rabbit, 
1:250; Wako Pure Chemical Industries Ltd, Osaka, Japan), and a secondary Alexa Fluor 
594 goat anti-rabbit (1:1000; Invitrogen Corporation, Carlsbad, CA, USA). To identify the 
total number of cells, microglial nuclei were stained with Hoechst 33258 dye. 
Fluorescence was visualized using an AxioCam HRm camera adapted to an 
AxioSkope® microscope (Zeiss). Pairs of U.V. and red-fluorescence images of ten 
random microscopic fields (original magnification: 400X) were acquired per sample. To 
better characterize microglia morphology we used the particle measurement feature in 
ImageJ (1.47v, USA) to automatically obtain the 2D area, perimeter, circularity, and 
Feret’s diameter of single microglia cells. Circularity of microglia was calculated using 
the formula: Circularity = 4 (area/perimeter2). A circularity value of 1.0 indicates a 
perfectly circular cell, and values near zero indicate elongated and ramified cells. Feret’s 
(maximum) diameter, a measure of cell length, is the greatest distance between any two 
points along the cell perimeter. 
 
 Microglia migration assessment 
Cell migration is often assessed with the classic Boyden Chamber assay, where 
cells loaded in the upper well are allowed to migrate through filter pores to the lower well 
of the chamber. Assays were performed in a 48-well microchemotaxis Boyden chamber 
(Neuro Probe, Gaithersburg, MD, USA), as previously described (Miller and Stella, 
2009), with minor modifications. The bottom wells were filled with control medium 
(DMEM-Ham’s F12) and Aβ (1000 nM) to evaluate the ability of microglia to move 
towards Aβ. ATP (10 µM) applied in the lower well was also used as a positive control 
for microglia migration, since it is a known chemoattractant for microglia. The 8 µm 
diameter polycarbonate membranes with polyvinylpyrrolidone (PVP) surface treatment 
was equilibrated in control medium and after chamber set up, 50 µl of cell suspension 
containing 2 x 104 was added to each top well. After 6 h incubation in a CO2 incubator at 
37ºC to allow microglia migration, membrane was fixed with cold methanol and cells 
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stained with 10% Giemsa in PBS. Non-migrated cells on the upper side of the membrane 
were wiped off with a filter wiper. The rate of migration was determined by counting the 
cells on the lower membrane surface, using 10 microscopic fields (original magnification: 
100X) that cover all the well. Images were acquired with a Leica DFC490 camera 
adapted to an AxioSkope HBO50 microscope. For each experiment, at least data from 
three wells per condition were acquired. 
 
 Evaluation of metalloproteinase-2 and -9 activities 
Assessment of matrix metalloproteinases (MMPs)-2 and MMP9 activities in the 
extracellular medium was based on their ability to degrade gelatin. For that, 20 µl of 
incubation medium was resolved using a SDS-PAGE zymography of 0.1% gelatin – 10% 
acrylamide gel. After electrophoresis, gels were washed for 1 h with 2.5% TritonX-100 
(in 50 nM CaCl2; 1 µM ZnCl2) to remove SDS and renature MMP species in the gel. To 
allow gelatin degradation by MMPs, gels were incubated overnight, at 37ºC, in the 
developing buffer (50 mM Tris pH 7.4; 5 mM CaCl2; 1 µM ZnCl2). For enzyme activity 
analysis, the gels were stained with 0.5% Coomassie Brilliant Blue R-250 and distained 
in 30% ethanol/10% acetic acid/H2O. Gelatinase activity, detected as a white band on a 
blue background, was measured by computerized image analysis (Image Lab™ 
Software 3.0, Bio-Rad Laboratories Inc., USA) and normalized to cellular protein content 
(Silva et al., 2010). 
 
 Gene expression profiling 
Quantitative RealTime PCR (qRT-PCR) was performed for mRNA expression, as 
usual in our laboratory (Barateiro et al., 2013). Total RNA was extracted from microglia 
using TRIzol® (LifeTechnologies), according to manufacturer’s instructions. Total RNA 
was quantified using Nanodrop ND-100 Spectrophotometer (NanoDrop Technologies, 
Wilmington, DE, USA). Aliquots of 0.5 μg of total RNA were treated with DNase I and 
then reverse transcribed cDNA using oligo-dT primers and SuperScript II Reverse 
Transcriptase under the recommended conditions. qRT-PCR was performed on a 7300 
Real time PCR System (Applied Biosystems) using a SYBR Green qPCR Master Mix 
(Fermentas) and -actin as an endogenous control to normalize the expression level of 
the different genes. Primer sequences that were used are indicated in Table 3.1. PCR 
was performed in 96 well plates and triplicate analysis was accomplished for each 
sample. No-template control was included for each amplificate. Cycling conditions were 
94ºC for 3 min followed by 40 cycles at 94ºC for 0.15 min, 62ºC for 0.2 min and 72ºC for 
0.15 min. A melt-curve analysis was used to verify the specificity of the amplification, 
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immediately after the amplification protocol. Non-specific products of PCR were not 
found in any case. Relative mRNA concentrations were calculated using the Pfaffl 
modification of the ΔΔCT equation (CT, cycle number at which fluorescence passes the 
threshold level of detection), taking into account the efficiencies of individual genes. The 
results were normalized to -actin in the same sample and the initial amount of the 
template of each sample determined as relative expression by the formula 2-ΔΔCT. ΔCT 
in each sample derives from the difference between the mean CT value of each gene 
and the mean CT value of -actin. ΔΔCT of one sample is the difference between its 
ΔCT value and ΔCT of the selected reference, in our case the 2 DIV control cells. 
 
 Determination of microglia senescence and autophagy 
Microglial senescence was determined using the Cellular senescence assay kit 
(Millipore) that evaluates the activity of senescence-associated β-galactosidase, 
according to the manufacturer instructions. Microglial nuclei were counterstained with 
hematoxylin. Light microscopy images of ten random microscopic fields (original 
magnification: 400X) were acquired per sample. Turquoise blue stained microglia were 
considered senescent and their percentage calculated relatively to the total number of 
cells. 
Autophagy was determined by immunocytochemistry based on the punctate pattern 
of the microtubule-associated-protein-light-chain-3 (LC3). Measurements of Beclin-1 
bands by Western Blot were normalized to the correspondent -actin bands, as 
previously described (Caldeira et al., 2014). 
 
 Evaluation of microglial phagocytic ability 
The efficiency of the microglial phagocytosis was assessed by counting the number 
of ingested beads per cell, considering the total number of cells, to obtain the average 
amount of ingested beads per cell, and by the percentage of cells phagocytosing less 
than 5, 5-10 or more than 10 beads. The method consisted in incubating the primary 
microglial cultures, differently aged in culture with 0.0025% (w/w) of 1 μm fluorescent 
latex beads (Sigma Chemical Co., St. Louis, MO, USA) for 75 min at 37ºC. Thereafter, 
cells were fixed with freshly prepared 4% (w/v) paraformaldehyde in PBS. Microglia were 
stained for Iba-1 and nuclei counterstained with Hoechst dye. Fluorescence was 
visualized and acquired as above mentioned. 
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Table 3. 1 – List of primer sequences used for gene expression 
Gene Sense (5’-3’)  Antisense (5’-3’) 
Β-actin GCTCCGGCATGTGCAA  AGGATCTTCATGAGGTAGT 
MFG-E8 TGACTTTGGACACACAGCGT  GTGTAGAACAACGGGAGGCT 
TNF-α TACTGAACTTCGGGGTGATTGGTCC  CAGCCTTGTCCCTTGAAGAGAACC 
IL-1β CAGGCTCCGAGATGAACAAC  GGTGGAGAGCTTTCAGCTCATA 
IL-6 CCGGAGAGGAGACTTCACAG  GGAAATTGGGGTAGGAAGGA 
HMGB1 CTCAGAGAGGTGGAAGACCATGT  GGGATGTAGGTTTTCATTTCTCTTTC 
IL-18 TGGTTCCATGCTTTCTGGACTCCT  TTCCTGGGCCAAGAGGAAGTG 
NLRP3 TGCTCTTCACTGCTATCAAGCCCT  ACAAGCCTTTGCTCCAGACCCTAT 
TLR2 TGCTTTCCTGCTGAAGATTT  TGTACCGCAACAGCTTCAGG 
TLR4 ACCTGGCTGGTTTACACGTC  GTGCCAGAGACATTGCAGAA 
CX3CR1 TGCTCTTCACGTTCGGTCTG  CTCAAGGCCAGGTTCAGGAG 
iNOS ACCCACATCTGGCAGAATGAG  AGCCATGACCTTTCGCATTAG 
MHC class II TGGGCACCATCTTCATCATTC  GGTCACCCAGCACACCACTT 
Arginase 1 CTTGGCTTGCTTCGGAACTC  GGAGAAGGCGTTTGCTTAGTTC 
TGF-β CAGAGCTGCGCTTGCAGAG  GTCAGCAGCCGGTTACCAAG 
 
 Detection of specific microRNA expression changes 
To evaluate changes in microRNAs (miRNAs) with a crucial role in microglia 
function/dysfunction we assessed the expression of miR-124, miR-155 and miR-146a by 
qRT-PCR. Total RNA was extracted from primary microglia cultures using the 
miRCURY™ Isolation Kit – Cells (Exiqon), according to the manufacturer’s 
recommendations for cultured cells. Briefly, after cell lysis, the total RNA was adsorbed 
to a silica matrix, washed with the recommended buffers and eluted with 35 µl RNase-
free water by centrifugation. After RNA quantification, conversion to cDNA was 
performed using the universal cDNA Synthesis Kit (Exiqon) and 20 ng total RNA 
according to the following protocol: 60 min at 42ºC followed by heat-inactivation of the 
reverse transcriptase for 5 min at 95ºC. qRT-PCR was performed in an 7300 Real time 
PCR System (Applied Biosystems) using 96-well plates. For miRNA quantification the 
miRCURY LNA™ Universal RT microRNA PCR system (Exiqon) was used in 
combination with pre-designed primers (Exiqon), represented in Table 3.2 using 
SNORD110 as reference gene. The reaction conditions consisted of polymerase 
activation/denaturation and well-factor determination at 95ºC for 10 min, followed by 50 
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amplification cycles at 95ºC for 10 s and 60ºC for 1 min (ramp-rate 1.6º/s). The miRNA 
fold increase or fold decrease with respect to control samples was determined by the 
Pfaffl method, taking into consideration different amplification efficiencies of miRNAs in 
all experiments. The amplification efficiency for each target was determined according 
to the formula: E = 10(-1/S) – 1, where S is the slope of the obtained standard curve. 
 
Table 3. 2 - List of primer sequences used for microRNA expression 
miRNA Target Sequence (5’-3’) 
mmu-miR-155-5p UUAAUGCUAAUUGUGAUAGGGGU 
hsa-miR-146a-5p UGAGAACUGAAUUCCAUGGGUU 
hsa-miR-124-3p UAAGGCACGCGGUGAAUGCC 
SNORD110 Reference gene 
 
 
 Separation of CD11b and CD86 microglia populations by flow cytometry 
Cells were resuspended in PBS and kept in flow buffer (PBS plus 2% FBS and 
0.02% sodium azide). To prevent non-specific binding, cells were incubated for 20 min 
with CD16/CD32 (1:100) to block Fc receptors, at 4°C. Afterwards, cell suspension was 
incubated with the fluorescent labeled antibodies (CD11b PerCp-Cy5, CD45 PE and 
CD86 Bio-SAV PE) for 30 min, at 4°C (1:100). Following the incubation, cells were 
washed with flow buffer, incubated with streptavidin (1:100) for the CD86 Bio-SAV PE 
antibody during 30 min, and then resuspended in flow buffer. Expression of surface 
antigens was evaluated using the BD FACSCalibur flow cytometer and data analyzed 
using the FlowJo software. 
 
 Statistical analysis 
Results of at least four different experiments are expressed as mean ± SEM. 
Significant differences between control and Aβ treated groups were determined by t-test. 
To compare the effects of Aβ treatment and microglia differently aged in culture, two-
way ANOVA was used using GraphPad Prism® 5.0 (GraphPad Software, San Diego, 
CA, USA). Statistical significance was considered for p < 0.05. 
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3. Results 
 Microglia treated with A do not show age-dependent changes in cell 
viability 
In the present work we used our established model of reactive and age-like microglia 
phenotypes, in which the cells are maintained for 2 DIV and 16 DIV in culture, 
respectively, after isolating microglia from the mixed cultures with astrocytes (Caldeira 
et al., 2014). Our main interest was to see whether activated/young cells would respond 
differently from the aged cells to Aβ. For that, we decided to incubate the cells with a 
mixture of Aβ oligomers and fibrils, as we have accomplished in the N9 microglial cell 
line (Falcão et al., 2016), to recapitulate the neuropathology of AD associated to the 
different activation processes of microglia by such species (Sondag et al., 2009). 
Although we have tested 50 nM and 1000 nM Aβ concentrations, already used in our 
previous study (Falcão et al., 2016), the effects obtained in differently aged microglia 
function/dysfunction were more notorious for the highest level, reason why we decided 
to only assess and present the results obtained with Aβ 1000 nM for a 24 h treatment 
period. 
As a first step, and in order to guarantee that the viability of the aged-cultured 
microglia (16 DIV) was equivalent to that of the acutely (2 DIV) isolated cells, we 
determined the percentage of viable, early-apoptotic and late-apoptotic/necrotic cells by 
flow cytometry in both adherent and detached cells, as described in Materials and 
Methods Section.  As indicated in Table 3.3, although a slight increase was obtained in 
the number of cells showing late-apoptosis/necrosis by treatment with Aβ, namely in the 
16 DIV microglia, the lack of significance of such effects attests no direct influence on 
the events that will be presented in the following sections. 
 
Table 3. 3 – Microglia viability is not altered by amyloid-β treatment  
 2 days in vitro  16 days in vitro 
 Control Aβ (1000nM)  Control Aβ (1000nM) 
Viable 73.6 (±9.1) 65.6 (±6.7)  70.7 (±7.1) 66.5 (±5.7) 
Early-apoptosis 18.8 (±8.6) 17.8 (±4.8)  21.7 (±8.1) 21.6 (±5.3) 
Late-apoptosis/ necrosis 2.9 (±1.4) 3.7 (±1.4)  5.8 (±1.0) 9.1 (±2.4) 
Results are expressed as percentage of the total number ofcells. Values are means ± SEM from at least 
four independent experiments. Microglial cells were kept in culture for 2 days in vitro (DIV) and 16 DIV and 
treated with amyloid-β (Aβ) at 1000 nM for 24h. The percentage of viable microglia and microglia in early- 
and late-apoptosis/necrosis was determined by flow cytometer with phycoerythrin-conjugated annexin V 
(annexin V-PE) and 7-amino-actinomycin D (7-AAD).  The three populations were distinguished as follow: 
viable cells (annexin V-PE and 7-AAD negative), early apoptotic cells (annexin V-PE positive and 7-AAD 
negative), and late stages of apoptosis or dead cells (annexin V-PE and 7-AAD positive). 
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 Young and aged cultured microglia show soma enlargement by A 
treatment 
Characterization of morphometric features of microglial cells has been associated 
to microglia polarization and state of inflammatory processes (Torres-Platas et al., 2014). 
While the ramified morphology relates with the surveilling cell type function, the 
amoeboid microglia are associated to activation and believed to favor phagocytosis and 
mobility (Lull and Block, 2010).  
The cells cultured for 2 DIV (young/reactive) show a predominant amoeboid 
morphology as a consequence of the acutely isolation protocol that leads to the activation 
of the cells (Figure 3.1A), as we previously stated (Caldeira et al., 2014). When 
maintained in culture for 16 DIV (aged), the cells exhibit polarized and ramified 
populations, including rod-like and bipolar morphology appearance, thus showing an 
increased cell perimeter and Feret’s maximum diameter (1.6-fold, p < 0.05) (Figure 
3.1B,C). Curiously, while A treatment of 2 DIV reactive microglia promoted a prevalent 
ovoid shape with an enlarged cell area (1.9-fold, p < 0.05) (Figure 3.1D), 16 DIV cells 
exposed to A show a more heterogeneous morphology with polarized microglia bearing 
one or two large processes, or a large lamellipodia with a thin process. In this case the 
cells show a reduction in cell perimeter and in Feret’s maximum diameter (0.7-fold, p < 
0.05), as well as an increased circularity (1.2-fold, p < 0.05) (Figure 3.1E). These 
morphometric alterations suggest that both young and aged cells increase soma volume, 
although the process shortening after A treatment was not so evident in aged cells. 
However, whether these changes represent a similarly activated microglia or a separate 
functional state will be assessed in the next result sections. 
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Figure 3. 1 – Reactive and aged cultured microglia evidence soma enlargement and amoeboid 
morphology after treatment with Aβ. Microglia that were kept in culture for 2 and 16 days in vitro (DIV) 
were treated with 1000 nM amyloid-β (Aβ) for 24 h. Cells were immunostained for Iba1 and characterized 
for their morphometric features. (A) Representative images show increased ramification by age, which is 
counteracted by Aβ exposure. Microglia perimeter (B), Feret’s diameter (C), area (D) and circularity values 
(E) were measured using the computer program ImageJ and expressed in graph bars as mean ± SEM. 
Cultures, n = 4 per group.  Two-way ANOVA (Post-hoc Bonferroni test): *p < 0.05 and **p < 0.01 vs. 
respective non-treated Control; †p < 0.05 vs. 2 DIV. Scale bar equals 50 µm. 
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 A differently upregulates the activation of MMP2 and MMP9 in reactive and 
aged cultured cells 
Matrix metalloproteinases (MMPs) were shown to be important for the degradation 
of Aβ (Qiu et al., 1997) and MMP3, MMP12 and MMP13 to be activated by Aβ stimulation 
(Ito et al., 2007). In addition, MMP2 and MMP9 were found differently activated in animal 
models, AD patients and in in vitro microglia cultures, as well as in some studies related 
with the aggravation of AD disease (Brkic et al., 2015). Our data indicate that Aβ leads 
to increased activation of both MMP2 and MMP9 in the aged cells, while only stimulates 
MMP9 in the young reactive microglia, once no changes were detected for MMP2 
activation (Figure 3.2). Data indicate that aged microglia by releasing these inflammatory 
components in the presence of Aβ may facilitate tau aggregation, but the dual roles of 
MMPs complicate the understanding of their beneficial or harmful effects in AD (Wang 
et al., 2014). 
 
Figure 3. 2 – Release of metalloproteinase(MMP)-2 and MMP9 is differently induced by A in reactive 
and aged cultured microglia. Microglia that were kept in culture for 2 and 16 days in vitro (DIV) were 
treated with 1000 nM amyloid-β (Aβ) for 24 h. Activities of MMP2 (A) and MMP9 (B) were evaluated by 
gelatin zymography. Results are expressed in graph bars as mean ± SEM. Cultures, n = 4 per group.  Two-
way ANOVA (Post-hoc Bonferroni test): *p < 0.05 and **p < 0.01 vs. respective non-treated Control; ††p < 
0.01 vs. 2 DIV. 
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 A induces age-dependent changes in the autophagy-related Beclin-1 gene 
and LC3 puncta, and increase cellular senescence-associated biomarkers in 2 
DIV microglia 
Autophagy, or cellular self-digestion, is a highly regulated and evolutionarily 
conserved process that was shown to be impaired in AD (Zare-Shahabadi et al., 2015). 
We first evaluated microglia autophagic capacity by assessing the expression of Beclin-
1, a protein known to be recruited to phagosomal membranes, and as participating in the 
early stages of autophagy and LC3-associated phagocytosis (Chifenti et al., 2013). We 
observed that Beclin-1 was upregulated by Aβ in young/activated 2 DIV cells (1.6-fold, p 
< 0.05, Figure 3.3A), but markedly decreased in the aged 16 DIV cells, with a slight and 
not significant increase upon Aβ stimulation. Based on the importance of LC3 processing 
for autophagosome formation, we next determined LC3-positive puncta indicative of 
autophagosome formation/accumulation (Klionsky et al., 2016). As indicated in Figure 
3.3B, A only slightly increased the number of 2 DIV cells presenting LC3-positive 
puncta. Intriguingly, the aged cells revealed to upregulate autophagy under A treatment 
toward values of 2 DIV cells, either treated or untreated. Because Beclin-1 levels were 
shown to decline by aging (Shibata et al., 2006), we next assessed the cells that 
positively stained for senescence-associated beta-galactosidase (SA--gal) activity, a 
biomarker of cellular senescence (Sikora et al., 2011). We observed that the 
young/reactive microglia after being exposed to A show increased cell staining for SA-
-gal (2.1-fold, p < 0.05, Figure 3.3C) very closely approaching the values of 16 DIV 
aged cells, where no further response was obtained for the presence of A. To validate 
A as an inducer of senescence-like response in 2 DIV microglial cells we additionally 
assessed changes in the expression of the microRNA (miR)-146a in both aged microglial 
cells. Actually, besides its numerous described functions and targets (Cardoso et al., 
2016), miR-146a was reported to contribute to age-related dysfunction of macrophages 
(Jiang et al., 2012), and to loss of mitochondrial integrity and function in aged cells (Rippo 
et al., 2014). As anticipated, miR-146a increased expression was noticed in the 2 DIV 
microglia after treatment with A, although values of 16 DIV cells were even superior 
(Figure 3.3D). These results suggest that A promotes the formation of 
autophagosomes which turnover is impaired in aged microglia contributing to A 
accumulation within these cells. In addition, A switches the reactive 2 DIV microglia 
towards a senescent-like cell phenotype, probably compromising the response to 
stressors. 
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Figure 3. 3 - Autophagy and senescence are differently promoted by A stressful stimulus in reactive 
and aged cultured microglia. Microglia that were kept in culture for 2 and 16 days in vitro (DIV) were 
treated with 1000 nM amyloid-β (Aβ) for 24 h. (A) Total cell lysates were analyzed for the presence of Beclin 
1. (B) LC3-positive puncta cells were detected by immunostaining for LC3. (C) Activity of SA--gal was 
determined using a commercial kit, and SA--gal-positive cells were counted. (D) microRNA (miR)-146a 
expression was evaluated by RealTime PCR. Results are expressed in graph bars as mean ± SEM. Cultures, 
n = 4 per group.  Two-way ANOVA (Post-hoc Bonferroni test): *p < 0.05 and **p < 0.01 vs. respective non-
treated Control; †p < 0.05 and ††p < 0.01 vs. 2 DIV. 
 
 Migration and phagocytic ability are impaired in the aged cultured microglia 
Microglia migration dynamics together with synaptic pruning and phagocytic 
capacity of neuronal cells and their debris are part of their important functions in the 
central nervous system (Xavier et al., 2014; Zhang et al., 2016). Cell migration can be 
triggered by several chemoattractants, including ATP that when released by damaged 
neurons acts on P2Y12 and P2X4 receptors in microglia stimulating their migration (Miller 
and Stella, 2009). Our data show a higher fraction of migration for young cultured 
microglia as compared with the aged cells (Figure 3.4). In addition, while the 2 DIV cells 
positively respond to Aβ (1.7-fold, p < 0.01) and ATP chemotactic signals (2.0-fold, p < 
0.01) the 16 DIV microglia failed to be attracted and to migrate towards either A or ATP. 
These findings suggest that aging delays cell migration, a finding that is consistent with 
a compromised A clearance by dysfunctional microglia. 
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Figure 3. 4 – Activated 2 DIV microglia show increased migration ability towards Aβ and ATP, while 
the aged cultured microglia are immotile and irresponsive to such chemoattractants. Microglia were 
kept in culture for 2 and 16 days in vitro (DIV) and cellular chemotactic migration to 1000 nM amyloid-β (Aβ) 
and 10 M ATP (positive chemotactic control) was evaluated after 6 h incubation using the Boyden chamber 
method. (A) Representative images of migrated cells to Aβ and ATP. (B) Number of migrated cells was 
counted and results are expressed in graph bars as mean ± SEM. Cultures, n = 4 per group. Two-way 
ANOVA (Post-hoc Bonferroni test): **p < 0.01 vs. respective non-treated Control; ††p < 0.01 vs. 2 DIV. Scale 
bar equals 50 µm. 
 
When microglia are activated they acquire an amoeboid phenotype and are able to 
exert phagocytosis, an important protective role for the efficient elimination of apoptotic 
cells and for neuronal circuitry reshape (Xavier et al., 2014). Our results corroborate 
previous data showing a reduction in phagocytosis when microglia are aged in culture 
(Caldeira et al., 2014). Newest results here presented show that 24 h incubation of 
reactive microglia with Aβ trigger a cellular response that equals that of aged cells, 
independently of being exposed or not to Aβ stimulus at this later time point, and 
represents a 2-fold reduction (p < 0.01) as depicted in Figure 3.5A. In addition, the 
number of cells able to engulf more than 10 beads was dramatically decreased upon Aβ 
interaction (10-fold reduction, p < 0.01, Figure 3.5B). Interestingly the number of 16 DIV 
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cells able to phagocytose 5-10 beads even further decrease in the presence of Aβ. These 
results suggest that Aβ reduces microglia phagocytosis in the reactive young cell toward 
the values of the aged and irresponsive microglia. 
  
Figure 3. 5 – Aβ-treatment decreases the phagocytic ability of the activated 2 DIV microglia towards 
the low levels shown by the aged cultured cells. Microglia that were kept in culture for 2 and 16 days in 
vitro (DIV) were treated with 1000 nM amyloid-β (Aβ) for 24 h. Phagocytic capacity was assessed after 75 
min incubation with fluorescent latex beads. (A) Number of phagocytozed beads per cell and (B) number of 
microglial cells phagocytosing less than 5, 5 to 10 and more than 10 beads was counted. (C) Expression of 
milk fat globule-EGF factor 8 protein (MFG-E8) that regulates microglial phagocytosis was evaluated by 
RealTime PCR. Results are expressed in graph bars as mean ± SEM.  Cultures, n = 4 per group.  Two-way 
ANOVA (Post-hoc Bonferroni test): *p < 0.05 and **p < 0.01 vs. respective non-treated Control; †p < 0.05 
and ††p < 0.01 vs. 2 DIV. 
 
Milk Fat Globule Factor-E8 (MFG-E8) was shown to be released by microglia and 
to recognize phosphatidylserine “eat me” signals on the surface of apoptotic neurons 
and other cells, thus contributing to enhance microglia phagocytic properties (Fuller and 
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Van Eldik, 2008; Liu et al., 2013). Therefore, we decided to test whether Aβ was able to 
interfere with the expression of MFG-E8. Interestingly, we observed that treatment with 
Aβ triggers more than a 2-fold reduction (p < 0.01) in the expression of MFG-E8 in the 2 
DIV microglia (Figure 3.5C). As before, the aged cells show downregulated expression 
of this phagocytic-related protein that was maintained after incubation with Aβ, 
reinforcing their irresponsive nature. We may conclude that despite the ability to migrate 
to sites of Aβ deposition the young activated microglia lose their phagocytosis capacity 
when facing Aβ, at least in primary cultures. 
  
 A reduces the expression of inflammatory-related miR-155 and miR-124 in 
2 DIV microglia 
Recent studies indicate that miR-155 and miR-124a regulates T-cell functions during 
inflammation (Heyn et al., 2016). Both miRNAs are directly involved in microglia 
polarization, where miR-124 is considered to be associated with an anti-inflammatory 
phenotype, and miR-155 as having a determinant role in microglia activation (Ponomarev 
et al., 2013). To gain insight into the A-induced alterations in microglia polarization we 
assessed the expression of these inflamma-miRNAs in the 2 DIV and 16 DIV microglia 
(Figure 3.6). Interestingly, we obtained a downregulated expression of both miR-155 
and miR-124 by A treatment in the 2 DIV microglial cells (0.7-fold and 0.6-fold, 
respectively, p < 0.05). Now considering the aged cultured microglia, no changes were 
obtained by the incubation of these cells with A, probably due to the “dormancy” of 
these cells already showing an irresponsive phenotype with a reduced expression of 
either miR-155 or miR-124 (~0.5-fold as compared to the 2 DIV control microglia). These 
results suggest a direct repressor effect of A in microglia polarization as M2 (miR-124) 
or M1 (miR-155) phenotypes in the 2 DIV microglia already activated by the isolation 
procedure. Thus, presence of mixed subpopulations and less responsive microglia 
subtypes following A interaction should be envisaged as a consequence of this noxious 
stimulus. 
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Figure 3. 6 – Aβ-treatment reduces the expression of miR-155 and miR-124 in the activated 2 DIV 
microglia towards the levels displayed by the aged cultured cells. Microglia that were kept in culture for 
2 and 16 days in vitro (DIV) were treated with 1000 nM amyloid-β (Aβ) for 24 h. M1/pro-inflammatory-related 
miR-155 (A), and M2/anti-inflammatory-related miR-124 (B) expression was evaluated by RealTime PCR. 
Results are expressed in graph bars as mean ± SEM. Cultures, n = 4 per group. Two-way ANOVA (Post-
hoc Bonferroni test); *p < 0.05 vs. respective non-treated Control; †p < 0.05 and ††p < 0.01 vs. 2 DIV. 
 
 A-treated 2 DIV microglia show phenotypic features of microglia 
activation, which are lacking in 16 DIV cells 
To determine whether 2 DIV and 16 DIV microglia, despite the downregulation of 
miR-155 and miR-124 expression, were able to mount an inflammatory response upon 
A insult we assessed a serial of commonly associated biomarkers of microglia 
activation. We started by evaluating the gene expression of the first line cytokines TNF-
α, IL-1β and IL-6. We obtained a clear upregulation of all these pro-inflammatory 
cytokines in the young cultured 2 DIV cells (Figure 3.7A). The 16 DIV cells evidenced a 
10-fold reduction in the mRNA expression of TNF-α, IL-1β and IL-6 as compared with 
the 2 DIV cells (p < 0.01). Curiously, even so, these cells showed to react to the exposure 
to 1000 nM A by significantly increasing TNF-α and IL-1β gene expression, but not that 
of IL-6. Since we and others previously showed that high mobility group box-1 (HMGB1) 
is released by LPS-treated N9 microglia (Cunha et al., 2016) and promoted the synthesis 
of pro-IL-1β and pro-IL-18 (He et al., 2012), as well as the activation of NLRP3-
inflammasome (Chi et al., 2015), we aimed to further explore these signaling pathways 
in our differently aged microglia model treated with A. Interestingly, we observed a net 
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elevation of HMGB1 and IL-18 gene expression (1.6- and 2.1-fold, respectively, p < 
0.05), but not of NLRP3 in the 2 DIV microglia exposed to A. In contrast, significantly 
decreased levels were noticed in 16 DIV microglia (p < 0.01), which were almost 
unreactive to the stimulus (Figure 3.7B). 
 
Figure 3. 7 – Aged cultured microglia only show some of the inflammatory mediators expressed by 
the 2 DIV cells upon A-stressful stimulus. Microglia that were kept in culture for 2 and 16 days in vitro 
(DIV) were treated with 1000 nM amyloid-β (Aβ) for 24 h. The expression of inflammatory cytokines [e.g. 
tumor necrosis factor (TNF)-α, interleukin (IL)-1β and IL-6] (A) and inflammasome-related proteins [e.g. 
High-mobility group protein B1 (HMGB1), IL-18 and NOD-like receptor family pyrin domain containing 3 
(NLRP3)] (B) was evaluated by RealTime PCR. Results are expressed in graph bars as mean ± SEM. 
Cultures, n = 4 per group. Two-way ANOVA (Post-hoc Bonferroni test): *p < 0.05 vs. respective non-treated 
Control; ††p < 0.01 vs. 2 DIV. 
 
Surface Toll-like receptors are abundantly expressed in microglia and recruitment of 
TLR-2 and TLR-4 by HMGB1 and IL-1β was shown to amplify inflammation (Park et al., 
2004; Facci et al., 2014). In accordance with previous results, A triggered and enhanced 
expression of both TLR-2 and TLR-4 in 2 DIV, but not in 16 DIV cells (Figure 3.8A,B), 
which again revealed a suppressed basal expression of these receptors. The 
fractalkine/CX3CR1 signaling pathway was previously demonstrated to modulate 
microglial activation (Limatola and Ransohoff, 2014) and the receptor CX3CR1 to be 
associated with a less phagocytic and more inflammatory phenotype in in vivo AD 
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models (Merino et al., 2016). As documented for TLR-2 and TLR-4, a similar profile was 
obtained for the CX3XR1 expression in 2 DIV and 16 DIV aged microglia (Figure 3.8C), 
what reinforces the concept that only 2 DIV cells are able to sustain an inflammatory 
response upon A exposure, and confirms the low responsiveness of 16 DIV microglia 
in conformity with a more irresponsive and senescent-like phenotype. 
 
  
Figure 3. 8 – Aβ-treatment increases the expression of Toll-like receptor (TLR)2, TLR4 and CX3C 
chemokine receptor 1 (CX3CR1) in the activated 2 DIV microglia, but not in the aged cultured cells. 
Microglia that were kept in culture for 2 and 16 days in vitro (DIV) were treated with 1000 nM amyloid-β (Aβ) 
for 24 h. Expression of TLR2 (A), TLR4 (B) and CX3CR1 (C) was evaluated by RealTime PCR. Results are 
expressed in graph bars as mean ± SEM. Cultures, n = 4 per group.  Two-way ANOVA (Post-hoc Bonferroni 
test): *p < 0.05 vs. respective non-treated Control; ††p < 0.01 vs. 2 DIV. 
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 Imbalance of M1 and M2 phenotypes in 2 DIV and 16 DIV microglia suggests 
dysregulation of microglia activation by A incubation 
From previous data, the elevation on IL-1β expression, mainly in 2 DIV microglia, 
indicates that the cell assumes preferentially the M1 phenotype upon A exposure. 
However, the CX3CR1 increased expression also indicates microglia subsets with M2a 
polarization (Chhor et al., 2013). Therefore, we decided to further characterize the 
microglia phenotypes in 2 DIV and 16 DIV exposed to A by evaluating additional M1 
and M2 markers. For that we first evaluated mRNA expression of inducible nitric oxide 
synthase (iNOS) and major histocompatibility (MHC) class II, which are considered 
M1/pro-inflammatory microglia markers, although MHCII has also been attributed to M2b 
polarized macrophages (Roszer, 2015). As shown in Figure 3.9A, while iNOS is highly 
induced by A both in young and aged microglia (4.7- and 5.4-fold for 2 and 16 DIV, p < 
0.05 and p < 0.01, respectively), MHC class II is only markedly increased in young 
cultured cells (11.4-fold, p < 0.01), suggesting a preferential M1 polarization in 2 DIV 
cells and a mixture of phenotypes in the 16 DIV microglia. Then, we proceded for the 
characterization of mRNA expression of M2/anti-inflammatory microglia markers, such 
as Arginase 1 (prevalent in M2a activation state) and transforming growth factor-β (TGF-
β) [suggested to be increased in the M2a/M2c/M2d subtypes (Roszer, 2015)]. As 
observed in Figure 3.9B, Arginase 1, considered to be a repair/regenerative gene 
(Chhor et al., 2013), is only increased by A in young cultured cells (2.6-fold, p < 0.05), 
with levels that, although slightly elevated upon A, represented in the 16 DIV cells less 
than 40% (p < 0.01) of those in 2 DIV cells. In what concerns TGF-β expression, with 
neuroprotective and pro-survival properties (Dobolyi et al., 2012; Ryu et al., 2012), both 
young and aged A-treated cells evidenced an increased expression (2.4- and 2.3-fold, 
respectively, p < 0.05). Overall these results suggest that both M1 and M2 
subpopulations are present upon A treatment. However while 2 DIV cells mainly 
express M1 markers, a phenotypic dysregulation with overlapping of microglial M1 and 
M2 markers is more the signature of the aged microglia. These cells additionally showed 
a decreased ability in mounting an adequate inflammatory response when stressed with 
A. 
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Figure 3. 9 – Aβ-treatment triggers an age-dependent shift in M1/pro-inflammatory and M2/anti-
inflammatory polarization markers. Microglia that were kept in culture for 2 and 16 days in vitro (DIV) were 
treated with 1000 nM amyloid-β (Aβ) for 24 h. The expression of M1/pro-inflammatory [e.g. inducible nitric 
oxide synthase (iNOS) and major histocompatibility (MHC) class II] (A) and M2/anti-inflammatory [e.g. 
Arginase and transforming growth factor-β (TGF-β)] (B) were evaluated by RealTime PCR. Results are 
expressed in graph bars as mean ± SEM. Cultures, n = 4 per group.  Two-way ANOVA (Post-hoc Bonferroni 
test): *p < 0.05 and **p < 0.01 vs. respective non-treated Control; †p < 0.05 and ††p < 0.01 vs. 2 DIV. 
 
 Proportion of CD11b and CD86 positive microglia differs between 2 DIV and 
16 DIV cells after incubation with A 
To further understand whether the lower reactivity of 16 DIV microglia towards A 
was associated with an increased expression of CD86 which as previously indicated to 
be age-related (Kohman et al., 2013), we evaluated changes in the proportion of the M1 
markers CD11b+ (co-stimulatory ligand) and CD86+ (integrin αM) cells, after A 
stimulus, in our microglia aged model of 2 DIV and 16 DIV by flow cytometry. As depicted 
in Figure 3.10A, the naïve aged microglia showed a decreased number of CD11b+ cells 
when compared to young/activated 2 DIV cells. In addition, these aged cells revealed to 
have an increased number of CD11b-/CD86- (~50%), together with elevated proportions 
of mixed CD11b-/CD86+ and CD11b+/CD86+ populations, than those of 2 DIV microglia, 
corroborating the aging-like profile status of 16 DIV microglia (Figures 3.10B,C, Table 
3.4). When treated with A both 2 DIV and 16 DIV cells showed a decreased population 
of CD11b+ cells. While 2 DIV microglia shifted from medium to high density of CD11b-
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/CD86-, the number of CD11b-/CD86+ in 16 DIV cells increased 4-fold (~25%) upon A 
treatment and represent a 24-fold increase as compared with their 2 DIV counterparts (p 
< 0.01). No relevant changes were noticed when we assessed the expression of both 
CD11b and CD45 (data not shown). These results further highlight that in vitro aging 
reduces CD11b+ microglia reactivity, while indicate a gain of function of 16 DIV cells to 
co-stimulate other immune cells through CD86 signaling, namely in the presence of A. 
 
Figure 3. 10 – Microglia CD11b+ cells decrease with aging and Aβ-treatment contrasting with CD86+ 
cells whose prevalence increase by the same conditions. Microglia that were kept in culture for 2 and 
16 days in vitro (DIV) were treated with 1000 nM amyloid-β (Aβ) for 24 h. The population of CD11+ and 
CD86+ cells was detected by flow cytometry. (A) Analysis of microglia expressing CD11+. Results are 
expressed in graph bars as mean ± SEM. Cultures, n = 4 per group.  Two-way ANOVA (Post-hoc Bonferroni 
test): *p < 0.05 and **p < 0.01 vs. respective non-treated Control; †p < 0.05 vs. 2 DIV. (B) Representative 
flow cytogram of CD11+ and CD86+ cells in the population of 2 DIV activated and aged cultured microglia. 
(C) Results are expressed in 2D pie graphs as mean. Cultures, n = 4 per group. Two-way ANOVA (Post-
hoc Bonferroni test): *p < 0.05 and **p < 0.01 vs. respective non-treated Control; †p < 0.05 and ††p < 0.01 
vs. 2 DIV. 
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Table 3. 4 – Flow cytometry analysis of the expression of CD11b and CD86 in microglia 
 2 DIV  16 DIV 
 Control Aβ  Control Aβ 
CD11b-/CD86+ 1.15 (±0.72) 0.96 (±0.15)  7.16 (±3.06) 24.87 (±6.45) *†† 
CD11b+/CD86+ 3.08 (±0.71) 2.88 (±0.21)  10.26 (±4.17) † 9.51 (±2.32) †† 
CD11b+/CD86- 56.56 (±6.68) 31.64 (±5.87) *  31.12 (±3.48) †† 14.95 (±2.64) ** 
CD11b-/CD86- 39.21 (±9.54) 64.52 (±9.03) *  51.46 (±8.90) 50.67 (±9.59) 
All results are means ± SEM from at least four independent experiments. Microglial cells were kept in culture 
for 2 days in vitro (DIV) and 16 DIV and treated with amyloid-β (Aβ) at 1000 nM for 24 h. The population of 
CD11+ and CD86+ expressing microglia was detected by flow cytometry using specific antibodies. Two-way 
ANOVA (Post-hoc Bonferroni test) *p < 0.05, **p < 0.01 vs. respective Control; †p < 0.05, ††p < 0.01  vs. 2 
DIV. 
 
 
4. Discussion 
 In the present manuscript we used an in vitro aging model developed in our 
laboratory (Caldeira et al., 2014) to assess whether activated microglia at 2 DIV (as a 
consequence of the isolation procedure) and mature microglia at 16 DIV (aged in culture) 
will differently react to Aβ stimulation. Our purpose was to better realize the complexity 
of microglia activation and cell malfunction processes in AD and the association of 
immunosenescence to AD emergence, as an attempt to understand the existence of 
different microglia polarized phenotypes along the progression of the disease and the 
controversial results published so far about the role of subacute neuroinflammation in 
AD. Actually, AD pathophysiology is overlaid by the aging effects on the CNS, and 
microglia were shown to be dysfunctional in aging and AD (Mosher and Wyss-Coray, 
2014; Cykowski et al., 2016). 
 
Here, we observed that several neuroprotective functions, namely phagocytosis and 
migration abilities, as well as autophagy, are impaired by in vitro aging. Furthermore, Aβ-
induced inflammatory response is also reduced in aged 16 DIV cells with compromised 
expression of inflamma-miRs and typical CD11b marker, but enhanced expression of the 
co-stimulatory CD86 molecule. In addition, our data show that Aβ is a stressor-inducer 
of microglia senescence based on the characteristics displayed by the activated cells 
upon interaction with Aβ. Our data is not without precedent since the population of 
senescent astrocytes was previously shown to increase in human brain during aging and 
AD (Bhat et al., 2012), and dystrophic microglia was found in the brain of AD patients 
(Streit et al., 2009). Results are supportive that not only aged microglia have 
compromised function, but also that Aβ treatment reduces the ability of the activated 
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microglia to fully develop neuroprotective and inflammatory reaction towards the noxious 
Aβ stimulus. 
 
In accordance with our previous data showing that the impaired cell function by in 
vitro aging is not associated with loss of cell viability (Caldeira et al., 2014), we did not 
observe age-dependent changes in cell death, either in the absence or in the presence 
of Aβ treatment, reinforcing the validity of our in vitro model to evaluate cell signaling 
perturbing effects by aging and Aβ. Changes in microglia morphology are associated 
with different functional states, where activation relates with larger somata and shorter 
processes that progress to an amoeboid morphology with downregulation of the ramified 
phenotype, characteristic of the surveilling microglia (Harry, 2013).  Moreover, aged 
microglia also revealed to be smaller and less branched and less effective in mounting 
a normal response to injury.  These cells with dystrophic appearance and less capacity 
to phagocytose and migrate, probably due to intracellular oxidative stress, were indicated 
to be senescent (Streit et al., 2008). We previously demonstrated that cells acutely 
isolated and maintained for 2 DIV in culture behave as activated microglia, while when 
maintained in culture for 16 DIV the cells exhibit a more bipolar shape and shorter large 
processes (Caldeira et al., 2014). Here, we further identified aged cells with altered nuclei 
morphology showing a thin and elongated shape. This type of cells commonly called as 
rod cells, have been associated to chronically inflamed cerebral cortex (Hof and Mobbs, 
2009) and acutely dementing processes (Graeber, 2010). Curiously, when these cells 
were exposed to Aβ they shift to an amoeboid morphology, more notoriously in the 2 DIV 
stimulated microglia, a morphometric alteration characteristic of a reactive microglia 
(Nakajima and Kohsaka, 2004), thus suggesting that Aβ causes cell shape alterations 
compatible with an activated cell. To note, however, that the aged 16 DIV cells evidence 
the presence of microglia morphological subclasses, a finding also recently observed in 
the hippocampus of AD patients (Bachstetter et al., 2015). 
 
Activation of MMPs has been implicated in AD pathogenesis, playing an important 
role in Aβ degradation (Miners et al., 2011). Here we show that the 2 DIV cells only 
secrete MMP9, and not MMP2, upon Aβ treatment. Surprisingly, the aged cells by 
secreting increased levels of MMP2 and MMP9 reveal to be somehow activated by the 
Aβ stimulus. MMP2 was suggested to be the major protective gelatinase in AD and to 
be overexpressed in astrocytes surrounding senile plaques in the transgenic mice brain, 
while MMP9 expression is considered a characteristic of AD with a potential neurotoxic 
side effect (Wang et al., 2014). Indeed, expression and higher activation of MMP9, but 
not MMP2, were reported in serum and brain samples of mild cognitive impairment (MCI) 
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and AD patients (Lorenzl et al., 2008; Bruno et al., 2009). Our data reinforce the role of 
microglia in MMPs release following Aβ insult highlighting an increased expression with 
age. 
 
Microglia migration is an important feature of the activated cell (Kettenmann et al., 
2011). As in our previous study (Caldeira et al., 2014), we show that aged microglia is 
significantly less susceptible to ATP-induced chemotactic signals. In ex vivo retinal 
explants, the motility process in microglia obtained from aged mice (18 to 24 months of 
age) was also reduced relatively to the young adult animal cells (2 to 3 months of age) 
(Damani et al., 2011). A recent study similarly reported that the intranasally, or 
intravenously, administered microglia to mice is only lately detected if derived from young 
donors (Leovsky et al., 2015), further reinforcing microglia migration impairment with 
age. Young microglia, but not the aged ones, revealed to also migrate towards Aβ, an 
effect probably related with the release of ATP promoted by both fibrillar and oligomeric 
Aβ1-42 species (Kim et al., 2012). Functional impairment of microglia was likewise shown 
to coincide with Aβ deposition in a mice model of AD due to a decline in their phagocytic 
capacity (Krabbe et al., 2013). Actually, microglial-mediated clearance of tissue debris 
was demonstrated to decay with aging (Neumann et al., 2009), to be compromised in 
older AD animal models (Njie et al., 2012), and to be associated with immunosenescence 
(Li, 2013). In our microglia in vitro aging the phagocytic ability of 2 DIV microglia was 
reduced by Aβ, in terms of beads per cell and maximum amount in each cell, to levels 
close of the 16 DIV aged cells. Microglia phagocytosis is also related with the recognition 
of phosphatidylserine receptors following docking of the MFG-E8 molecule (Li, 2012), 
which was also downregulated by aging and Aβ in our model. Reduction of phagocytic 
efficiency could arise from decreased chemotactic responses, but also from impairment 
in the detection of targets caused by downregulation of certain receptors (Mosher and 
Wyss-Coray, 2014). This is not the case of TLR-2 and TLR-4 that revealed to be 
enhanced in young cells and upon Aβ interaction. However, they showed marked 
reduced levels in the aged cells, probably accounting for impaired phagocytosis and 
migration of the older cells.  
 
Numerous studies support the pivotal role of miRNAs in the regulation of microglial 
phenotype by promoting microglial quiescence (miR-124), or by driving microglial 
inflammatory and immune responses (miR-155 and miR-146a) (Ponomarev et al., 2013). 
While miR-124 was shown to be downregulated in hippocampal brain samples of AD 
patients ranging from early to severe disease stages (Lukiw, 2007), miR-155 was 
reported to be overexpressed in circulating fluids and cells of AD individuals (Alexandrov 
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et al., 2012; Guedes et al., 2016), as well as in the brain of the 3xTg-AD mice model 
(Guedes et al., 2014). However, in other works miR-155 expression was found 
significantly reduced in old individuals (Noren Hooten et al., 2010). Our results indicate 
that both miR-124 and miR-155 are decreased in 16 DIV cells, but that their 
downregulation in 2 DIV microglia is also a result of Aβ interaction. Such reduction may 
have important consequences in AD progression since miR-155 was recently proposed 
to have a protective role as an anti-inflammatory factor (Li et al., 2016). 
 
Despite inflammatory-miRNA reduction in the presence of Aβ, the gene expression 
of pro-inflammatory cytokines, HMGB1 and IL-18, but not NLRP3, increased in 2 DIV 
cells upon Aβ treatment, while only TNF-α and IL-1β were enhanced in the 16 DIV cells. 
The understanding of the pro-inflammatory cytokines signaling pathways associated to 
AD is crucial to dissect their beneficial and harmful effects on AD progression and to 
define the relevance of using NSAIDs. Our data suggest, that neuroinflammation by aged 
microglia is at a much lower level than that of the activated and recently isolated cells 
leading to questioning the usefulness of NSAIDs in AD late stages. However, further 
studies are required to decide on the existence of different inflammation-associated 
stages during AD progression and the different therapeutic approaches that should be 
accomplished. Indeed, based on our data, M1 polarized 2 DIV microglia are much less 
prevalent in the aged microglia. The increase of TNF-α and IL-1β in AD, a consensual 
concept and suggested to be implicated in AD pathogenesis (Wang et al., 2015), are 
here manifested as targets for selective tuning, once are transversal to both 2 DIV and 
16 DIV microglia. Relatively to the other inflammatory-related mediators in the 
pathogenesis of AD they remain still elusive, mainly when considering the aging effects, 
and need additional investigations. Relatively to IL-6, also indicated to be elevated in AD, 
it is important to note that this cytokine is released by cells other than microglia, such 
neurons and astrocytes, and dual effects with an important role in controlling 
inflammation and promoting neurogenesis. Aged microglia clearly showed to produce 
low levels, which even slightly decrease with Aβ. Relationship between IL-6 
concentrations and aging are not clearly established, and although suggested to be 
increased, no identification of the donor cell is provided and conflicting results have been 
produced (Maggio et al., 2006). We evidenced that Aβ and LPS trigger the release of 
HMGB1 from microglia. HMGB1, a nuclear protein acting as a co-factor for gene 
transcription, is considered a pro-inflammatory cytokine that signals trough TLR2 and 
TLR4 when released into the extracellular fluid (Park et al., 2004). HMGB1 was lately 
showed to induce neurite degeneration and to be involved in AD pathology (Fujita et al., 
2016). The molecule is more frequently indicated to act on microglia to mediate 
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neuroinflammation (Gao et al., 2011) than to be released by the stimulated cell (Sun et 
al., 2014). Anyway, young activated microglia is more prone in secreting HMGB1 than 
the aged cells after Aβ exposure, what also relates with the low serum levels observed 
in aged individuals (Fu et al., 2016). TLR2 and TLR4 showed the same expression profile 
suggesting that their activation may result from the HMGB1 probably released to the cell 
milieu. Although IL-18 has been indicated to be produced downstream of NLRP3 (Zaki 
et al., 2010), it was recently associated to NLRP1 inflammasome, as well (Murphy et al., 
2016). Our results do not sustain NLRP3 activation, although clearly show upregulated 
IL-18, again more notoriously in the 2 DIV cells than in 16 DIV cells.  In a recent paper 
both inflammasome components were indicated to be activated in AD, but their direct 
association with microglia was not accomplished (Saresella et al., 2016). Most 
interesting, dendritic cells from elderly mice not only revealed defective NLRP3 
activation, but also increased expression of pro-IL-18, when compared to young infected 
mice with influenza virus, highlighting impaired inflammasome signaling pathway by 
aging. Relatively to the increased expression of CX3CR1 in the 2 DIV cells activated with 
Aβ it sustains the less phagocytic and the inflammatory phenotype of these cells, as 
observed in in vivo AD models (Merino et al., 2016). Similar increase was not noticed in 
the 16 DIV cells, corroborating their less responsive phenotype as previously observed 
for the above mentioned inflammatory biomarkers and also found in aged mice (Wynne 
et al., 2010). 
 
CX3CR1 increased expression and secretion of TGFβ are related with the M2 
polarization, which is thought to down-regulate M1-mediated inflammatory responses 
(Chhor et al., 2013; von Bernhardi et al., 2015). However, there are indications that M2 
cytokines are also associated with a chronic inflammatory process status. Our data 
further suggest that we may have a mixture of M1 and M2 phenotypes in both different 
aged cells populations, although with a high prevalence of the M1 phenotype in the 2 
DIV cells. Actually M1 and M2 phenotypes are the extreme subtypes and the existence 
of different heterogeneous activation states, which have been later documented in aging 
and AD (Bachstetter et al., 2015; Grabert et al., 2016) reflecting the plastic nature of 
microglia. Increase of iNOS and MHC class II are more associated with the M1 
phenotype while that of Arginase 1 and TGFβ are associated with the M2 subtype (Chhor 
et al., 2013). Nevertheless, MHC class II has also been attributed to M2 polarized 
macrophages (Roszer, 2015). Increased microglial iNOS and TGFβ signaling by aging 
and Aβ was previously documented (Dheen et al., 2005; Doyle et al., 2010; Mosher and 
Wyss-Coray, 2014; von Bernhardi et al., 2015). These findings may help to justify why 
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we found elevation of TGFβ and iNOS gene expression elevation in the aged cells 
treated with Aβ, when all the other tested biomarkers were found almost unchanged. 
 
Further accounting for the presence of heterogeneous microglia populations mainly 
in the 16 DIV microglia, are the existence of four separate types of microglia, i.e CD11b-
/CD86-, CD11b-/CD86+, Cd11b+/CD86- and Cd11b+/CD86+, differently represented in 
2 DIV microglia and 16 DIV microglia. These distinct subsets may derive from 
dissimilarities in the differentiation stages that may contribute to morphological and 
functional diversities, as well as for discrepancies that are often found in the literature. 
Major differences induced by Aβ are the decrease in CD11b+ cells in 2 DIV and the 
increase in CD86+ cells in 16 DIV microglia. This age effect is in line with previous 
studies showing that aged mice have a higher proportion of CD86+ microglia (Kohman 
et al., 2013). CD86, usually expressed by antigen-presenting cells, acts as a co-
stimulatory molecule for T cell activation (Tambuyzer et al., 2009). Actually, microglia 
showed to be efficient A antigen-presenting cells upon interferon-γ stimulation, 
supporting CD86-dependent A-reactive T cell activation (Monsonego et al., 2003). Our 
results corroborate that aging and A may potentiate interactions between microglia and 
infiltrating T cells, thus concurring for immune dysfunction. Interestingly, the M2b 
polarized microglia with either pro- or anti-inflammatory functions and associated with 
the recruitment of regulatory T cells show high MHC class II and CD86 expression, what 
seems to preferentially occur in our aged A-treated cells. In addition, loss of 2 DIV 
CD11b, also known as αMβ2 integrin, by A interaction may correlate with the decreased 
microglia phagocytic and migration abilities. Indeed, integrin αMβ2 is reported to be 
implicated in phagocytosis, cell-mediated killing, chemotaxis and cellular activation 
(Cougoule, et al. 2004; Chen, et al. 2008). 
 
 
5. Conclusions 
Data show that microglia activation by A depends on the polarization state of the 
cell. If already activated, microglia react with increased migration and expression of all 
major inflammatory biomarkers (except NLRP3), but also showing dysfunctional 
consequences as low phagocytic ability, increased senescence-like behavior, decreased 
CD11b immunoreactivity and reduced inflammatory miR-155 and miR-124. Changes are 
much less notorious in the already mature/aged microglia that only respond by activation 
of MMP2 and MMP9, increased LC3-punta and CD86 immunostaining, together with 
elevated iNOS, TGFβ and TNF-α gene expression. In addition, the distribution of M1 and 
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M2 polarized markers indicate that the 2 DIV cells assume a predominant M1 phenotype 
contrasting with that of 16 DIV cells showing diverse microglia subtypes that include M2 
subclasses. Overall, our results point to age-related behavioral alterations suggestive to 
differently influence AD initiation and progression. 
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Abstract 
 
Alzheimer's disease (AD), the most common cause for age-associated dementia, 
has a complex nature being characterized by a spatial and temporal accumulation of 
amyloid-β (Aβ) peptide, neurofibrillary tangle formation, and neuronal loss. Reactive 
astrocytes and microglia in the vicinity of senile plaques release inflammatory mediators 
that contribute for the neuroinflammatory status that characterize AD pathogenesis. 
Microglia may have either a neuroprotective or neurotoxic function, depending on the 
progression stage. The current study examines the temporal profile of microglia 
deactivation/activation in the 3xTg-AD mouse model prior to neurofibrillary tangle 
detection. Samples from the cortex and hippocampus of 3-, 6- and 9-months old 3xTg-
AD animals were used to determine microglia inflammatory specific markers. Here, we 
observed an intriguing CD11b downregulation at the 3-months 3xTg-AD animals, both in 
cortex and hippocampus, suggesting the existence of an inhibitory niche at this early AD 
stage. This finding revealed to also be associated with a depressed expression profile of 
inflammatory cytokines (e.g. TNF-α, IL-1β, IL-6, IL-18 and HMGB1) and, although the 
cause for such inhibition is unknown, may reflect a protective role against 
neurodegeneration. However, overexpression of some of these inflammatory mediators 
were detected either the hippocampus or the cortex, or both, at 9-months of age. 
Coincident with the current results, differential M1 (e.g. MHC class II and CEBP-α) and 
M2 (e.g. SOCS1, TGF-β and Arginase 1) phenotypic markers were obtained between 
the earlier and later stages of neuropathogenesis, if we consider their low expression at 
3-months, together with their upregulation (e.g. iNOS, SOCS1 and Arginase 1) at 9-
months. Contrasting with these findings, inflammatory microRNAs (inflamma-miRs) 
associated to these polarized microglia phenotypes (e.g. miR-124, miR-155 and miR-
146a) were found elevated at the 3-months animals. Interestingly, only miR-155 
maintained a temporal upregulation in both hippocampus and cortex, sustaining its 
potential as a predictive AD biomarker. We next searched candidate target genes of miR-
155 and identified new immune-related molecules that were mostly underexpressed in 
the 3xTgAD animals by comparison with the wild type mice, both at 3-months and 9-
months of age. Overall, our data clearly indicate a dysfunctional immune response of 
3xTgAD animals when compared to aged-matched WT. While inhibition of microglial 
function is a feature of the early neuropathogenesis towards neuroprotection, a 
dysfunctional inflammatory status is later observed. These findings corroborate the 
existence of diverse pathological stages along AD progression, with distinct microglia 
phenotypes, reinforcing the need of different disease-modifying therapies.  
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1. Introduction 
Alzheimer’s disease (AD) is nowadays the most common cause of dementia in 
elderly people, without any effective treatment. Therefore, it is extremely important to 
understand the causes of Alzheimer’s and make an easy diagnosis as early as possible. 
To address this issue, animal models become essential to further understand the 
molecular and cellular markers that trigger the onset of AD-related cognitive decline, as 
well as to perform preclinical testing of novel therapeutics. Several mouse models have 
been generated in an effort to express similar behavior and neuropathology to that 
observed in human AD patients, although it is now believed that no model can completely 
mimic AD. To date, most used animal models are transgenic mice that overexpress 
human genes associated with familial AD, leading to the formation of senile plaques of 
peptide amyloid-β (Aβ) [e.g. overexpression of human amyloid precursor protein (APP) 
alone or with Presenilin 1 (PS1)] and neurofibrillary tangles of hyperphosphorylated tau 
protein (e.g. overexpression of human MAPT), two hallmarks of AD (Drummond and 
Wisniewski, 2017). Recently, the validity of such models has been questioned by the 
high failure rate of clinical trials of AD therapeutics (>99%) that were successful in 
preclinical trials using these models (Cummings et al., 2014). Nevertheless, the data 
generated by experimental AD animal models can bring new highlights about specific 
aspects of AD pathogenesis if researchers take into account the limitations of each 
model. 
Although the introduction of wild-type forms of APP and PS1, as found in normal 
and non-familial AD cases, does not elicit AD pathology in mice, the transgenic mice 
overexpressing pathological human mutant proteins easily show Aβ aggregation, 
cognitive deficits and some abnormal tau-phosphorylation (Duyckaerts et al., 2008; 
Howlett and Richardson, 2009; Morrissette et al., 2009). The mice model APP/PS1E9 
that express APP with the Swedish mutation and mutant human PS1 with a deletion of 
exon 9 show formation of amyloid plaques prior to typical cognitive impairments 
(Jankowsky et al., 2004; Volianskis et al., 2010), being used to examine 
pathophysiological events associated to preclinical AD (Zou et al., 2016). Another useful 
model of intraneuronal A-induced neurodegeneration is the 5XFAD (Eimer and Vassar, 
2013). This mouse model expresses five familiar AD mutations, two for PS1 and three 
for APP, that induces A overproduction, to accelerate plaque development (Oakley et 
al., 2006). Consequently, 5XFAD mice develop intraneuronal A at 1.5-months of age, 
amyloid plaques at 2-months, and significant neuron loss at 9-months (Oakley et al., 
2006). However, these models do not exhibit the development of neurofibrillary tangles, 
as well as massive neuronal loss (Schwab et al., 2009). On the other hand, the triple-
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transgenic mice model (3xTg-AD) progressively develops both Aβ plaques and 
neurofibrillary tangles with a temporal and spatial distribution that recapitulates the 
disease in humans (Oddo et al., 2003a; Oddo et al., 2003b). These animals express 
three major genes associated with AD: APPSwe, PS1M146V, and tauP301L, leading to 
intraneuronal Aβ accumulation first in cortical region that later spreads into hippocampus, 
followed by the emergence of neurofibrillary tangles in hippocampus that then spread to 
cortical regions (Oddo et al., 2003a; Oddo et al., 2003b). In these animals cognitive 
decline is detected as early as 4-months, when intraneuronal Aβ accumulates in cortex, 
hippocampus and also in amygdala (Billings et al., 2005), which is consistent with the 
amyloid cascade hypothesis. Interestingly, the 3xTg-AD animals also show extensive 
astrogliosis and microgliosis with upregulation of inflammatory molecules after 6-months 
(Janelsins et al., 2008; Caruso et al., 2013), which is prior to neurofibrillary tangle 
detection. 
An elevated number of activated astrocytes and microglia are usually found close to 
neurons and Aβ plaques (Rubio-Perez and Morillas-Ruiz, 2012). Microglia, the resident 
immunocompetent and phagocytic cells in the central nervous system (CNS) (Krause 
and Muller, 2010), can be either neuroprotective or neurotoxic, which may promote a 
decrease or worsening of disease progression (Schwartz et al., 2006). In fact, while 
microglia phagocytic capacity contributes to CNS neuroprotection from excessive Aβ, 
microglial activation by Aβ soluble oligomers promotes excitotoxicity and 
neurodegeneration by the release of several inflammatory cytokines, such as tumour 
necrosis factor (TNF)-α and interleukin (IL)-1β, contributing to onset and progression of 
AD (Mizuno, 2012; Lopategui Cabezas et al., 2014). This M1/pro-inflammatory microglia 
phenotype has been widely reported in AD studies, however upregulation of the 
M2/resolution of damage marker Arginase 1 (Colton et al., 2006) and co-expression of 
M1, M2a, M2b and M2c markers were also detected in AD cases (Wilcock, 2012; 
Sudduth et al., 2013). In addition, a dystrophic microglia phenotype was also identified 
in AD patient autopsied samples (Bachstetter et al., 2015). 
We have previously addressed changes in microglia reactivity with age and Aβ 
challenge using an in vitro aging model developed in our laboratory (Caldeira et al., 
2014). We showed that several neuroprotective functions, including phagocytosis, 
migration abilities, and autophagy are impaired by in vitro ageing (Caldeira et al., 2014), 
while Aβ-induced inflammatory response is also reduced in aged cells with compromised 
expression of inflamma-miRs (Caldeira et al., 2017). Most attractively we demonstrated 
that exposure of young/reactive microglia to Aβ promote cellular senescence (Caldeira 
et al., 2017), in accordance with the link between AD and immunosenescence (Richartz 
et al., 2005).  
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In the present study we decided to further evaluate the microglia response and 
different phenotype populations in the animal model of AD that develops both amyloid-β 
and Tau pathology (Oddo et al., 2003a) in parallel with inflammation and microglia 
activation (Janelsins et al., 2005), the 3xTg-AD. Based on our previous studies and in 
recent literature we hypothesized that microglia may present differential populations 
along disease progression in the in vivo model. Hence, our main interest was to 
determine microglia specific markers in the cortex and hippocampus of 3-, 6- and 9-
months old 3xTg-AD animals. For that, we evaluated the mRNA expression of specific 
markers of microglia reactivity, namely CD11b, inflammatory cytokines, M1 and M2-
associated molecules and inflamma-miRs. 
Our results surprisingly showed that CD11b was markedly reduced at 3-months both 
in cortex and hippocampus, suggesting reduced microglia reactivity at this earlier time-
point. This response profile was also observed for the expression of inflammatory 
cytokines (e.g. TNF-α, IL-1β, IL-6, IL-18 and HMGB1), as well as for both M1 (e.g. MHC 
class II and CEBP-α) and M2 (e.g. SOCS1, TGF-β and Arginase 1) phenotypic markers, 
followed by later increase of specific markers.  Interestingly, inflamma-miRs associated 
with microglia polarization was all elevated at 3-months animals, but only miR-155 kept 
elevated at 9-months animals, suggesting a potential role as an early AD biomarker. 
MiR-155 target analysis further detected new immune-related molecules that are 
differently expressed in WT vs. 3xTg-AD animals both at early (3-months) and more 
advanced (9-months) stages of AD. Collectively, we may hypothesize that the 3xTg-AD 
animals show a dysfunctional immune response when compared to aged-matched WT, 
showing first a constrained microglia response, possibly to hold damage, followed by an 
inflammatory response in parallel with failure of immune neuroprotective role. 
 
 
2. Materials and Methods 
 Animals 
Animal care followed the recommendations of the European Convention for the 
Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes 
(Council Directive 86/609/EEC) and National Law 1005/92 (rules for protection of 
experimental animals). All animal procedures were approved by the Institutional animal 
care and use committee. Every effort was made to minimize suffering and the number of 
animals used in this study. 
The triple-transgenic animal model of Alzheimer’s disease, 3xTg-AD mice, have 
three mutations associated with AD, namely human amyloid precursor protein Swedish 
(APPSwe), human presenilin-1 M146V (PS1M146V), and the P301L mutation of human tau 
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(tauP301L), allowing the development of amyloid plaques, acceleration of the deposition 
rate, and neurofibrillary tangle pathology, respectively (Oddo et al., 2003b). The 3xTg-
AD mice was supplied from a colony implemented in the animal house facilities of the 
Center for Neuroscience and Cell Biology, University of Coimbra, Portugal, obtained from 
Dr Frank LaFerla laboratory at the Department of Neurobiology and Behavior and 
Institute for Brain Aging and Dementia, University of California at Irvine. The animals 
were found to have the same phenotypic and behavioral characteristics, as previously 
described by Dr Frank LaFerla group (Oddo et al., 2003a; Oddo et al., 2003b). The 
animals were maintained under controlled light and environmental conditions (12 h 
dark/light cycle, 23 ± 1ºC, 55 ± 5% relative humidity), having access to food and water. 
Age-matched non-transgenic/wild-type (WT) animals were used as controls. The 
animals were killed at 3- or 9-months of age and the brains were removed following 
transcardial perfusion with 20 ml of an ice-cold 0.9% NaCl solution. The brain 
hemispheres were separated and used for protein and mRNA extraction. For this 
purpose, the hemisphere was placed on an acrylic matrix and a 4 mm coronal section 
was cut with a stainless steel razor. The hippocampal and cortical regions from this 
section were dissected and kept at -80 ºC until protein or mRNA extraction. 
 
 Evaluation of APP/A expression 
Detection of APP/Aβ protein expression was processed by Western Blot as usual 
in our laboratory (Barateiro et al., 2012). Total protein extracts were obtained from brain 
extracts collected from the cortex and hippocampus of 3xTg-AD mice and their WT 
littermates. Briefly, tissues samples were lysed using TRIzol® (LifeTechnologies), 
according to manufacturer’s instructions. Protein extracts were obtained as previously 
described (Simões et al., 2013) with minor alterations, and stored at -80ºC. Protein 
concentrations were determined using BioRad protein assay (Bio-Rad, CA, USA). Cell 
extracts containing equal amounts of protein (100-150 µg) were separated on a 10 to 
15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and 
transferred to a nitrocellulose membrane. The membranes were blocked with 5% non-
fat milk, incubated with the primary antibody mouse anti-Aβ (6E10) antibody (1:200, 
BioLegend), that detects both APP and Aβ species, and mouse β-actin (1:5,000; Sigma-
Aldrich) overnight at 4ºC, and then with horseradish peroxidase-labeled secondary 
antibodies for 1 h at room temperature. After extensive washes with saline buffer, 
immunoreactive bands were detected by LumiGLO® (Cell Signaling, Beverly, MA, USA) 
and visualized by chemiluminescence with ChemiDoc (Bio-Rad, CA, USA). Expression 
was quantified by computerized image analysis using the Quantity One 1-D Analysis 
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Software (Bio-Rad, CA, USA). Results were normalized to β-actin expression and 
expressed as fold vs. 3-month cortex WT. 
 
 Gene and microRNA expression profiling 
Determination of mRNA expression was performed by RealTime PCR (RT-PCR) as 
usual in our laboratory (Barateiro et al., 2013). Total RNA was extracted from 
hippocampal and cortical tissue of 3xTg-AD and WT animals using TRIzol® 
(LifeTechnologies), according to manufacturer’s instructions. Total RNA was quantified 
using Nanodrop ND-100 Spectrophotometer (NanoDrop Technologies, Wilmington, DE, 
USA).  Aliquots of 1 µg of total RNA were treated with DNase I and then reverse 
transcribed into cDNA using oligo-dT primers and SuperScript II Reverse Transcriptase 
under the recommended conditions. Quantitative RT-PCR (qRT-PCR) was performed 
using β-actin as an endogenous control to normalize the expression level of transcription 
factors. The sequences used as primers are represented in Table 4.1. qRT-PCR was 
performed on a RT-PCR detection (Applied Biosystems 7300 Fast Real-Time PCR 
System, Applied Biosystems, Madrid, Spain) using a SensiFAST SYBR® High-ROX kit 
(Bioline). The PCR was performed in 96-well plates with each sample performed in 
triplicate, and no-template control was included for each amplification product. qRT-PCR 
was performed under optimized conditions: 50ºC for 2 min followed by 95ºC for 2 min 
and finally 40 cycles at 95ºC for 0.05 min and 62ºC for 0.30 min. In order to verify the 
specificity of the amplification, a melt-curve analysis was performed, immediately after 
the amplification protocol. Non-specific products of PCR were not found in any case. The 
results were normalized to β-actin in the same sample and relative mRNA concentrations 
calculated by the formula 2-ΔΔCT , taking into account 100% efficiency for each genes. 
ΔCT is the value obtained, for each sample, by performing the difference between the 
mean CT value of each gene and the mean CT value of β-actin. ΔΔCT of one sample is 
the difference between its ΔCT value and ΔCT of the sample chosen as reference, in our 
case the 3-month cortex of WT mice.  
For microRNA (miRNA) analysis, cDNA conversion was performed with the 
universal cDNA Synthesis Kit (Exiqon) (Cardoso et al., 2012), using 5 ng total RNA 
according to the following protocol: 60 min at 42ºC followed by heat-inactivation of the 
reverse transcriptase for 5 min at 95ºC. qRT-PCR was performed in an Biosystems 7300 
Fast Real-Time PCR System (Applied Biossystems) using 96-well plates. For miRNA 
quantification the miRCURY LNA™ Universal RT microRNA PCR system (Exiqon) was 
used in combination with pre-designed primers (Exiqon) for miR-155, miR-124, miR-
146a and SNORD110 (reference gene) (Table 4.2). The reaction conditions consisted 
of polymerase activation/denaturation and well-factor determination at 95ºC for 10 min, 
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followed by 50 amplification cycles at 95ºC for 10 s and 60ºC for 1 min (ramp-rate 1.6º/s). 
The miRNA fold change with respect to 3-month cortex WT was determined by the Phaffl 
method, taking into consideration different amplification efficiencies of miRNAs in all 
experiments. The amplification efficiency for each target or reference RNA was 
determined according to the formula: E = 10(-1/S) – 1, where S is the slope of the obtained 
standard curve. 
 
Table 4. 1 – Primer sequence used for gene expression 
Gene Primer Sequence 
Arginase1 
Sense 5’-CTTGGCTTGCTTCGGAACTC-3’ 
Anti-sense 5’-GGAGAAGGCGTTTGCTTAGTTC-3’ 
β-actin 
Sense 5’-GCTCCGGCATGTGCAA-3’ 
Anti-sense 5’-AGGATCTTCATGAGGTAGT-3’ 
CD11b 
Sense 5’-CAGATCAACAATGTGACCGTATGGG-3’ 
Anti-sense 5’-CATCATGTCCTTGTACTGCCGCTTG-3’ 
CEBP-α 
Sense 5’-AGCTTACAACAGGCCAGGTTTC-3’ 
Anti-sense 5’-CGGCTGGCGACATACAGTAC-3’ 
HMGB1 
Sense 5’-CTCAGAGAGGTGGAAGACCATGT-3’ 
Anti-sense 5’-GGGATGTAGGTTTTCATTTCTCTTTC-3’ 
IL-1β 
Sense 5’-CAGGCTCCGAGATGAACAAC-3’ 
Anti-sense 5’-GGTGGAGAGCTTTCAGCTCATA -3’ 
IL-18 
Sense 5’-TGGTTCCATGCTTTCTGGACTCCT-3’ 
Anti-sense 5’-TTCCTGGGCCAAGAGGAAGTG-3’ 
iNOS 
Sense 5’-ACCCACATCTGGCAGAATGAG-3’ 
Anti-sense 5’-AGCCATGACCTTTCGCATTAG-3’ 
MHC class II 
Sense 5’-TGGGCACCATCTTCATCATTC-3’ 
Anti-sense 5’-GGTCACCCAGCACACCACTT-3’ 
SOCS1 
Sense 5’-CACCTTCTTGGTGCGCG-3’ 
Anti-sense 5’-AAGCCATCTTCACGCTGAGC-3’ 
TGF-β 
Sense 5’-CAGAGCTGCGCTTGCAGAG-3’ 
Anti-sense 5’-GTCAGCAGCCGGTTACCAAG-3’ 
TNF-α 
Sense 5’-TACTGAACTTCGGGGTGATTGGTCC -3’ 
Anti-sense 5’-CAGCCTTGTCCCTTGAAGAGAACC -3’ 
 
Table 4. 2 – Primer sequences used for microRNA expression 
miRs  Target Sequence (5’-3’) 
miR-124-3p UAAGGCACGCGGUGAAUGCC 
miR-146a-5p UGAGAACUGAAUUCCAUGGGUU 
miR-155-5p UUAAUGCUAAUUGUGAUAGGGGU 
 
 Assessement of miR-155 target expression 
To assess the expression of genes regulated by mir-155, total RNA was extracted 
from cortical tissue of 3xTg-AD and WT animals and quantified as described above. 500 
ng of total RNA of each animal were pooled and mixed according to age (3- and 9-
months) and disease condition (WT vs. 3xTgAD). Aliquots of 500 ng of total mixed RNA 
were reverse transcribed into cDNA using the RT2 First Strand Kit (Qiagen, Hilden, 
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Germany), according to manufacturer’s instructions.  qRT-PCR was performed on a RT-
PCR detection (QuantStudio™ 7 Flex Real-Time PCR System, Applied Biosystems, 
Madrid, Spain) using the RT2 Profiler PCR Array 384-Well (4 x 96) Format (Qiagen, 
Hilden, Germany), and a RT2 SYBR® Green qPCR Mastermix (Qiagen, Hilden, 
Germany). The PCR was performed in 384-well plates, and reverse transcription control 
(RTC) and positive PCR control (PPC) was included to determine the reverse 
transcription efficiency and PCR reaction, respectively. The results were normalized to 
a standard set of reference genes. The threshold cycle (CT) values were analyzed with 
the RT2 Profiler PCR Array Data Analysis Webportal, and geometrically averaged and 
used for CT calculations. Fold change was calculated by using CT method (Livak 
and Schmittgen, 2001), corresponding to the ratio of gene expression between the 
reference or Control Group (WT) and Test Group. Fold regulation was used to better 
read and interpret data. Fold change values greater than 1, the fold regulation and fold 
change values are the same and indicate upregulated or increased gene expression. 
Fold change values less than 1 implies that fold-regulation is the negative inverse of the 
fold change, and indicate downregulated or decreased gene expression. The results 
were presented in a heat map and further detailed in scatter plot that compares the 
normalized expression of each gene between two groups (WT vs. 3xTgAD). Gene-
specific 2–ΔCT value in reference group was plotted on one axis against the 
corresponding value in test group on the other axis on a log base 10 scale to observe 
gene expression changes. Boundary lines were used to allow better visualization of 
upregulated and downregulated genes above and below a selected fold change value. 
The central line indicates unchanged gene expression. The section of the scatter plot 
above the fold change boundary lines contains genes upregulated in the y-axis group as 
compared to the x-axis group, and the section of the scatter plot below the fold change 
boundary lines contains genes downregulated in the y-axis group as compared to the x-
axis group. 
 
 Statistical Analysis 
Results of at least four different animals per experimental group are expressed as 
mean ± SEM. Significant differences between the parameters evaluated were 
determined by the two-tailed Student’s t-test performed on the basis of equal and 
unequal variance, as appropriate, using GraphPad Prism® 5.0 (GraphPad Software Inc., 
San Diego, CA, USA). p value less than 0.05 were considered statistically significant. 
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3. Results 
 The 3xTg-AD animals express APP from 3-months forward 
The 3xTg-AD mouse model, developed in LaFerla’s laboratory, present cortical 
intraneuronal Aβ as early as 3-months, followed by cortical extracellular deposits and 
hippocampal intraneuronal Aβ at 6-months, and diffuse plaque formation at 15-months 
(Oddo et al., 2003a). So, first we decided to evaluate APP/Aβ protein expression in 3-, 
6- and 9-month animals before further analysis to be sure that 3xTg-AD expressed 
increased levels of these proteins. Using the Aβ (6E10) antibody that detects both APP 
and Aβ we could only detect the APP species as shown in Figure 4.1. As expected, we 
observed a marked increase of APP expression in 3-months 3xTg-AD, when compared 
to age-matched WT animals that was maintained, although with lower magnitude in 6- 
and 9-months animals. Since Tau phosphorylation was only described in these 3xTg-AD 
at 12-months (Oddo et al., 2003a), a posterior time-point than the ones we evaluated, 
we have not assessed this protein. 
 
Figure 4. 1 - APP expression is increased in the 3xTg-AD animal model. Cortical samples from wild-
type (WT) and 3xTg-AD animals were collected at 3-, 6- and 9-months and analyzed for APP expression by 
Western Blot using the Aβ (6E10) antibody. Representative bands of n = 2 animals per experimental group 
are shown. 
 
 Microglia activation is decreased at early-AD stage in the 3xTg-AD animal 
model 
Our previous in vitro studies showed that microglia aged in vitro became 
irresponsive even when challenged with Aβ1-42 oligomers and fibrils (Caldeira et al., 2014; 
Caldeira et al., 2017). Since microglia was described to behave differently along AD 
progression in different animal models of the disease directed to Aβ pathology (Landel 
et al., 2014; Martin et al., 2017), our main interest was to address the temporal 
expression of microglia specific markers in the 3xTg-AD animal. First, we evaluated 
CD11b expression in 3-, 6- and 9-months 3xTg-AD animals and aged-matched WT. We 
observed a marked reduction of CD11b expression in 3-months 3xTg-AD animals in both 
cortical and hippocampal tissues (~55% and ~65%, respectively, p < 0.01, Figure 4.2), 
that was lost in older animals. These results corroborate prior findings showing a slight 
decrease of F4/80-positive microglia in the hippocampus and entorhinal cortex of the 
3xTg-AD animals (Janelsins et al., 2005). These surprising results suggest that there 
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may be an initial constrain of microglia response in very early stages of AD, possibly to 
hold an inflammatory response to the initial increase of Aβ expression already observed 
at 3-months as described above. 
 
Figure 4. 2 - Microglia activation is decreased at 3-months in the 3xTg-AD animal model. Cortical and 
hippocampal samples from wild-type (WT) and 3xTg-AD (Tg) animals were collected at 3-, 6- and 9-months 
and analyzed for CD11b mRNA by qRT-PCR. Results are expressed as mean ± SEM, representative of n = 
4 animals per experimental group and expressed as fold change vs. 3-month cortex WT mice. t- test **p < 
0.01 vs. respective WT. 
 
 Microglia Inflammatory response is decreased at early-AD stage in the 
3xTg-AD animal model 
Microglia is usually described to be activated in early AD stages of human patients 
and associated with the release of pro-inflammatory cytokines (Sudduth et al., 2013). 
Nevertheless, only a few studies using AD animal models have looked at early months 
and in those cases pro-inflammatory cytokine expression is usually similar to WT animals 
(Martin et al., 2017) or even reduced (Guedes et al., 2014; Iwahara et al., 2017). First, 
we looked at cytokines that we previously showed to be released by microglia when 
exposed to Aβ1-42 oligomers and fibrils (Caldeira et al., 2017). Although we first assessed 
animal samples from 3-, 6- and 9-months, as described above, the effects on 3- and 9-
months were more conclusive, reason why we only present the results obtained for these 
end-points. As indicated in Figure 4.3, all the evaluated cytokines show a reduced 
mRNA expression in 3-month 3xTg-AD when compared to WT animals, but some are 
elevated at 9-months. Indeed, TNF-α, IL- 6, IL-1β and IL-18 expression is decreased in 
the cortex of 3-months 3xTg-AD by more than 40% (p < 0.05), while TNF-α, IL-18 and 
HMGB1 is also reduced in the hippocampus of these animals (p < 0.05). Interestingly, 
TNF-α and IL-6 were still reduced in the cortex of 9-month 3xTg-AD but increased in the 
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hippocampal area (2- and 1.5-fold, respectively, p < 0.01). On the other hand, IL-1β 
increased in the hippocampus (2.4-fold, p < 0.01), IL-18 in the cortex (1.4-fold, p < 0.01) 
and HMGB1 both in the cortex and hippocampus (1.3- and 2.1-fold, respectively, p < 
0.05) of these older transgenic animals. These results, corroborate the previous findings 
on IL-6, TNF-α and IL-1β hippocampal reduction observed at 3-months in the same AD 
model (Janelsins et al., 2005; Guedes et al., 2014), and show for the first time the marked 
reduction of inflammatory molecules for very early stages of disease which is in 
accordance with the lower CD11b expression demonstrated above. 
 
Figure 4. 3- Pro-inflammatory cytokines are reduced at 3-months in the 3xTg-AD animal model. Brain 
samples from wild-type (WT) and 3xTg-AD animals were collected at 3-months and analyzed for (A) TNF-
α, (B) IL-6, (C) IL-1β, (D) IL-18 and (E) HMGB1 mRNA expression by qRT-PCR. Results are expressed in 
graph bars as mean ± SEM, representative of n = 4 animals per experimental group and expressed as fold 
change vs. 3-month cortex WT mice. t- test *p < 0.05, **p < 0.01 vs. respective WT. 
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 Microglia M1 and M2 phenotype markers are decreased at early-AD stage 
in the 3XTg-AD animal model 
Most cytokines were reduced at 3-months in the 3xTg-AD animals but further 
increased either at the cortex or hippocampus of 9-month transgenic animals, suggesting 
a first loss of microglia M1 polarization in early periods of the disorder followed by 
increased M1 reactivity. This later effect was also demonstrated in other AD models such 
as the TgAPP/PS1, the TgAPP/PS1dE9 and 5xFAD (Landel et al., 2014; Martin et al., 
2017). Therefore, we further decided to characterize microglia polarization for both 3- 
and 9-months animals. For that we evaluated the mRNA expression of MHC class II, 
iNOS and CEBP-α, which are considered M1/pro-inflammatory microglia markers, and 
SOCS1, TGF-β and Arginase 1 as M2/anti-inflammatory microglia markers.  
MHC class II is associated with microglial participation in the adaptive immune response, 
though it is debatable whether it is a marker of amoeboid/activated or ramified/quiescent 
microglia (Walker and Lue, 2015), being also associated with M2b polarized 
macrophages (Roszer, 2015). Here, we observed that MHC class II is reduced by ~60% 
at 3-months both in cortex and hippocampus (p < 0.05), and was still reduced at 9-
months in the hippocampus (~60%, p < 0.05, Figure 4A). Curiously, also in the 
APP/PS1dE9 model there were no changes in microglia MHC class II along disease 
progression (Martin et al., 2017). CEBP-α has been described to regulate the 
transcription of the MHC class II gene in murine microglia (Ponomarev et al., 2011b). In 
accordance, we also found a decreased expression of CEBP-α in the cortex and 
hippocampus of 3-months 3xTg-AD animals (>35%, p < 0.05), but no changes were 
observed at 9-months (Figure 4B). The expression of iNOS is mostly involved in innate 
immune response of classic activated microglia by producing NO, which has cytotoxic 
effects (Colton, 2009). Although there is a tendency for reduced iNOS expression in 3-
months 3xTg-AD it did not reached significance. Nevertheless, a marked increase of 
iNOS expression was observed at 9-months, namely in the hippocampus (~2.9-fold, p < 
0.05, Figure 4C). In accordance, it was shown a microglia increase of iNOS expression 
also in the APP/PS1 and APP/PS1dE9 models but only after 10-15-months (Martin et 
al., 2017).  
It has been reported that SOCS1 is involved in the shift of macrophages from M1 to 
M2 state (Whyte et al., 2011) and was shown to attenuate Aβ-Induced Inflammation in a 
microglia murine cell line (Cai et al., 2016). Once again we saw a marked reduction of 
SOCS1 in the cortex of 3-month 3xTg-AD animals (~50%, p < 0.05) that was sustained 
after 9-months (~25%, p < 0.05), but increased in the hippocampus only at 9-months 
(~1.8-fold, p < 0.05, Figure 5A). This pattern was also observed for Arginase 1 
expression (~40%, p < 0.05, cortex at 3-months; and ~2.2-fold, p < 0.05, hippocampus 
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at 9-months, Figure 5B), a typical marker of alternative activated and deactivated 
microglia (Walker and Lue, 2015). Concerning TGF-β, suggested to be increased in the 
M2 phenotype (Roszer, 2015), was only reduced in the cortex of 3-month 3xTg-AD 
animals (~70%, p < 0.05, Figure 5C) with no further alteration.  
Overall, both microglia M1 and M2 phenotypes are reduced in the 3xTg-AD mice in 
early stages when there is single cortical intraneuronal Aβ, increasing afterwards only 
concerning a directed innate immune response and a specific deactivated polarization.   
 
 
 
Figure 4. 4 - Microglia M1 pro-inflammatory markers are downregulated at 3-months in the 3xTg-AD 
animal model. Brain samples from wild-type (WT) and 3xTg-AD animals were collected at 3-months and 
analyzed for (A) MHC class II, (B) C/EBP-α and (C) iNOS mRNA expression by qRT-PCR. Results are 
expressed in graph bars as mean ± SEM, representative of n = 4 animals per experimental group and 
expressed as fold change vs. 3-month cortex WT mice. t-test *p < 0.05 vs. respective WT. 
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Figure 4. 5 - Microglia M2 anti-inflammatory/damage resolution markers are decreased at 3-months 
in the 3xTg-AD animal model. Brain samples from wild-type (WT) and 3xTg-AD animals were collected at 
3-months and analyzed for (A) SOCS1, (B) Arginase 1 and (C) TGF-β mRNA expression by qRT-PCR. 
Results are expressed in graph bars as mean ± SEM, representative of n = 4 animals per experimental 
group and expressed as fold change vs. 3-month cortex WT mice. t-test *p < 0.05, **p < 0.01 vs. respective 
WT. 
 
 Inflamma-miRs are elevated at early-AD stage in the 3XTG-AD animal model 
but only the miR-155 maintain this elevation at 9-months 
Inflamma-miRs including the miR-124, miR-155 and miR-146a are known to play a 
fundamental role in the regulation of microglial polarization by targeting specific 
molecules involved in key signaling pathways (Ponomarev et al., 2013). Since we 
observed, a marked downregulation of M1 and M2 genes in 3-months 3xTg-AD animals, 
it became important to evaluate whether also these miRs could be influencing such 
results. Moreover, miR-155 and miR-146a were reported to be upregulated in samples 
from AD patients (Alexandrov et al., 2012), while miR-124 were shown to be 
downregulated (Wang et al., 2011), suggesting once more that changes at this 
epigenetic level could also be occurring in the 3xTg-AD mice model.  
The miR-155 is considered a pro-inflammatory miRNA, as its expression in murine 
microglia cell line is upregulated in response to LPS (Cunha et al., 2016), and its 
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overexpression directly inhibit the expression of SOCS1 (Cardoso et al., 2012). Here, we 
observed a ~4-fold increase in the cortex of 3-month 3xTgTg-AD animals (p < 0.01) 
which was sustained at 9-months for both cortical and hippocampal areas (~2-fold, p < 
0.05, Figure 6A). These results corroborate previous findings that showed miR-155 
upregulation at 3- and 12-months of the 3xTg-AD mice (Guedes et al., 2014). 
Interestingly, since SOCS1 is a target of miR-155, increased miR-155 may justify the 
reduced levels of SOCS1 found in cortex samples of the 3xTg-AD as described above. 
 The miR-124 is a brain-enriched miRNA, whereas it is particularly expressed in neurons 
(Jovicic et al., 2013). In microglia, miR-124 targets CEBP-α, a known M1 phenotype 
marker as described before (Ponomarev et al., 2011a). Although we detected an 
upregulation of miR-124 in the cortex of 3xTg-AD animals (~1.8-fold, p < 0.05), this miR 
was downregulated at 9-months in both cortical and hippocampal regions (~30% and 
~15%, respectively, p < 0.05, Figure 6B). These results are in accordance with the 
downregulation of its target CEBP-α seen at 3-months, followed by a tendency for 
upregulation at 9-months as demonstrated above. 
The miR-146a, also considered a brain-enriched miRNA, is thought to be more 
strongly expressed in microglia than in neurons (Jovicic et al., 2013). Although 
upregulated in murine microglial cell line LPS (Cunha et al., 2016), miR-146a negatively 
regulates NF-κB (Taganov et al., 2006) attenuating both the immune and inflammatory 
responses. Our results show an upregulation of miR-146a in 3-month 3xTg-AD animals 
at cortex and hippocampus (~1.8- and 1.4-fold, respectively, p < 0.05) followed by a 
downregulation at 9-months (~35% and ~25% for cortex and hippocampus, respectively, 
p < 0.05, Figure 6C), which may explain the increase of inflammatory molecules at this 
later stage. Our results do not corroborate a previous report showing that mir-146a is 
only upregulated at 10-month 3xTg-AD and 3-months 5xFAD, but not in earlier stages 
(Li et al., 2011b). 
Although all the inflamma-miRs evaluated were increased at the early stage of the 
3xTg-AD mice, only miR-155 kept this upregulation for the late stage, suggesting that it 
may be a continuous marker for AD manifestation. Moreover, since miR-155 is 
considered a pro-inflammatory molecule that was detected prior to the expression of 
other inflammatory markers we may hypothesize its potential use as an early biomarker 
for the emergence of symptomatic AD. 
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Figure 4. 6 - While all inflamma-miRs are elevated at the early-AD stage of the 3xTg-AD mice, only miR-
155 is kept elevated also at 9-months. Brain samples from wild-type (WT) and 3xTg-AD animals were 
collected at 3- and 9-months and analyzed for (A) miR-155, (B) miR-124 and (C) miR-146a expression by 
qRT-PCR. Results are expressed as mean ± SEM, representative of n = 4 animals per experimental group 
and expressed as fold change vs. 3-month cortex WT mice. t-test *p < 0.05, **p < 0.01 vs. respective WT.  
 
 MiR-155 mainly downregulates protective-associated microglial genes at 
early-AD stage in the 3xTg-AD mice and even more at 9-months 
As miR-155 was found to be a potential biomarker in the early stage of the disease, 
we decided to explore the expression profile of known target genes regulated by this 
miR. For that we assessed a pool of samples from WT and 3xTg-AD mice at 3- and 9-
months using a miR-155 Targets PCR Array. A preliminary analysis of the results 
showed that although we used samples from transgenic mice that had increased 
expression of miR-155 when compared with aged-matched WT, that would supposedly 
result in downregulation of the respective targets, we still found a few genes that were 
upregulated. As shown in Figure 4.7, a heat map analysis of the expression of miR-155 
targets first cluster the WT animals at both animals, then the WT animals with 3-month 
3xTg-AD and only after with the 9-month 3xTg-AD. These results clearly show that WT 
animals have similar expression patterns that are more related with the 3-month 
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transgenic animal and that 9-month 3xTgAD have the more distinct profile from WT 
animals. 
 
A more detailed scatter plot analysis of the expression of miR-155 targets in 3-
months 3xTg-AD vs. WT (Figure 4.8) show that transgenic animals have 12 upregulated 
genes in parallel with 26 downregulated genes, which are listed in Table 4.2. Concerning 
the expression of miR-155 targets in 9-months 3xTg-AD vs. WT (Figure 4.9) the scatter 
plot analysis identify that transgenic animals have only 3 upregulated genes and a higher 
number of 35 downregulated ones, which are listed in Table 4.2. 
 
Among the different genes, Septin 11 gene appeared upregulated in both 3- and 9-
month 3xTg-AD animals. This gene encodes for a protein member of a conserved family 
of cytoskeletal GTPases that is involved in vesicle trafficking and may play a role in 
synaptic connectivity (Roseler et al., 2011). Curiously, it was already reported the 
presence of transcript variants of Septin 8, another member from the same family, in AD 
patient samples that favoured the β-amyloidogenic processing of APP by promoting 
endosome accumulation of BACE1 (Kurkinen et al., 2016). Also MafB gene that is 
upregulated in 3-months 3xTg-AD animals plays a role in microglia function. MafB is a 
transcription factor involved in microglia differentiation (Koshida et al., 2015), and 
maintenance of homeostasis in adulthood, since it microglia-specific knockout lead to 
increased expression of inflammation pathways (Matcovitch-Natan et al., 2016). So, 
MafB upregulation may be associated with the observed downregulation of the 
inflammatory markers in the 3-month transgenic mice as described.  
 
Exploring the downregulated genes we can find the downregulation of the SOCS1 
gene in the 9-month 3xTg-AD mice corroborating our results described above. Moreover, 
the downregulation of CEBP-β gene, that mediates the transcription of anti-inflammatory 
agents (He et al., 2009;Worm et al., 2009), may justify the observed reduction of M2 
markers in the 3-months 3xTg-AD mice. Interestingly, the Runx2 gene, which is involved 
in microglia phagocytosis and is activated downstream of CEBP-β cascade (Nakazato 
et al., 2015), was also downregulated in the 3xTg-AD animals, suggesting once more a 
reduced ability of microglia response in these animals. In addition, the FOXO3 gene was 
downregulated in both 3- and 9-month 3xTg-AD. However, this survival gene was shown 
to have contradictory functions along AD progression. While initially activated Foxo3 
promotes the MnSOD expression and oxidative stress resistance, continuous activation 
leads to activation of pro-apoptotic genes Bim and FasL leading to cell death, and also 
to neurotoxic Aβ processing (Shi et al., 2016). 
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Figure 4. 7 - Heat map of miR-155 Targets PCR Array results for a pool of samples from 3xTg-AD mice 
(tg) and aged-matched wild-type (WT) mice. RNA from cortical brain samples from WT and 3xTg-AD 
animals were isolated at 3- and 9-months and analyzed for miR-155 targets gene expression by qRT-PCR. 
Chapter 4 
 
182 
 
 
 
Figure 4. 8 - Scatter plot representation of the expression of miR-155 targets in 3-months 3xTg-AD 
vs. wild-type (WT) mice. RNA from cortical brain samples from WT and 3xTg-AD animals were isolated at 
3- and 9-months and analyzed for miR-155 targets gene expression by qRT-PCR. 
 
 
 
 
Figure 4. 9 - Scatter plot representation of the expression of miR-155 targets in 9-months 3xTgAD 
vs. wild-type (WT) mice. RNA from cortical brain samples from WT and 3xTg-AD animals were isolated at 
3- and 9-months and analyzed for miR-155 targets gene expression by qRT-PCR. 
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Table 4. 3 - Mouse miR-155 target genes expression at 3-months in the 3xTg-AD vs. wild-type (WT) 
mice  
Genes upregulated Genes downregulated 
Gene  Fold regulation Gene Fold regulation 
Septin 11 1314.551 Aak1 -122.87 
Tceb1 538.838 Zfp652 -23.544 
Tm6sf1 143.186 Sec14l5 -23.476 
Mafb 51.209 Ldoc1 -17.99 
Gdf6 28.071 Nfatc2ip -17.159 
Ifngr1 16.511 Ndfip1 -15.305 
Gapdh 7.956 Card11 -12.27 
Skiv2l2 6.776 Lpar6 -11.942 
Smad1 5.384 Foxo3 -11.472 
Cyr61 5.016 Runx2 -9.585 
Nova1 4.829 Zfp407 -9.067 
Aicda 3.679 Gusb -8.814 
  Tab2 -8.525 
  Kras -5.327 
  Stxbp5l -4.763 
  Cebpb -4.676 
  Mlh1 -4.22 
  Peli1 -3.995 
  Bach1 -3.84 
  Pld5 -3.5 
  Hnmpa3 -3.46 
  Irak3 -3.412 
  Myo10 -3.401 
  Zfp236 -3.261 
  Mef2a -3.171 
  Fadd -3.073 
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Table 4. 4 – Mouse miR-155 target genes expression at 9-months in the 3xTg-AD vs. wild-type (WT) 
mice 
Genes overexpressed Genes underexpressed 
Gene  Fold regulation Gene Fold regulation Gene Fold regulation 
MGDC 2160132.239 Kras -268.814 Hnmpa3 -3.986 
Septin11 131567.175 Cyr61 -113.564 Tceb1 -3.966 
Ikbke 5.699 Mecp2 -26.774 Irak3 -3.953 
  Runx2 -21.285 Ski -3.715 
  Ndfip1 -20.299 Gusb -3.605 
  Fgf7 -16.183 Pea15a -3.539 
  Foxo3 -13.309 Ets1 -3.248 
  Stxbp5l -12.971 Bcorl1 -3.247 
  G3bp2 -12.318 Zic3 -3.118 
  Lpar6 -11.39 Tle4 -3.088 
  Tab2 -11.381   
  Nfatc2ip -10.592   
  Zfp407 -9.474   
  Det1 -9.026   
  Rreb1 -8.283   
  Card11 -7.964   
  Zfp652 -5.937   
  Sec14l5 -5.397   
  Zfp236 -5.144   
  Uqcr11 -4.848   
  Fadd -4.839   
  Dync1i1 -4.614   
  Ldoc1 -4.576   
  Nova1 -4.503   
  Socs1 -4.497   
 
 
4. Discussion 
Experiments in this study were established to assess the temporal profile of 
microglial reactivity employing the 3xTg-AD mice model of AD, with particular focus on 
cortex and hippocampus, two of the brain areas most affected by AD (Braak et al., 1993). 
Here, we observed that microglia refrains their reactivity at very early AD stages (3-
months), indicated by reduced expression of inflammatory cytokines, M1 and M2 
phenotype markers, while neuroinflammation is increased for later AD stage (9-months). 
Interestingly, all inflamma-miRs were elevated at the early stage, including the typical 
M1-related miR-155, which kept upregulated also in the later AD stage, suggesting that 
it may be an early indicator of the subsequent inflammation and a biomarker of AD. 
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AD is a progressive and irreversible neurodegenerative disorder that gradually 
reduces memory and thinking skills, leading to inability to perform simple daily tasks 
(Rubio-Perez and Morillas-Ruiz, 2012). Alzheimer’s brain is characterized by elevated 
levels of some microglial-derived cytokines suggestive of a chronic inflammatory milieu 
in the AD brain, which may be neurotoxic and contribute to disease progression 
(Lopategui Cabezas et al., 2014). AD is complex, and at this moment there is no drug or 
intervention that successfully cures it. Thus, it is extremely important to understand the 
causes of Alzheimer’s and make an easy diagnosis as early as possible. For these 
findings, animal models are important tools to identify the molecular markers that trigger 
the onset of AD-related cognitive decline, as well as to assay potential pharmacological 
interventions. So, in our work we used the 3xTg-AD mice model of AD which 
progressively develops both Aβ plaques and neurofibrillary tangles with a temporal and 
spatial distribution that closely mimics that observed in the human AD brain (Oddo et al., 
2003a; Oddo et al., 2003b). The sequence of neuropathological development in this 
model suggests that Aβ is the initiating trigger of cognitive decline (Oddo et al., 2003a). 
Therefore, the 3xTg-AD mice model of AD provides a promising tool for understanding 
the neuropathology of AD, since it express AD pathology in an age-dependent manner, 
beyond the associated behavioral changes (Sterniczuk et al., 2010) that occur with the 
disease progress in human patients (Vandenberghe and Tournoy, 2005). Intraneuronal 
Aβ accumulation is seen in the cortex around 3-months, spreading to the hippocampus 
and amygdala by 6-month, also when diffuse amyloid plaques are detected in the 
cerebral cortex (Oddo et al., 2003b; Billings et al., 2005). However, senile plaques 
widespread are only detected at 12-months (Oddo et al., 2003a; Rodriguez et al., 2010), 
coupled with the emergence of conformational changes in tau (Oddo et al., 2003b). Our 
detection of APP/Aβ protein, confirms the expression of high levels of APP right at 3-
months in the 3xTg-AD animal, which is maintained along 6- and 9-months. 
 
An increased density of GFAP immunoreactive astrocytes and Iba1 immunoreactive 
microglia, as well as upregulation of inflammatory markers were shown in 3xTg-AD mice 
compared with WT at 6/7-months (Janelsins et al., 2008; Caruso et al., 2013), suggesting 
that it may be a response to Aβ accumulation. Curiously, we found a marked 
downregulation of the microglia activation marker CD11b at 3-months in cortex and 
hippocampus of the 3xTg-AD as compared with age-matched WT. Our findings 
corroborate the previous report by Janelsins and colleagues, showing a decrease F4/80-
positive microglia in the hippocampus of 3- and 6-month 3xTg-AD (Janelsins et al., 
2005), and that of Rodriguez and colleagues showing an increased density of both 
resting/ramified and activated microglia in the hippocampus of 9-month 3xTg-AD, prior 
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to senile plaque spread (Rodriguez et al., 2010). This increased density of ramified 
microglia may be a preparation phase to refrain the damage and to become prepared to 
fight the subsequent increased load of extracellular Aβ that is to come. Moreover, ours 
results are also consistent with data that shown activated microglia almost exclusively 
surrounding the senile plaques (Rodriguez et al., 2010), which are not detected in the 
very early stage of animal life that we analyzed (Oddo et al., 2003a; Rodriguez et al., 
2010). 
 
It has been described that microglia activation promotes the release of potentially 
cytotoxic molecules, which contributes to the onset and/or progression of AD (Lopategui 
Cabezas et al., 2014). Several cytokines, including IL-1β, IL-18 and TNF-α were shown 
to be overexpressed in AD brain (Ojala et al., 2009; Rubio-Perez and Morillas-Ruiz, 
2012). In the present study, and in accordance with the reduced expression of CD11b 
previously detected, we observed a marked reduction of TNF-α, IL-6, IL-1β and IL-18 
essentially in the cortex, and of HMGB1 in the hippocampus, corroborating the reduced 
activation of microglia in these earlier development of the 3xTg-AD animals. In 
accordance, other studies using the same 3xTg-AD model also showed a reduction of 
hippocampal expression of  IL-6, TNF-α and IL-1β at 3-months (Janelsins et al., 
2005;Guedes et al., 2014), while in the APP/PS1E9 TNF-α and IL-1β production only 
occurred after 10-months (Martin et al., 2017), and in the 5xFAD the inflammatory genes 
were only upregulated after 4-6 months, namely in the hippocampus (Landel et al., 
2014). Therefore it seems that an inflammatory response in the different AD animal 
models is only activated following Aβ accumulation. Curiously, at 9-months 3xTg-AD we 
observed a higher upregulation of TNF-α, IL-1β and HMGB1 at the hippocampus, 
suggesting a greater involvement of these cytokines for disease progression. TNF-α and 
IL-1β have been described for long as mediators of AD pathogenesis (Wang et al., 2015). 
HMGB1 was reported to accumulate extracellularly on Aβ plaques, being the protein 
level increased in AD brains (Takata et al., 2003). More recently, HMGB1 was implicated 
in the pathogenesis of AD by causing a microglial Aβ phagocytosis dysfunction (Takata 
et al., 2012) and neurite degeneration (Fujita et al., 2016). 
 
Interestingly, a recent study using frontal cortex samples of early AD patients 
showed 2 distinct populations, one with a typical M1/pro-inflammatoy phenotype with 
very high expression levels of IL-1β, TNF-α and IL-12A, and other with a M2/resolution 
of damage polarization with upregulation of IL-1ra, Arginase 1 and FIZZ expression 
(Sudduth et al., 2013). The authors further associated these phenotypes with the 
presence of different Aβ species, while M1 phenotype was seen in patients with 
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increased soluble Aβ, the M2 phenotype was more evident in patients with increased 
insoluble Aβ (Sudduth et al., 2013), suggesting that oligomeric Aβ acts as a more pro-
inflammatory challenge, while senile plaques favor a resolution of damage polarization. 
Our results clearly show that all M1 and M2 specific markers, except for iNOS, were 
downregulated in the 3-months 3xTg-AD essentially in the cortex, corroborating once 
again the refrained microglia reactivity. On the other hand, there was an increase of 
iNOS, Arginase 1 and SOCS1 in the 9-month 3xTg-AD animals, suggesting a later 
activation. iNOS, the typical M1 marker, is involved in innate immune response and uses 
arginine to produce nitric oxide, which has cytotoxic effects (Colton, 2009). On the other 
hand, the M2 marker Arginase 1 competes with iNOS for the arginine to produce L-
ornitine, required for the formation of collagen (Colton, 2009). The activity and protein 
expression of both iNOS and Arginase 1 were found to be altered with age and in AD 
(Liu et al., 2014), which justify the later increase observed in our animals. 
 
MiRs are known to be involved in almost all biological functions, to further regulate 
intracellular processes by targeting multiple mRNA molecules simultaneously, and to 
control immune cell phenotypes (Guedes et al., 2014). Several studies have reported 
dysregulation of some miRNAs related with innate immunity and neuroinflammation in 
AD patient brains (Lukiw et al., 2008; Li et al., 2011a), and with modulation of microglia 
responses (Su et al., 2015). Recently, miR-155 expression has been described to be 
altered in AD brain tissue (Culpan et al., 2011) and to enhance neuroinflammation in AD 
course in a 3xTg-AD animal model of AD (Guedes et al., 2014). The increased level of 
miR-155 expression that we observed in the 3xTg-AD animal model at early and late 
stages of the disease is in line with this study. This early miR-155 upregulation in 3xTg-
AD animals, in contrast to downregulation of inflammatory biomarkers and microglia 
activation markers, may be an initial indicator of changes in microglia immune response, 
and probably contribute to the later production of inflammatory mediators. In addition, 
the reduction of SOCS1 expression that we observed, in parallel with increased miR-155 
expression, agrees with the fact that SOCS1 is a target of miR-155 (Cardoso et al., 2012; 
Liu and Abraham, 2013). Recent evidence showed that miR-155 was significantly 
upregulated by HMGB1 mediated by the TLR2/MyD88 pathway (Wen et al., 2013). The 
significant increase of HMGB1 expression, in both cortical and hippocampal tissues at 
9-months may be involved in continuous miR-155 upregulation along disease 
progression and its potential use as an AD biomarker. MiRs affect neuroimmune 
functions, by playing important regulatory roles. It was shown that, over an infection and 
inflammatory process, while miR-155 usually acts to promote microglia-mediated pro-
inflammatory responses, miR-146a acts as a negative feedback of inflammation by 
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inhibiting NF-κB transcriptional activity and the expression of pro-inflammatory cytokines 
(Su et al., 2015), by acting in TLR signaling (Taganov et al., 2006). The decrease 
observed in miR-146a expression, accompanied by upregulation of miR-155 during AD 
progression in 3xTg-AD animals, may be due to negative feedback role that miR-155 
has over miR-146a. Also miR-124 was related to downregulation of activated microglia 
(Ponomarev et al., 2013), contributing to the surveillance/quiescent state (M0) of 
microglia (Caldeira et al., 2014) by acting on its target CEBP-α (Ponomarev et al., 
2011a). Indeed, we found an upregulation of miR-124 at 3-months in 3xTg-AD mice, 
which is in accordance with the reduced CEBP-α expression observed. In addition, 
Ponomarev and colleagues related that upregulation of miR-124 promote microglia M2-
phenotype by downregulation of M1-associated markers, like TNF-α, iNOS and MHC 
class II (Ponomarev et al., 2011a), corroborating our findings. However, the increase of 
M2-related markers that they have found, such as TGF-β and Arginase 1, was not 
observed in our work.  
 
As already mentioned, miR-155 can regulate many cellular functions by modulating 
multiple targets. Looking at the expression of some miR-155 validated and predicted 
targets, it was interesting to see that, besides all the individual variation that we had in 
our previous results, control animals clustered together representing an increased 
similarity in their expression profile, followed by 3-month 3xTg-AD and then the 9-month 
transgenic animal. These preliminary data, that need to be verified, suggest that changes 
between the 3xTg-AD and aged-matched WT animals increase with age.  We further 
observed that besides we looked at samples where the miR-155 was elevated when 
compared to WT, we still have upregulated targets in the transgenic animals but in lower 
amount than the downregulated ones. Curiously, a first analysis showed an altered 
expression of some genes that have been implicated in microglia reactivity and AD. 
Indeed, genes from Septin family, are involved in vesicle trafficking (Roseler et al., 2011), 
and favor the β-amyloidogenic processing of APP through BACE1 accumulation 
(Kurkinen et al., 2016), while MafB gene is involved in microglia inflammatory control 
(Matcovitch-Natan et al., 2016). On the other hand, CEBP-β gene was confirmed to be 
a direct target of mir-155 in this AD model, as previously described (Guedes et al., 2014). 
Furthermore, Runx2 gene is involved in microglia phagocytosis (Nakazato et al., 2015), 
while FOXO3 gene is involved in an earlier oxidative stress resistance but later apoptosis 
induction and neurotoxic Aβ processing (Shi et al., 2016). These findings open new 
avenues for further target evaluation concerning distinct microglia reactivity along AD 
onset and progression. 
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Overall, our results suggest that microglia at 3-months of 3xTg-AD animals has a 
more irresponsive phenotype, probably being in a more surveillance/quiescent stage. In 
fact, a recent study on transcriptional changes in AD shows a global downregulation of 
the expression of the genes that encode proteins that are metastable to aggregation 
(Ciryam et al., 2016). This downregulation may help to attenuate anomalous protein 
aggregation when protein homeostasis becomes compromised in AD (Ciryam et al., 
2016). Meanwhile, upregulation of both miR-155, TNF-α, IL-1β and HMGB1 found at 9-
months in 3xTg-AD mice together with downregulation of miR-124 and miR-146a, 
indicates a more pro-inflammatory microglial response at this stage of disease. These 
age-dependent neuroinflammatory changes may be critical in cognitive decline in AD 
(Olah et al., 2011), which may explain the fact that treatments with NSAIDs only act to 
prevent disease progression when initiated at an earlier stage of inflammation 
establishment (Varvel et al., 2009; Krause and Muller, 2010).  
 
 
5. Conclusions 
Overall, our results suggest an immunodepressed status of microglia, in the 3xTg-
AD animal model, at initial phase of disease (3-months), as if in preparation for the 
ensuing activation process to combat the subsequent extracellular Aβ accumulation 
characteristic of the later stages of AD. This deregulated microglia response at the early 
stages of disease may result to an exacerbated disease progression. Interestingly, miR-
155 revealed to be an early biomarker of inflammation in AD. Thereby, microglia cells 
are phenotypically and functionally distinct during disease course reinforcing the need of 
distinct therapeutic strategies depending on the disease stage (Figure 4.10).  
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Figure 4. 10 - Microglia activation profile during Alzheimer’s disease (AD) progression in the 3xTg-
AD mice model. Microglial cells showed an attenuated response in disease onset (3-months) in 3xTg-AD 
mice, presenting a resting/quiescent state (M0) and without prevalence of a pro-inflammatory M1-phenotype 
(classical activation) or anti-inflammatory M2-phenotype (alternative activation). The upregulation of pro-
inflammatory microRNA-155 (miR-155) at this stage, revealed to be an early biomarker of inflammation in 
AD. At 9-months it was observed increased microglia reactivity (M1-phenotype) and the presence of an 
inflammatory milieu with upregulation of inflammatory-mediators and miR-155 (II). This distinct microglia 
reactivity along AD course highlights the need for different therapeutic approaches depending on the stage 
of disease. 
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1. Concluding Remarks and Perspectives 
The main goal of this thesis was to explore how different microglia phenotypes and 
aging may influence Alzheimer’s disease (AD) pathogenesis and neuroinflammation. We 
assessed the microglia reactivity of 2 days in vitro (DIV) (activated) and 16 DIV (aged) 
cells upon treatment with 50 nM and 1000 nM A for 24 h, and the inflammatory status 
of cortical and hippocampal samples from triple transgenic mice-AD (3xTg-AD) at 3, 6 
and 9 months-old. Globally, we observed that the recently isolated microglia behave as 
an activated cell, while that maintained longer time in culture showed an irresponsive 
phenotype. When treated with A these cells revealed the existence of key-aging 
associated alterations, with a predominant microglia M1 polarization and loss of 
phagocytic ability in the 2 DIV cells, together with a decreased reactivity of the 16 DIV 
microglia towards the stressful stimulus. In addition, we further observed that in early 
neuropathogenesis, the 3 months-old 3xTg-AD mice show a down-regulated 
inflammatory status that progress to a dysfunctional inflammatory grade in the 9 months 
animals. Data suggest the existence of diverse pathological stages along AD progression 
that may require different disease-modifying therapies. 
 
AD is pathologically characterized by the presence of extracellular accumulation of 
A peptides into amyloid plaques, intracellular neurofibrillary tangles (NFTs), 
neurodegeneration, neuroinflammation and cognitive dysfunction (Rezai-Zadeh et al., 
2011; Ardestani et al., 2017). Chronic neurodegeneration leads to microglial activation, 
however the contribution of inflammation to the disease progression remains to be 
clarified (Cunningham et al., 2009). In fact, the effect of non-steroidal anti-inflammatory 
drugs (NSAIDs) has only been shown to be beneficial against the development of AD if 
administered prior to the development of neurodegeneration (Weggen et al., 2001; 
Etminan et al., 2003), and may be harmful if given at later stages of the disease (Martin 
et al., 2008). Furthermore, some studies reported that microglia become more 
senescent/dystrophic (Graeber and Streit, 2010), as well as less reactive to stimuli, with 
age (Njie et al., 2012; Streit and Xue, 2012), leading to the loss of their neuroprotective 
capacities which may increase susceptibility and promote neurodegeneration with AD 
progression. 
Over time, several studies have been carried out in order to evaluate and better 
understand the response and behavior of microglial cells with ageing and AD 
progression. Several in vitro and in vivo experimental models, and brain samples from 
AD patients, have been used, but it has not yet been possible to define which model 
better mimics what happens in the human brain. In vitro models of microglia, cell lines, 
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or primary microglia obtained from embryos (Gingras et al., 2007) and newborn animals 
(Floden and Combs, 2007), do not mimic the adult or aged behavior of microglial cells 
(Sierra et al., 2007; Harry, 2013). The same happens when using microglia obtained 
from animals of different ages (von Bernhardi, 2010; Njie et al., 2012; Lai et al., 2013), 
which, in addition to be very time-consuming, also does not correctly reproduce microglia 
senescence. These facts highlight the need to set up an experimental model that allows 
the evaluation how a mild activated microglia respond to a further A stimulus, in 
comparison with an aged more irresponsive cell, a difficult issue if we consider that there 
are no protocols to isolate degenerative microglia for study (Njie et al., 2012). 
This led us to develop an in vitro model to age naturally primary microglial cells in 
vitro, in order to characterize the behaviour and changes of cultured microglia over time 
in culture, as well as to evaluate whether their response to A stimulus is altered by the 
age of the cells. This model although established the phenotype acquired by the acutely 
isolated and activated microglia when treated A, allows the comparison with the 
correspondent aged-like cell. After understanding the effects of ageing and A exposure 
in in vitro microglia, we performed in vivo studies to better evaluate microglial response 
and its influence for the inflammatory status at differently aged animals, using a triple 
transgenic AD (3xTg-AD) mouse model.  
 
In the first study (Chapter 2) we demonstrated that microglia isolated from newborn 
mice and maintained in in vitro for long term culture change from an activated/reactive 
phenotype (2 DIV) to a more irresponsive one (16 DIV) with ageing-associated changes, 
as it was observed in in vitro ageing of astrocytes and neurons (Falcão et al., 2005, 
2006). So, this study was pioneer in ageing primary microglia cells in in vitro cultures. 
Our data show that cultured aged microglia changes their amoeboid morphology to a 
more ramified shape indicative of a less activated phenotype with age. This is in line with 
results obtained by Lai and colleagues who observed that microglia isolated from adult 
and aged animals have a propensity to acquire a more ramified morphology (Lai et al., 
2013). Our aged microglia also exhibited cells with a bipolar shape and shorter large 
processes that are signs of microglia senescence (Streit et al., 2004). These 
morphological changes are accompanied by diminished basal nuclear factor-kappaB 
(NF-κB) activation, like a marked downregulation observed in cultured senescent human 
WI-38 fibroblasts (Helenius et al., 1996). Thus, our cultured aged microglia appear to 
acquire a dystrophic and irresponsive phenotype as observed in mice with AD-
associated disorder (Krabbe et al., 2013). Also the impaired migration capacity of 
microglia observed with time in culture is in line with studies showing that aged microglia 
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become less dynamic with slower acute responses and lower rates of process motility 
(Damani et al., 2011). In addition, our in vitro aged microglia show an impaired ability to 
phagocytose, probably due to the presence of a senescent phenotype, that is in 
accordance with data obtained with microglia from aged mice that internalized less A 
than microglia from neonatal or young mice (Njie et al., 2012). This is also related with 
the low expression of TLR2 and TLR4 that mediate the phagocytosis of infectious 
pathogens (Napoli and Neumann, 2009). The reduced efflux of glutamate we obtained 
in aged microglia cultures is in line with age-dependent decline of glutamate release in 
mice (Minkeviciene et al., 2008). Similarly, the decreased activation of MMP9 we 
observed in aged microglia was also noticed by others (Bonnema et al., 2007; Paczek 
et al., 2008). This study was the first to provide the inflamma-miRNA signature for 
microglial ageing in primary cultures. Microglia showed increased miR-146a expression 
and SA--gal activity, consistent with the existence of senescent cells in aged microglia 
culture. In fact, miR-146a was implicated in age-related dysfunction of macrophages 
(Jiang et al., 2012). Additionally, reduced expression of miR-155 and miR-124 that 
revealed a negative correlation with age (Fichtlscherer et al., 2010; Noren Hooten et al., 
2010; Smith-Vikos and Slack, 2012), reinforces that cultured microglial cells at 16 DIV 
mainly represent an increased population of aged-associated microglia subclass. 
Moreover, the decreased autophagic capacity we observed in 16 DIV microglia was also 
shown to occur by ageing (Bergamini, 2006), further suggesting the presence of a 
dystrophic and irresponsive phenotype characteristic of aged microglia, in our 
experimental model. 
Altogether, this chapter describes the development and characterization of an in 
vitro model to age microglial cells, allowing a better characterization of such microglia 
subtype, in addition to the 2 DIV microglia, more closely representing a mild activated 
state. 
 
In Chapter 3 we evaluated the response of primary microglia cultured in our in vitro 
ageing model when exposed to A stimulation. We did not observe significant age-
dependent cell death changes, either in the presence or absence of A stimulus, 
reinforcing the validity of our model. Thus, the impairment of microglial neuroprotective 
functions, such as migration, phagocytosis and autophagy observed in the study is a 
result of in vitro ageing. Furthermore, we demonstrated that microglial response to A 
depends on the activation state of the cell. If microglia are already activated they respond 
with increased migration, probably due to the release of ATP promoted by both fibrillar 
and oligomeric A1-42 forms used (Kim et al., 2012), as well as expression of most of the 
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pro-inflammatory biomarkers, with the exception of NLRP3, suggesting a higher 
neuroinflammatory level of the young microglia vs the aged one. However, these cells 
showed a diminished inflammatory miR-155 and miR-124 expression as a result of A 
interaction, as well as decreased phagocytosis, indicating a loss of function as observed 
in other studies (Neumann et al., 2009; Li, 2012; Njie et al., 2012; Li, 2013). In line with 
this, we observed an increased senescence-associated phenotype and reduced CD11b 
immunoreactivity when the mildly activated cells were exposed to A, corroborating 
findings that have shown increased senescence of astrocytes with aging and AD (Bhat 
et al., 2012), as well as the observation of dystrophic microglia in the brain of AD patients 
(Streit et al., 2009). Overall, these results suggest that A treatment impair the ability of 
young microglia to carry out its neuroprotective role, although developing an 
inflammatory response to the stress-stimulating A. All these responses are less 
noticeable in the aged microglia, which still reacts to A with elevated activity of MMPs, 
autophagy and CD86 positive cells, accompanied by increased iNOS, TGF- and TNF-
α gene expression. Our results indicate, that neuroinflammation by aged microglia is 
lower when compared with that of the young cells, which again leads to question the 
relevance of using NSAIDs in later stages of the disease. However, further studies are 
needed to confirm the existence of distinct inflammation states during the course of AD. 
In fact, our data show that young microglia show a predominant M1 phenotype, while 
aged cells present a mixture of M1 and M2 subtypes, which have been related to ageing 
and AD (Bachstetter et al., 2015; Grabert et al., 2016). 
Overall, our data of Chapter 3 indicate age-associated behavioral changes which 
are accentuated by A presence promoting heterogeneous responses in microglia cells 
during AD onset and progression, suggesting that different therapeutic approaches 
according to the stage of disease may be required. 
 
Lastly, in our final experimental approach (Chapter 4) we determined the temporal 
expression of microglia specific markers in the 3xTg-AD mice model. This model, in 
contrast to other familial AD models, including the APP/PS1E9 and the 5xFAD that do 
not exhibit the development of neurofibrillary tangles, as well as massive neuronal loss 
(Schwab et al., 2009), progressively develops both A plaques and neurofibrillary tangles 
with a temporal and spatial distribution that recapitulates the disease in humans (Oddo 
et al., 2003a; Oddo et al., 2003b). Here, we show a reduced CD11b expression at the 
early-stage of the disease (3-months), probably to counteract an inflammatory response 
to the initial increase of intraneuronal A expression already observed at this time-point. 
This is in line with the reported decrease of F4/80-positive microglia in 3xTg-AD animals 
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(Janelsins et al., 2005). In addition, we evaluated microglia inflammatory response and 
observed a marked decreased of inflammatory molecules, such as TNF-α, IL-1, IL-6, 
IL-18, and HMGB1 in the very early stages of disease. However, TNF-α, IL-1 and 
HMGB1 expression increased at 9-months. As suggested by other studies the depressed 
microglia pro-inflammatory phenotype in an early-stage of disease switch to M1 polarized 
microglia (Landel et al., 2014; Martin et al., 2017). In addition, our data show that both 
M1 (MHC class II and CEBP-α) and M2 (SOCS1, TGF- and Arginase 1) phenotypes 
were decreased in our mice model in early stages when cortical intraneuronal A 
appears, increasing at 9-months only the ones related with an innate immune response 
(iNOS) and a specific deactivated polarization (SOCS1 and Arginase 1). Inflamma-
miRNAs, such as miR-155 and miR-146a, were shown to be increased in AD patient 
brains (Alexandrov et al., 2012) while miR-124 was reduced (Wang et al., 2011). Here, 
we observed that all the inflamma-miRNA were increased at the early stage of the 
disease, except miR-155 that was increased and with a sustained elevation at a late 
stage. Furthermore, since miR-155 is considered a pro-inflammatory marker with early 
appearance relatively to other inflammatory markers, this fact suggests that it may be an 
early biomarker for the onset of AD. In addition, miR-155 target analysis showed a 
predominant downregulation in the 3xTg-AD animals by comparison with the wild type 
mice, both at 3-months and 9-months of age. 
Altogether, these data indicate an immunodepressed state of microglia at early-AD 
stage in the 3xTg-AD mice model, probably as a reaction to the presence of intraneuronal 
A, probably as a defense mechanism, that is followed by an upregulation of some 
inflammatory biomarkers when extracellular A deposition is detected. Further, miR-155 
revealed to be an early biomarker of inflammation in AD which may be targeting 
important microglial immune functions. 
  
Altogether, the results presented in this thesis are schematically represented in 
Figure 5.1. Here, we developed an in vitro experimental model to age microglial cells 
which showed to become dysfunctional and may justify the association of age with AD 
symptoms. Moreover, treatment of microglia with A further clarified the distinct reactivity 
of young/activated and aged microglia to a stressing stimulus, which corroborates the 
additional microglia dysfunction and disease progression upon A accumulation. On the 
other hand, the in vivo studies revealed that the presence of intraneuronal A may lead 
to an immunodepressed microglial response at early-AD stage, while the later 
accumulation of extracellular A upregulated some inflammatory biomarkers, being miR-
155 an early biomarker of inflammation in AD. Overall, these findings show different 
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microglia reactivity during disease onset and progression, reinforcing the need to have 
different therapeutic approaches depending on the stage of AD. 
To note that given the high failure rate of clinical trials of AD therapeutics (>99%) 
after revealing clear efficacy in preclinical trials using these animal models (Cummings 
et al., 2014), indicates an urgent need of other experimental models that better 
recapitulate the disease to better understand the differences between early and late 
microglial inflammatory responses, and validate their modulation by using more directed 
and specific therapeutic approaches. One of the most attractive, innovative and improved 
model are the promising use of neural cells and microglia derived from iPSCs generated 
from AD patients. Such human microglia, better recapitulating the cellular response of 
the AD patients may be represent a substantial advance to identify microglia subtypes, 
biomarkers for early AD diagnosis and molecular targets in a human context, leading to 
the design of new therapeutic strategies and medicines to efficiently prevent and control 
disease progression. 
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Figure 5. 1 - Schematic representation of the major findings achieved in the present work. Studies 
performed in vitro in microglia primary cultures from neonatal CD1 mice, showed that ageing switches 
microglia into a more age-like/desensitized phenotype, characterized by a ramified morphology, impaired 
migration, reduced phagocytic and autophagic ability, decreased expression of inflamma-microRNAs (miR-
155 and miR-124) and increased senescence [senescence-associated -galactosidase (SA--gal) and miR-
146a]. It was also observed increased matrix metalloproteinase (MMP)-2 activity, accompanied by 
decreased MMP9 and glutamate release, as well as reduced nuclear factor-kappaB (NF-κB) and Toll-like 
receptors (TLR)-2 and TLR4. In addition, treatment with amyloid- (A1-42) peptide induced a mixture of 
microglia subtypes, with a predominant deregulated phagocytic and migration abilities, as well as a 
decreased expression of inflammatory mediators and surface receptors, while promoted autophagy in young 
cells, and increased the activity of SA--gal and of miR-146a expression. Additionally, A promoted a 
downregulation of miR-155, miR-124 and CD11b reactive cells in young microglia, while increased the 
number of CD86 positive cells in the aged cell. Finally, in vivo studies in 3xTg-AD animal model showed that 
these mice have a marked reduction of CD11b reactive cells at 3-months, as well as diminished expression 
of pro-inflammatory cytokines and inflammatory molecules, being some of those elevated at 9-months. M1 
pro-inflammatory microglia markers were reduced at 3-months and maintained during disease progression, 
with the exception of inducible nitric oxide synthase (iNOS), as well as of M2 anti-inflammatory/damage 
resolution markers. Inflamma-miRNAs showed to be increased at the early-AD stage, and only miR-155 kept 
this upregulation for the late stage. 
Chapter 5 
 
206  
2. References 
Alexandrov, P.N., Dua, P., Hill, J.M., Bhattacharjee, S., Zhao, Y., and Lukiw, W.J. (2012). 
microRNA (miRNA) speciation in Alzheimer's disease (AD) cerebrospinal fluid 
(CSF) and extracellular fluid (ECF). Int J Biochem Mol Biol 3:365-373.  
Ardestani, P.M., Evans, A.K., Yi, B., Nguyen, T., Coutellier, L., and Shamloo, M. (2017). 
Modulation of neuroinflammation and pathology in the 5XFAD mouse model of 
Alzheimer's disease using a biased and selective beta-1 adrenergic receptor 
partial agonist. Neuropharmacology 116:371-386. doi:S0028-3908(17)30010-2 
[pii] 
Bachstetter, A.D., Van Eldik, L.J., Schmitt, F.A., Neltner, J.H., Ighodaro, E.T., Webster, 
S.J., et al. (2015). Disease-related microglia heterogeneity in the hippocampus 
of Alzheimer's disease, dementia with Lewy bodies, and hippocampal sclerosis 
of aging. Acta Neuropathol Commun 3:32. doi:10.1186/s40478-015-0209-z 
Bergamini, E. (2006). Autophagy: a cell repair mechanism that retards ageing and age-
associated diseases and can be intensified pharmacologically. Mol Aspects Med 
27:403-410. doi:S0098-2997(06)00016-1 [pii] 
Bhat, R., Crowe, E.P., Bitto, A., Moh, M., Katsetos, C.D., Garcia, F.U., et al. (2012). 
Astrocyte senescence as a component of Alzheimer's disease. PLoS One 
7:e45069. doi:10.1371/journal.pone.0045069 
Bonnema, D.D., Webb, C.S., Pennington, W.R., Stroud, R.E., Leonardi, A.E., Clark, L.L., 
et al. (2007). Effects of age on plasma matrix metalloproteinases (MMPs) and 
tissue inhibitor of metalloproteinases (TIMPs). J Card Fail 13:530-540. 
doi:S1071-9164(07)00154-6 [pii] 
Cummings, J.L., Morstorf, T., and Zhong, K. (2014). Alzheimer's disease drug-
development pipeline: few candidates, frequent failures. Alzheimers Res Ther 
6:37. doi:10.1186/alzrt269 
Cunningham, C., Campion, S., Lunnon, K., Murray, C.L., Woods, J.F., Deacon, R.M., et 
al. (2009). Systemic inflammation induces acute behavioral and cognitive 
changes and accelerates neurodegenerative disease. Biol Psychiatry 65:304-
312. doi:S0006-3223(08)00895-0 [pii] 
Damani, M.R., Zhao, L., Fontainhas, A.M., Amaral, J., Fariss, R.N., and Wong, W.T. 
(2011). Age-related alterations in the dynamic behavior of microglia. Aging Cell 
10:263-276. doi:10.1111/j.1474-9726.2010.00660.x 
Etminan, M., Gill, S., and Samii, A. (2003). Effect of non-steroidal anti-inflammatory 
drugs on risk of Alzheimer's disease: systematic review and meta-analysis of 
observational studies. BMJ 327:128. doi:10.1136/bmj.327.7407.128 
Falcão, A.S., Fernandes, A., Brito, M.A., Silva, R.F., and Brites, D. (2005). Bilirubin-
induced inflammatory response, glutamate release, and cell death in rat cortical 
astrocytes are enhanced in younger cells. Neurobiol Dis 20:199-206. doi:S0969-
9961(05)00077-X [pii] 
Falcão, A.S., Fernandes, A., Brito, M.A., Silva, R.F., and Brites, D. (2006). Bilirubin-
induced immunostimulant effects and toxicity vary with neural cell type and 
maturation state. Acta Neuropathol 112:95-105. doi:10.1007/s00401-006-0078-4 
Fichtlscherer, S., De Rosa, S., Fox, H., Schwietz, T., Fischer, A., Liebetrau, C., et al. 
(2010). Circulating microRNAs in patients with coronary artery disease. Circ Res 
107:677-684. doi:CIRCRESAHA.109.215566 [pii] 
Floden, A.M., and Combs, C.K. (2007). Microglia repetitively isolated from in vitro mixed 
glial cultures retain their initial phenotype. J Neurosci Methods 164:218-224. 
doi:S0165-0270(07)00207-5 [pii] 
Gingras, M., Gagnon, V., Minotti, S., Durham, H.D., and Berthod, F. (2007). Optimized 
protocols for isolation of primary motor neurons, astrocytes and microglia from 
embryonic mouse spinal cord. J Neurosci Methods 163:111-118. doi:S0165-
0270(07)00103-3 [pii] 
 Final Considerations 
207 
Grabert, K., Michoel, T., Karavolos, M.H., Clohisey, S., Baillie, J.K., Stevens, M.P., et al. 
(2016). Microglial brain region-dependent diversity and selective regional 
sensitivities to aging. Nat Neurosci 19:504-516. doi:nn.4222 [pii] 
Graeber, M.B., and Streit, W.J. (2010). Microglia: biology and pathology. Acta 
Neuropathol 119:89-105. doi:10.1007/s00401-009-0622-0 
Harry, G.J. (2013). Microglia during development and aging. Pharmacol Ther 139:313-
326. doi:10.1016/j.pharmthera.2013.04.013 
Helenius, M., Hanninen, M., Lehtinen, S.K., and Salminen, A. (1996). Changes 
associated with aging and replicative senescence in the regulation of 
transcription factor nuclear factor-kappa B. Biochem J 318 ( Pt 2):603-608.  
Janelsins, M.C., Mastrangelo, M.A., Oddo, S., Laferla, F.M., Federoff, H.J., and Bowers, 
W.J. (2005). Early correlation of microglial activation with enhanced tumor 
necrosis factor-alpha and monocyte chemoattractant protein-1 expression 
specifically within the entorhinal cortex of triple transgenic Alzheimer's disease 
mice. J Neuroinflammation 2:23. doi:1742-2094-2-23 [pii] 
Jiang, M., Xiang, Y., Wang, D., Gao, J., Liu, D., Liu, Y., et al. (2012). Dysregulated 
expression of miR-146a contributes to age-related dysfunction of macrophages. 
Aging Cell 11:29-40. doi:10.1111/j.1474-9726.2011.00757.x 
Kim, H.J., Ajit, D., Peterson, T.S., Wang, Y., Camden, J.M., Gibson Wood, W., et al. 
(2012). Nucleotides released from Abeta(1)(-)(4)(2) -treated microglial cells 
increase cell migration and Abeta(1)(-)(4)(2) uptake through P2Y(2) receptor 
activation. J Neurochem 121:228-238. doi:10.1111/j.1471-4159.2012.07700.x 
Krabbe, G., Halle, A., Matyash, V., Rinnenthal, J.L., Eom, G.D., Bernhardt, U., et al. 
(2013). Functional impairment of microglia coincides with Beta-amyloid 
deposition in mice with Alzheimer-like pathology. PLoS One 8:e60921. 
doi:10.1371/journal.pone.0060921 
Lai, A.Y., Dibal, C.D., Armitage, G.A., Winship, I.R., and Todd, K.G. (2013). Distinct 
activation profiles in microglia of different ages: a systematic study in isolated 
embryonic to aged microglial cultures. Neuroscience 254:185-195. doi:S0306-
4522(13)00781-1 [pii] 
Landel, V., Baranger, K., Virard, I., Loriod, B., Khrestchatisky, M., Rivera, S., et al. 
(2014). Temporal gene profiling of the 5XFAD transgenic mouse model highlights 
the importance of microglial activation in Alzheimer's disease. Mol Neurodegener 
9:33. doi:#N/A [pii] 
Li, W. (2012). Eat-me signals: keys to molecular phagocyte biology and "appetite" 
control. J Cell Physiol 227:1291-1297. doi:10.1002/jcp.22815 
Li, W. (2013). Phagocyte dysfunction, tissue aging and degeneration. Ageing Res Rev 
12:1005-1012. doi:10.1016/j.arr.2013.05.006 
Martin, B.K., Szekely, C., Brandt, J., Piantadosi, S., Breitner, J.C., Craft, S., et al. (2008). 
Cognitive function over time in the Alzheimer's Disease Anti-inflammatory 
Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen 
and celecoxib. Arch Neurol 65:896-905. doi:2008.65.7.nct70006 [pii] 
Martin, E., Boucher, C., Fontaine, B., and Delarasse, C. (2017). Distinct inflammatory 
phenotypes of microglia and monocyte-derived macrophages in Alzheimer's 
disease models: effects of aging and amyloid pathology. Aging Cell 16:27-38. 
doi:10.1111/acel.12522 
Minkeviciene, R., Ihalainen, J., Malm, T., Matilainen, O., Keksa-Goldsteine, V., 
Goldsteins, G., et al. (2008). Age-related decrease in stimulated glutamate 
release and vesicular glutamate transporters in APP/PS1 transgenic and wild-
type mice. J Neurochem 105:584-594. doi:JNC5147 [pii] 
Napoli, I., and Neumann, H. (2009). Microglial clearance function in health and disease. 
Neuroscience 158:1030-1038. doi:S0306-4522(08)00972-X [pii] 
Neumann, H., Kotter, M.R., and Franklin, R.J. (2009). Debris clearance by microglia: an 
essential link between degeneration and regeneration. Brain 132:288-295. 
doi:awn109 [pii] 
Chapter 5 
 
208  
Njie, E.G., Boelen, E., Stassen, F.R., Steinbusch, H.W., Borchelt, D.R., and Streit, W.J. 
(2012). Ex vivo cultures of microglia from young and aged rodent brain reveal 
age-related changes in microglial function. Neurobiol Aging 33:195 e191-112. 
doi:10.1016/j.neurobiolaging.2010.05.008 
Noren Hooten, N., Abdelmohsen, K., Gorospe, M., Ejiogu, N., Zonderman, A.B., and 
Evans, M.K. (2010). microRNA expression patterns reveal differential expression 
of target genes with age. PLoS One 5:e10724. 
doi:10.1371/journal.pone.0010724 
Oddo, S., Caccamo, A., Kitazawa, M., Tseng, B.P., and Laferla, F.M. (2003a). Amyloid 
deposition precedes tangle formation in a triple transgenic model of Alzheimer's 
disease. Neurobiol Aging 24:1063-1070. doi:S0197458003002033 [pii] 
Oddo, S., Caccamo, A., Shepherd, J.D., Murphy, M.P., Golde, T.E., Kayed, R., et al. 
(2003b). Triple-transgenic model of Alzheimer's disease with plaques and 
tangles: intracellular Abeta and synaptic dysfunction. Neuron 39:409-421. 
doi:S0896627303004343 [pii] 
Paczek, L., Michalska, W., and Bartlomiejczyk, I. (2008). Trypsin, elastase, plasmin and 
MMP-9 activity in the serum during the human ageing process. Age Ageing 
37:318-323. doi:afn039 [pii] 
Rezai-Zadeh, K., Gate, D., Gowing, G., and Town, T. (2011). How to get from here to 
there: macrophage recruitment in Alzheimer's disease. Curr Alzheimer Res 
8:156-163. doi:BSP/CAR /0144 [pii] 
Schwab, C., Klegeris, A., and Mcgeer, P.L. (2009). Inflammation in transgenic mouse 
models of neurodegenerative disorders. Biochim Biophys Acta 1802:889-902. 
doi:S0925-4439(09)00249-X [pii] 
Sierra, A., Gottfried-Blackmore, A.C., Mcewen, B.S., and Bulloch, K. (2007). Microglia 
derived from aging mice exhibit an altered inflammatory profile. Glia 55:412-424. 
doi:10.1002/glia.20468 
Smith-Vikos, T., and Slack, F.J. (2012). MicroRNAs and their roles in aging. J Cell Sci 
125:7-17. doi:125/1/7 [pii] 
Streit, W.J., Braak, H., Xue, Q.S., and Bechmann, I. (2009). Dystrophic (senescent) 
rather than activated microglial cells are associated with tau pathology and likely 
precede neurodegeneration in Alzheimer's disease. Acta Neuropathol 118:475-
485. doi:10.1007/s00401-009-0556-6 
Streit, W.J., Sammons, N.W., Kuhns, A.J., and Sparks, D.L. (2004). Dystrophic microglia 
in the aging human brain. Glia 45:208-212. doi:10.1002/glia.10319 
Streit, W.J., and Xue, Q.S. (2012). Alzheimer's disease, neuroprotection, and CNS 
immunosenescence. Front Pharmacol 3:138. doi:10.3389/fphar.2012.00138 
Von Bernhardi, R. (2010). Immunotherapy in Alzheimer's disease: where do we stand? 
Where should we go? J Alzheimers Dis 19:405-421. doi:10.3233/JAD-2010-1248  
Weggen, S., Eriksen, J.L., Das, P., Sagi, S.A., Wang, R., Pietrzik, C.U., et al. (2001). A 
subset of NSAIDs lower amyloidogenic Abeta42 independently of 
cyclooxygenase activity. Nature 414:212-216. doi:10.1038/35102591 
 
